

[ HPLC AND UHPLC ]

# Application Highlights



Waters

THE SCIENCE OF WHAT'S POSSIBLE.®

# Table of Contents

|   |          |
|---|----------|
| <b>How to Choose a Column Guide .....</b>   | <b>8</b> |
| <b>Applications by Relevant Compound</b>  |          |
| Abacavir .....  | 12       |
| Abacavir Related Compounds.....   | 13       |
| 6-Acetylmorphine and Morphine.....  | 14       |
| Acrylamide, Methacrylic Acid, and Methacrylamide.....   | 15       |
| Aflatoxins in Red Pepper.....   | 16       |
| Aflatoxins Standard .....   | 17       |
| Allantoin.....  | 18       |
| Allergenic and Carcinogenic Dyes in Industrial, Cosmetics,<br>Personal Care, and Consumer Products..... | 19       |
| Amoxicillin Oral Suspension.....  | 20       |
| Antibacterials by HPLC .....  | 21       |
| Antibacterials by UHPLC.....  | 22       |
| Ascorbic and Isoascorbic Acid by Gradient HPLC .....  | 23       |
| Ascorbic and Isoascorbic Acid by Isocratic HPLC .....   | 24       |
| Avermectins in Meat .....   | 25       |
| Avermectins in Milk .....   | 26       |
| Basic Compounds .....   | 27       |
| Basic Drugs in River Water .....  | 28       |
| Basic Impurities .....  | 29       |
| Basic Impurities (Solid-Core Technology Comparison).....  | 30       |
| Beta Blockers.....  | 31       |
| Budesonide Nasal Spray.....   | 32       |
| Buprenorphine and Buprenorphine Glucuronide.....  | 33       |
| Caffeine and Metabolites Using XBridge BEH C <sub>18</sub> Columns.....                                 | 34       |
| Caffeine and Metabolites Using XBridge BEH Phenyl Columns.....  | 35       |

|  |    |
|--|----|
| Carbonyl Compounds in Drinking Water .....                     | 36 |
| Catechins .....  | 37 |
| Catecholamines by Isocratic HPLC .....                         | 38 |
| Catecholamines by Gradient HPLC .....                          | 39 |
| Cellulosic Hydrolysates .....                                  | 40 |
| Cephalosporin Antibiotics .....                                | 41 |
| Clarithromycin .....   | 42 |
| Cytosine, 5-Fluorocytosine, and Uracil .....                   | 43 |
| Dextromethorphan, Tetracaine, Triprolidine, and Warfarin ..... | 44 |
| Disperse Dyes .....  | 45 |
| DNPH Derivatives .....   | 46 |
| Dofetilide and Related Compounds .....                         | 47 |
| Donepezil Tablets .....  | 48 |
| Drugs and Metabolites .....                                    | 49 |
| Drugs of Abuse .....   | 50 |
| Estradiol .....  | 51 |
| Flavanoids in Fruit Juice .....                                | 52 |
| 5-Fluorouracil .....   | 53 |
| Food Additives and Preservatives .....                         | 54 |
| Food Sugars in Sports Drink .....                              | 55 |
| Food Sugars in Bran with Raisin Cereal .....                   | 56 |
| Food Sugars in Ketchup .....                                   | 57 |
| Food Sugars in Milk .....                                      | 58 |
| Food Sugars in Molasses .....                                  | 59 |
| Food Sugars in Potato Chips .....                              | 60 |
| Food Sugars in Prepared Foods .....                            | 61 |

|  |    |
|--|----|
| Food Sugars in Wine.....   | 62 |
| Food Sugars Standard.....  | 63 |
| Food Sugars/Saccharides in Beer by ELSD .....                    | 64 |
| Food Sugars/Saccharides in Beer by MS.....                       | 65 |
| Food Sugars/Saccharides in Cough Syrup.....                      | 66 |
| Food Sugars/Saccharides in Honey.....                            | 67 |
| Food Sugars/Saccharides in Maple Syrup .....                     | 68 |
| Food Sugars/Saccharides Standards by ELSD .....                  | 69 |
| Food Sugars/Saccharides Standards by MS.....                     | 70 |
| Formaldehyde in Ambient Air .....                                | 71 |
| Furanocoumarins in Fruit Juice .....                             | 72 |
| Galantamine and Related Substances.....                          | 73 |
| Ginsenoside Rb1 in Ginseng Root Powder Extract.....              | 74 |
| Ginsenoside Rb1 in Herbal Medicine Extract.....                  | 75 |
| Goldenseal .....   | 76 |
| Histidine Dipeptides.....  | 77 |
| Irbesartan Tablets.....  | 78 |
| Lamotrigine and Related Compounds .....                          | 79 |
| Levonorgestrel and Ethynodiol Diacetate Tablets.....             | 80 |
| Lipid Soluble Antioxidants Using Atlantis T3, 3 µm Columns.....  | 81 |
| Lipid Soluble Antioxidants Using CORTECS T3, 2.7 µm Columns..... | 82 |
| Local Anesthetics.....   | 83 |
| Loratadine Using XBridge BEH C <sub>18</sub> Columns.....        | 84 |
| Loratadine Using XBridge BEH C <sub>8</sub> Columns.....         | 85 |
| Loratadine Using CORTECS C <sub>8</sub> Columns.....             | 86 |
| 2- and 4-Methylimidazole in Beverages.....                       | 87 |

|  |     |
|--|-----|
| Metoclopramide Using a 5 µm HPLC Column.....   | 88  |
| Metoclopramide Using a 3.5 µm HPLC Column.....                                       | 89  |
| Metoclopramide Using a 2.5 µm UHPLCColumn.....                                       | 90  |
| Miconazole Nitrate Cream Using XBridge BEH Phenyl Columns.....                       | 91  |
| Miconazole Nitrate Cream Using CORTECS Phenyl Columns .....                          | 92  |
| Mometasone Furoate Ointment.....   | 93  |
| Mono- and Disaccharides and Selected Alditols in Juice, Beer, Wine, and Whiskey..... | 94  |
| Monoamine Neurotransmitters.....   | 95  |
| Monosaccharides .....  | 96  |
| Morphine and Related Compounds.....  | 97  |
| Morphine and Metabolites Using XBridge BEH HILIC Columns .....                       | 98  |
| Morphine and Metabolites Using CORTECS HILIC Columns .....                           | 99  |
| Mouthwash .....  | 100 |
| Nerve Agent Degradation Products in Drinking Water.....                              | 101 |
| Neurotransmitters.....   | 102 |
| Nimodipine.....  | 103 |
| Nitroaromatic Compounds.....   | 104 |
| Non-Steroidal Inflammatory Drugs (NSAIDS).....                                       | 105 |
| Nucleobases.....   | 106 |
| Nucleotide Phosphates .....  | 107 |
| Nutrients.....   | 108 |
| Oligonucleotides.....  | 109 |
| Omeprazole.....  | 110 |
| Organic Acids .....  | 111 |
| Organic Acids and Bases .....  | 112 |
| Organophosphoric Acids by Isocratic LC-MS .....                                      | 113 |

|   |         |
|---|---------|
| Organophosphoric Acids by Gradient LC-MS .....                  | 114     |
| Pain Management Drugs Using XBridge BEH Phenyl Columns .....    | 115     |
| Pain Management Drugs Using CORTEC C <sub>18</sub> Columns..... | 116     |
| Peppermint Extract.....   | 117     |
| Peptides.....   | 118     |
| Pesticides (AI 1, Tebuconazole).....                            | 119     |
| Pharmaceuticals in Environmental Samples .....                  | 120–121 |
| Polyethylene Glycols (PEGs) .....                               | 122     |
| Quality Control Reference Material – HILIC.....                 | 123     |
| Quality Control Reference Material – LCMS.....                  | 124     |
| Quality Control Reference Material – Reversed Phase .....       | 125     |
| Sialic Acid by HPLC.....  | 126     |
| Sialic Acid by UHPLC .....                                      | 127     |
| Simvastatin.....  | 128     |
| Soft Drink.....   | 129     |
| Soy Isoflavones in Foods and Dietary Supplements by HPLC.....   | 130     |
| Soy Isoflavones in Foods and Dietary Supplements by UHPLC ..... | 131     |
| Statins.....  | 132     |
| Stevia Related Compounds by ELSD.....                           | 133     |
| Stevia Related Compounds by MS.....                             | 134     |
| Sucralose.....  | 135     |
| Sudan Dyes.....   | 136     |
| Synthetic Cannabinoids .....                                    | 137     |
| Tetracyclines in Milk.....                                      | 138     |
| Thiourea.....   | 139     |
| Tioconazole and Related Compounds .....                         | 140     |

|  |            |
|--|------------|
| Topiramate.....                                  | 141        |
| Tricyclic Antidepressants .....                  | 142        |
| Tricyclic Antidepressants at pH 7.0 .....        | 143        |
| Tricyclic Antidepressants at pH 10.5 .....       | 144        |
| UPC <sup>2</sup> Gradient Standard by HPLC.....  | 145        |
| UPC <sup>2</sup> Gradient Standard by UHPLC..... | 146        |
| Uric Acids.....                                  | 147        |
| Water-Soluble Vitamins.....                      | 148        |
| Zidovudine.....                                  | 149        |
| Ziprasidone HCl.....                             | 150        |
| Ziprasidone HCl - Early-Eluting Impurities.....  | 151        |
| Ziprasidone HCl - Late-Eluting Impurities .....  | 152        |
| <b>Compound Index.....</b>                       | <b>153</b> |

# How to Choose a Column

Separation scientists continue to search for innovative solutions to improve chromatographic performance. With a wide array of column choices and formats, they have the ability to select the ideal column for their application. The following section introduces Waters' particle technologies and column formats to help you choose the best column to deliver throughput, resolution, and efficiency for your next chromatographic challenge.

## Particle Technology


Reproducibility and transferability are the cornerstones of Waters' BEH, CSH™ HSS, and solid-core particle technologies. Our premier lines of scalable LC columns exhibit all of the chemical and physical characteristics you would expect from modern LC packing materials.




| BEH Technology   | CSH Technology   | HSS Technology  | Solid-Core Technology  |
|--|--|---|--|
| <ul style="list-style-type: none"><li>■ High retentivity for basic compounds</li><li>■ Exceptional peak shape at elevated pH</li><li>■ Good universal column choice for a wide variety of compounds</li><li>■ Stable across a wide pH range</li><li>■ For separations at high temperatures (80 °C)</li></ul> | <ul style="list-style-type: none"><li>■ Good separations for basic compounds under low pH conditions</li><li>■ Excellent MS performance with formic acid as a mobile phase modifier</li><li>■ Fast pH switching and column equilibration</li></ul> | <ul style="list-style-type: none"><li>■ High retentivity for polar organic compounds and metabolites</li><li>■ Balanced retention of polar and hydrophobic analytes</li><li>■ High strength silica for mechanical stability</li></ul> | <ul style="list-style-type: none"><li>■ Maximum efficiency</li><li>■ Increased sensitivity</li><li>■ Seamless scalability from UPLC to UHPLC to HPLC</li></ul> |

### ETHYLENE BRIDGED HYBRID (BEH) PARTICLE TECHNOLOGY

Ethylene Bridged Hybrid (BEH) columns lead the industry for chromatographic versatility, chemical resistance, and mechanical stability. You can use them at extremes of pH and temperature to enhance retention and specificity for complex mixtures of acidic, alkaline, and neutral species. The BEH-particle family includes general-purpose and application-specific bonded phases that serve application areas that rely on ACQUITY UPLC®, ACQUITY® UPC²®, ACQUITY APC®, and XBridge® Columns.



### Particle Synthesis




\*US Patents 6,686,035; 7,223,473; 7,250,214.

Refer to "Ethylene-Bridged [BEH Technology™] Hybrids and Their Use in Liquid Chromatography" whitepaper (720001159EN) for further detail.

## CHARGED SURFACE HYBRID (CSH) PARTICLE TECHNOLOGY

Columns packed with charged surface hybrid particles manifest the best attributes of BEH particles. CSH stationary phases provide chromatographic selectivity and superior performance in the presence of mobile phases of low ionic strength. The optimized surface charge, pore properties, and bonded phases make charged-surface, hybrid-based columns ideal for rapid method development. ACQUITY UPLC CSH and XSelect® CSH HPLC Columns offer easily scaled analytical solutions, from sub-2- $\mu\text{m}$  to preparative-particle dimensions.


### The Charged-Surface Hybrid Particle



## HIGH STRENGTH SILICA (HSS) PARTICLE TECHNOLOGY

High strength silica [HSS] technology was developed specifically to complement the chromatographic performance of BEH and CSH particles. Compared with the ethylene-bridged BEH and CSH particles, the HSS particle's higher silanophilicity (100% silica) offers chromatographers significant advantages, including increased retention of polar compounds and significantly different selectivity. Additionally, as its name implies, the HSS particle possesses the mechanical strength to operate at pressures as high as 18,000 psi (1240 bar). ACQUITY UPLC HSS and XSelect HSS Columns are the first choice for proven silica-based chromatographic performance.

**HSS**  
HIGH STRENGTH SILICA



## SOLID-CORE PARTICLE TECHNOLOGY

Compared to columns packed with fully-porous particles, those packed with superficially porous particles demonstrate higher chromatographic efficiency and lower backpressures. The optimized porous layer that surrounds the solid-silica substrate gives rise to the key benefits of speed and efficiency. UPLC® Columns packed with CORTECS® 1.6  $\mu\text{m}$  particles yield maximum efficiency when used with the ultra-low dispersion ACQUITY UPLC instrument platform. Fully scalable CORTECS Columns packed with 2.7  $\mu\text{m}$  particles offer maximum flexibility, providing increased efficiencies at the backpressure limits of UHPLC and HPLC operation.

**Solid-Core Particle**  
The tightly controlled thickness of a highly porous silica layer surrounding the inner solid-core yields reproducible retention and method robustness for a wide range of sample conditions.

**Particle Diameter**  
Monodisperse particle sizing provides highly permeable columns and, consequently, low backpressures.



**Packing Efficiency**  
The increased efficiency of a solid-core particle produces more chromatographic resolution, which helps reduce the effort to separate co-eluting peaks.

**Bonding Technology**  
Packed with solid-core particles, CORTECS Columns complement our family of particle technologies, offering unique ligand attributes that aid in method development.

# Column Configurations for Any LC System

## COLUMN NOMENCLATURE

Our fully-scalable particle technologies ensure that our LC columns perform with a broad range of chromatographic instrumentation. Depending on the goals of a separation, the instrument platform used, or the sample type, you can choose the most suitable column that is matched to your system's configuration without adversely affecting the chromatographic result.

The following table serves as a guide for selecting an appropriate LC column according to instrument classification.

| Nano/Micro                           | UPLC                         | UHPLC                             | HPLC                                 | Preparative                    |
|--------------------------------------|------------------------------|-----------------------------------|--------------------------------------|--------------------------------|
| ACQUITY UPLC M-CLASS BEH<br>(1.7 µm) | ACQUITY UPLC BEH<br>(1.7 µm) | XBridge BEH <i>XP</i><br>(2.5 µm) | XBridge BEH<br>(3.5, 5 µm)           | XBridge BEH OBD™<br>(5, 10 µm) |
| ACQUITY UPLC M-CLASS CSH<br>(1.7 µm) | ACQUITY UPLC CSH<br>(1.7 µm) | XSelect CSH <i>XP</i><br>(2.5 µm) | XSelect CSH <i>XP</i><br>(3.5, 5 µm) | XSelect CSH OBD<br>(5, 10 µm)  |
| ACQUITY UPLC M-CLASS HSS<br>(1.8 µm) | ACQUITY UPLC HSS<br>(1.8 µm) | XSelect HSS <i>XP</i><br>(2.5 µm) | XSelect HSS <i>XP</i><br>(3.5, 5 µm) | XSelect HSS OBD<br>(5 µm)      |
| —                                    | CORTECS UPLC<br>(1.6 µm)     | CORTECS<br>(2.7 µm)               | —                                    | —                              |

## COLUMN CONFIGURATIONS

System dispersion, the combined effect of tubing and its connections, sample valves, flow cells, and column end-fittings, is inherent in every chromatographic system. Dispersion causes sample peaks to broaden, owing to dilution, that begins at the injector and ends at the detector's outflow. As the size of particles in an LC column are reduced or the internal diameter and length of the column is decreased, the potential peak broadening in a non-optimized LC system increases. Optimum column configuration, therefore, depends mainly on the extent of sample dispersion within the LC system.

The following table summarizes the characteristics of Waters LC Systems and matches the column configuration that maintains chromatographic efficiency.



| System           | NANO/MICRO  | UPLC            | UHPLC           | HPLC            | PREPARATIVE |
|------------------|-------------|-----------------|-----------------|-----------------|-------------|
| Dispersion       | 1 µL        | <20 µL          | 22–29 µL        | >40 µL          | —           |
| Routine Pressure | <15,000 psi | <18,000 psi     | <10,000 psi     | <4000 psi       | <4000 psi   |
| Particle Size    | <2 µm       | <2 µm           | 2–3 µm          | 3–5 µm          | >5 µm       |
| Column I.D.      | 75–300 µm   | 2.1 mm (1.0 mm) | 3.0 mm (2.1 mm) | 4.6 mm (3.0 mm) | >7.8 mm     |
| Column Length    | 50–250 mm   | <150 mm         | 50–150 mm       | 75–300 mm       | 50–300 mm   |

When you transfer LC methods, instrument bandspread is one of the most practical LC-instrument parameters to determine. Knowing the bandspread value helps you develop your own compatible methods, allowing you to seamlessly scale column dimensions or transfer methods between different instrumentation platforms and laboratory functions. The following table recommends column configurations based on nominal instrument bandspread values.

| System                                   | Bandspread* | Recommended Column Particle Sizes and I.D.s   |
|--|-------------|---|
| Shimadzu Prominence UFC                  | 41 µL       | XBridge 3.5, 5 µm   |
| Alliance 2695 HPLC                       | 29 µL       | XSelect 3.5, 5 µm<br>CORTECS 2.7 µm   |
| Agilent 1260 UHPLC (600 bar)             | 28 µL       | <b>3.0–4.6 mm I.D.</b><br>XBridge 2.5, 3.5, 5 µm  |
| Thermo Accela UHPLC                      | 21 µL       | XSelect 2.5, 3.5, 5 µm<br>CORTECS 2.7 µm  |
| Agilent 1290 UHPLC (1200 bar)            | 17 µL       | <b>3.0 mm I.D.</b><br>XBridge 2.5, 3.5, 5 µm<br>XSelect 2.5, 3.5, 5 µm<br>CORTECS 2.7 µm            |
| ACQUITY Arc™                             | 23 µL       | <b>3.0 mm I.D.</b><br>ACQUITY UPLC BEH 1.7 µm<br>ACQUITY UPLC CSH 1.7 µm<br>ACQUITY UPLC HSS 1.8 µm |
| ACQUITY UPLC                             | 12 µL       | ACQUITY UPLC BEH 1.7 µm<br>ACQUITY UPLC CSH 1.7 µm<br>ACQUITY UPLC HSS 1.8 µm                       |
| ACQUITY UPLC H-Class with Column Manager | 12 µL       | CORTECS UPLC 1.6 µm   |
| ACQUITY UPLC H-Class                     | 9 µL        | <b>2.1 mm I.D.</b><br>ACQUITY UPLC BEH 1.7 µm<br>ACQUITY UPLC CSH 1.7 µm<br>ACQUITY UPLC HSS 1.8 µm |
| ACQUITY UPLC I-Class (FTN)               | 7.5 µL      | CORTECS UPLC 1.6 µm   |
| ACQUITY UPLC I-Class (FL)                | 5.5 µL      | <b>1.0–2.1 mm I.D.</b>  |

\*These data are based on nominal values for unmodified systems. As such, they are intended for reference only. Any adjustment to a system's plumbing, connectivity, and configuration changes the instrument bandspread, affecting the quality of chromatography.

For complete experimental details, refer to full application note [720005104EN](#) at waters.com

## Analysis of Abacavir

### EXPERIMENTAL

#### LC conditions

System: Alliance HPLC with 2489 TUV detector

Column: CORTECS C<sub>18</sub>, 2.7 μm, 4.6 x 75 mm

Mobile phase A: 0.1% trifluoroacetic acid in water

Mobile phase B: 85% methanol in water

| Gradient: | Time  | %A | %B |
|-----------|-------|----|----|
|           | 0.00  | 95 | 5  |
|           | 6.38  | 70 | 30 |
|           | 10.37 | 10 | 90 |
|           | 11.83 | 10 | 90 |
|           | 12.12 | 95 | 5  |
|           | 15.00 | 95 | 5  |

Flow rate: 1.85 mL/min


Injection volume: 4 μL

UV detection: 254 nm

#### Sample preparation

Abacavir-related compounds (USP reference standard)

1.0 mg/mL in 100% HPLC-grade water



### ORDERING INFORMATION

| Description   | P/N                        |
|---|----------------------------|
| CORTECS C <sub>18</sub> , 2.7 μm,<br>4.6 x 75 mm Column | <a href="#">186007376</a>  |
| Waters LCGC Certified Vial<br>w/ Preslit Septa          | <a href="#">186000307C</a> |

For complete experimental details, refer to full application note [WA64697](#) at waters.com

## Analysis of Abacavir Related Compounds


### EXPERIMENTAL

#### LC conditions

|                 |   |           |           |              |
|-----------------|---|-----------|-----------|--------------|
| System:         | Alliance HPLC with 2998 PDA detector          |           |           |              |
| Column:         | CORTECS C <sub>18</sub> , 2.7 μm, 4.6 x 75 mm |           |           |              |
| Mobile phase A: | 0.1% trifluoroacetic acid in water            |           |           |              |
| Mobile phase B: | 85% methanol in water                         |           |           |              |
| Gradient:       | <u>Time</u>                                   | <u>%A</u> | <u>%B</u> | <u>Curve</u> |
|                 | Initial                                       | 95        | 5         | –            |
|                 | 6.38  | 70        | 30        | 6            |
|                 | 10.37   | 10        | 90        | 11           |
|                 | 11.83   | 10        | 90        | 11           |
|                 | 12.12   | 95        | 5         | 11           |
| Flow rate:      | 1.85 mL/min                                   |           |           |              |
| Column temp.:   | 30 °C   |           |           |              |
| UV detection:   | 254 nm  |           |           |              |

#### Sample preparation

|                 |                                |
|-----------------|--------------------------------|
| Sample:         | Abacavir USP related compounds |
| Sample diluent: | Water                          |



### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| CORTECS C <sub>18</sub> , 2.7 μm,<br>4.6 x 75 mm Column | <a href="#">186007376</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa         | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [WA64078](#) at waters.com

## Analysis of 6-Acetylmorphine and Morphine


### EXPERIMENTAL

#### LC conditions

|                   |  |           |           |
|-------------------|--|-----------|-----------|
| System:           | ACQUITY UPLC with TQD mass spectrometer                                    |           |           |
| Column:           | XBridge BEH HILIC, 3.5 $\mu$ m, 2.1 x 100 mm                               |           |           |
| Mobile phase A:   | 10 mM ammonium formate with 0.125% formic acid in 50/50 acetonitrile/water |           |           |
| Mobile phase B:   | 10 mM ammonium formate with 0.125% formic acid in 90/10 acetonitrile/water |           |           |
| Gradient:         | <u>Time</u>  | <u>%A</u> | <u>%B</u> |
|                   | 0.00   | 0.1       | 99.9      |
|                   | 1.05   | 0.1       | 99.9      |
|                   | 4.35   | 99.9      | 0.1       |
|                   | 4.50   | 0.1       | 99.9      |
|                   | 6.00   | 0.1       | 99.9      |
| Flow rate:        | 0.6 mL/min   |           |           |
| Column temp.:     | 30 °C  |           |           |
| Injection volume: | 10.0 $\mu$ L (PLNO, 20 $\mu$ L loop)                                       |           |           |
| Ionization mode:  | ESI+   |           |           |
| Acquisition mode: | MRM ( $m/z$ ): morphine 286 > 200.9; 6-acetylmorphine 328 > 164.9          |           |           |

#### Sample preparation

Sample concentration: 10 ng/mL each



### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH HILIC, 3.5 $\mu$ m, 2.1 x 100 mm Column | <a href="#">186004433</a>   |
| TruView LCMS Certified Vial w/ Preslit Septa        | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [WA64115](#) at waters.com

## Analysis of Acrylamide, Methacrylic Acid, and Methacrylamide

### EXPERIMENTAL


#### LC conditions

|                   |  |
|-------------------|--|
| System:           | Alliance HPLC with 2998 PDA detector   |
| Column:           | XBridge BEH Amide, 3.5 µm, 4.6 x 250 mm  |
| Mobile phase:     | 95/2.5/2.5 acetonitrile/isopropyl alcohol/water with 5 mM ammonium acetate, pH 9.0 |
| Separation mode:  | Isocratic  |
| Flow rate:        | 1.2 mL/min   |
| Column temp.:     | 25 °C  |
| Injection volume: | 40.0 µL  |
| UV detection:     | 210 nm   |

#### Sample preparation

Sample was diluted with 50:50 acetonitrile/water and filtered using 0.45 µm PVDF syringe filter.

Sample concentration: 30 µg/mL



### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| XBridge BEH Amide, 3.5 µm, 4.6 x 250 mm Column         | <a href="#">186004870</a>   |
| Acrodisc, Syringe Filter, PVDF, 13 mm, 0.45 µm, 100/pk | <a href="#">WAT200512</a>   |
| Waters LCMS Certified Vial                             | <a href="#">600000751CV</a> |

For complete experimental details, refer to full application note [720002600EN](#) at waters.com

## Analysis of Aflatoxins in Red Pepper


### EXPERIMENTAL

#### LC conditions

|                  |   |
|------------------|---|
| System:          | Alliance HPLC with 2475 Multi Wavelength Fluorescence           |
| Column:          | XBridge BEH C <sub>18</sub> , 5 µm, 4.6 x 250 mm                |
| Mobile phase:    | Acetonitrile/water/methanol (17:54:29, v/v/v)                   |
| Separation mode: | Isocratic   |
| Flow rate:       | 1 mL/min  |
| Injection:       | 100 µL  |
| FLR detection:   | Excitation wavelength = 333 nm;<br>Emission wavelength = 460 nm |

#### Sample preparation

Add 100 mL 80:20 methanol:water (v/v) to 50 g ground red pepper and 5 g sodium chloride. Blend at high speed for 1 minute. Filter extract with fluted filter paper, take 65 mL filtrate and dilute with 60 mL phosphate buffer saline, and filter through glass microfiber filter. Load 4 mL filtered diluted extract to AflaTest Affinity Column at a rate of ~1-2 drops/second. Wash column with 10 mL 20:80 methanol:water at a rate of ~2 drops/second, and repeat once more until air comes through column. Elute AflaTest column with 1 mL HPLC-grade methanol at a rate of 1 drop/second and collect eluate, dilute with 1 mL water.



### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH C <sub>18</sub> , 5 µm, 4.6 x 250 mm Column | <a href="#">186003117</a>   |
| Waters LCMS Certified Vial                              | <a href="#">600000751CV</a> |
| VICAM AflaOchra HPLC Columns, 25/pk                     | <a href="#">G1017</a>       |
| VICAM Glass Cuvette                                     | <a href="#">34000</a>       |

For complete experimental details, refer to full application note [WA60195](#) at waters.com

## Analysis of Aflatoxins Standard

### EXPERIMENTAL

#### LC conditions

|                   |   |
|-------------------|---|
| System:           | Alliance 2695 with a fluorescence detector                      |
| Column:           | XBridge Shield RP18, 5 µm, 4.6 x 150 mm                         |
| Mobile phase:     | Water/MeOH, 70/30, v/v  |
| Separation mode:  | Isocratic   |
| Flow rate:        | 0.6 mL/min  |
| Column temp.:     | 40 °C   |
| Injection volume: | 10 µL   |
| FLR detection:    | Excitation wavelength = 365 nm;<br>Emission wavelength = 455 nm |

#### Sample preparation


A commercial mixture of aflatoxins B1, B2, G1, and G2. A final solution was appropriately prepared to create the final concentrations:

B1: 250 pg/mL

B2: 25 pg/mL

G1: 250 pg/mL

G2: 25 pg/mL



### ORDERING INFORMATION

| Description                                       | P/N                         |
|---|-----------------------------|
| XBridge Shield RP18, 5 µm,<br>4.6 x 150 mm Column | <a href="#">186003009</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa   | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [WA64112](#) at waters.com

## Analysis of Allantoin

### EXPERIMENTAL


#### LC conditions

|                   |   |
|-------------------|---|
| System:           | Alliance HPLC with 2998 PDA detector    |
| Column:           | XBridge BEH Amide, 3.5 µm, 4.6 x 250 mm |
| Mobile phase:     | 90/10 acetonitrile/water                |
| Separation mode:  | Isocratic                               |
| Flow rate:        | 0.5 mL/min                              |
| Column temp.:     | 25 °C                                   |
| Injection volume: | 40.0 µL                                 |
| UV detection:     | 210 nm                                  |

#### Sample preparation

Sample was diluted with 50:50 acetonitrile/water and filtered using 0.45 µm PVDF syringe filter.

Sample concentration: 100 µg/mL



### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH Amide, 3.5 µm,<br>4.6 x 250 mm Column         | <a href="#">186004870</a>   |
| Acrodisc, Syringe Filter, PVDF,<br>13 mm, 0.45 µm, 100/pk | <a href="#">WAT200512</a>   |
| Waters LCMS Certified Vial                                | <a href="#">600000751CV</a> |

For complete experimental details, refer to full application note [720004492EN](#) at waters.com

## Analysis of Allergenic and Carcinogenic Dyes in Industrial, Cosmetics, Personal Care, and Consumer Products

### EXPERIMENTAL

#### LC conditions


|                   |  |           |           |
|-------------------|--|-----------|-----------|
| System:           | ACQUITY UPLC H-Class with Xevo TQD Mass Spectrometer |           |           |
| Column:           | XBridge BEH C <sub>18</sub> , 3.5 μm, 2.1 x 150 mm   |           |           |
| Mobile phase A:   | Water (5 mmol/L ammonium acetate)                    |           |           |
| Mobile phase B:   | Acetonitrile (5 mmol/L ammonium acetate)             |           |           |
| Gradient:         | <u>Time</u>  | <u>%A</u> | <u>%B</u> |
|                   | 0.00   | 90        | 10        |
|                   | 1.00   | 70        | 30        |
|                   | 4.00   | 60        | 40        |
|                   | 9.00   | 5         | 95        |
|                   | 12.00  | 5         | 95        |
|                   | 12.10  | 90        | 10        |
|                   | 17.00  | 90        | 10        |
| Flow rate:        | 0.3 mL/min   |           |           |
| Column temp.:     | 30 °C  |           |           |
| Injection volume: | 5 μL   |           |           |
| Ionization mode:  | ESI+ and ESI-  |           |           |
| Acquisition mode: | MRM  |           |           |

#### Sample preparation

Textile (0.5 g) was cut up and extracted with 20 mL of methanol for 15 minutes using an ultrasonic bath (50 °C). One hundred microliters of the extract was transferred in an LC vial and diluted with 900 μL of water.

Sample temp.: 10 °C

- |                      |                         |                        |
|----------------------|-------------------------|------------------------|
| 1. Acid red 26       | 9. Disperse blue 35     | 17. Disperse red 1     |
| 2. Basic red 9       | 10. Disperse blue 7     | 18. Disperse red 11    |
| 3. Basic violet 14   | 11. Disperse brown 1    | 19. Disperse red 17    |
| 4. Direct red 28     | 12. Disperse orange 1   | 20. Disperse yellow 1  |
| 5. Disperse blue 102 | 13. Disperse orange 11  | 21. Disperse yellow 23 |
| 6. Disperse blue 106 | 14. Disperse orange 149 | 22. Disperse yellow 3  |
| 7. Disperse blue 124 | 15. Disperse orange 3   | 23. Disperse yellow 39 |
| 8. Disperse blue 3   | 16. Disperse orange 37  | 24. Disperse yellow 49 |



#### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH C <sub>18</sub> , 3.5 μm, 2.1 x 150 mm Column | <a href="#">186003023</a>   |
| TruView LCMS Certified Vial w/ Preslit Septa              | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [720004078EN](#) at waters.com

## Analysis of Amoxicillin Oral Suspension


### EXPERIMENTAL

#### LC conditions

|                   |   |
|-------------------|---|
| System:           | Alliance 2695   |
| Column:           | XBridge BEH Shield RP18,<br>5 µm, 4.6 x 250 mm  |
| Mobile phase:     | 98:2 diluent:acetonitrile   |
| Diluent:          | 50 mM potassium phosphate,<br>monobasic in water - pH 5.0 with<br>potassium hydroxide |
| Separation mode:  | Isocratic   |
| Flow rate:        | 1.5 mL/min  |
| Injection volume: | 10 µL   |
| UV detection:     | 230 nm  |

#### Sample preparation

Amoxicillin oral suspension powder, reconstituted in water (50 mg/mL), made up to 1 mg/mL in diluent, filtered through a 0.2 µm nylon filter prior to analysis.



### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH Shield RP18, 5 µm,<br>4.6 x 250 mm Column | <a href="#">186003010</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa       | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [XBRIDGE15](#) at waters.com

## Analysis of Antibacterials by HPLC


### EXPERIMENTAL

#### LC conditions

|                   |  |    |    |
|-------------------|--|----|----|
| System:           | Alliance 2695 with 2996 PDA detector             |    |    |
| Column:           | XBridge BEH Phenyl,<br>3.5 $\mu$ m, 4.6 x 100 mm |    |    |
| Mobile phase A:   | 20 mM monopotassium phosphate, pH 2.5            |    |    |
| Mobile phase B:   | Acetonitrile                                     |    |    |
| Gradient:         | Time   | %A | %B |
|                   | 0.00   | 80 | 20 |
|                   | 2.00   | 80 | 20 |
|                   | 7.00   | 75 | 25 |
|                   | 15.00  | 70 | 30 |
|                   | 16.00  | 80 | 20 |
|                   | 20.00  | 80 | 20 |
| Flow rate:        | 1 mL/min   |    |    |
| Column temp.:     | 30 °C  |    |    |
| Injection volume: | 10 $\mu$ L                                       |    |    |
| UV detection:     | 254 nm   |    |    |

#### Sample preparation

|               |   |
|---------------|---|
| Sample:       | Carbadox (10 $\mu$ g/mL),<br>Thiamphenicol (100 $\mu$ g/mL),<br>Furazolidone (10 $\mu$ g/mL),<br>Oxolinic acid (10 $\mu$ g/mL),<br>Sulfadimethoxine (10 $\mu$ g/mL),<br>Sulfaquinoxaline (10 $\mu$ g/mL),<br>Nalidixic acid (10 $\mu$ g/mL)<br>in $\text{KH}_2\text{PO}_4/\text{ACN}$ (80/20) |
| Sample temp.: | 15 °C   |



#### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH Phenyl, 3.5 $\mu$ m,<br>4.6 x 100 mm Column | <a href="#">186003334</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa         | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [WA64696](#) at waters.com

## Analysis of Antibacterials by UHPLC

### EXPERIMENTAL

#### LC conditions

|                   |  |
|-------------------|--|
| System:           | ACQUITY UPLC H-Class with ACQUITY UPLC PDA Detector  |
| Columns:          | CORTECS C <sub>18</sub> , 2.7 µm, 4.6 x 50 mm; Fully-porous C <sub>18</sub> , 5 µm, 4.6 x 100 mm |
| Mobile phase A:   | 0.1% formic acid in water  |
| Mobile phase B:   | 0.1% formic acid in acetonitrile   |
| Gradient:         | Linear from 5–50% B  |
| Flow rate:        | 1 mL/min, 2 mL/min   |
| Column temp.:     | 30 °C  |
| Injection volume: | 3 µL, 1.5 µL   |
| UV detection:     | 254 nm   |


#### Sample preparation

Sample diluent: 20% acetonitrile in water

### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| CORTECS C <sub>18</sub> , 2.7 µm, 4.6 x 50 mm Column | <a href="#">186007375</a>   |
| TruView LCMS Certified Vial w/ Preslit Septa         | <a href="#">186005666CV</a> |

#### Antibacterials



For complete experimental details, refer to full application note [WA64118](#) at waters.com

## Analysis of Ascorbic and Isoascorbic Acid by Gradient HPLC

### EXPERIMENTAL

#### LC conditions

System: Alliance HPLC with 2998 PDA detector

Column: XBridge BEH Amide,  
3.5  $\mu$ m, 4.6 x 250 mm

Mobile phase A: 50/50 acetonitrile/water with  
10 mM ammonium acetate, pH 5.0

Mobile phase B: 90/10 acetonitrile/water with  
10 mM ammonium acetate, pH 5.0

| Gradient: | Time  | %A   | %B   |
|-----------|-------|------|------|
|           | 0.00  | 0.1  | 99.9 |
|           | 48.00 | 99.9 | 0.1  |
|           | 48.10 | 0.1  | 99.9 |
|           | 72.00 | 0.1  | 99.9 |

Flow rate: 0.5 mL/min

Column temp.: 25 °C


Injection volume: 60.0  $\mu$ L

UV detection: 260 nm

#### Sample preparation

Sample was diluted with 50:50 acetonitrile/water and filtered using 0.45  $\mu$ m PVDF syringe filter.

Sample concentration: 30  $\mu$ g/mL



### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| XBridge BEH Amide, 3.5 $\mu$ m,<br>4.6 x 250 mm Column         | <a href="#">186004870</a>   |
| Acrodisc, Syringe Filter,<br>PVDF, 13 mm, 0.45 $\mu$ m, 100/pk | <a href="#">WAT200512</a>   |
| Waters LCMS Certified Vial                                     | <a href="#">600000751CV</a> |

For complete experimental details, refer to full application note [WA6419](#) at waters.com

## Analysis of Ascorbic and Isoascorbic Acid by Isocratic HPLC

### EXPERIMENTAL


#### LC conditions

|                   |   |
|-------------------|---|
| System:           | Alliance HPLC with 2998 PDA detector                          |
| Column:           | XBridge Amide, 3.5 µm, 4.6 x 250 mm                           |
| Mobile phase:     | 80/20 acetonitrile/water with<br>2 mM monopotassium phosphate |
| Separation mode:  | Isocratic   |
| Flow rate:        | 0.5 mL/min  |
| Column temp.:     | 25 °C   |
| Injection volume: | 60.0 µL   |
| UV detection:     | 260 nm  |

#### Sample preparation

Sample was diluted with 50:50 acetonitrile/water and filtered using 0.45 µm PVDF syringe filter.

Sample concentration: 30 µg/mL



### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH Amide, 3.5 µm,<br>4.6 x 250 mm Column         | <a href="#">186004870</a>   |
| Acrodisc, Syringe Filter,<br>PVDF, 13 mm, 0.45 µm, 100/pk | <a href="#">WAT200512</a>   |
| Waters LCMS Certified Vial                                | <a href="#">600000751CV</a> |

For complete experimental details, refer to full application note [720004440EN](#) at waters.com

## Analysis of Avermectins in Meat

### EXPERIMENTAL

#### LC conditions

|                   |   |           |           |
|-------------------|---|-----------|-----------|
| System:           | ACQUITY UPLC with Xevo TQ-S Mass Spectrometer   |           |           |
| Column:           | XSelect CSH C <sub>18</sub> <b>XP</b> , 2.5 μm, 2.1 x 100 mm  |           |           |
| Mobile phase A:   | 5 mM ammonium acetate in water  |           |           |
| Mobile phase B:   | 5 mM ammonium acetate in methanol   |           |           |
| Gradient:         | <u>Time</u>   | <u>%A</u> | <u>%B</u> |
|                   | 0.00  | 30        | 70        |
|                   | 5.00  | 3         | 97        |
|                   | 8.00  | 3         | 97        |
|                   | 8.10  | 30        | 70        |
|                   | 10.00   | 30        | 70        |
| Flow rate:        | 0.40 mL/min   |           |           |
| Column temp.:     | 35 °C   |           |           |
| Injection volume: | 5 μL  |           |           |
| Ionization mode:  | ESI+  |           |           |
| Acquisition mode: | MRM (m/z): abamectin 890.5 > 305.5; ivermectin 892.5 > 307.5; doramectin 916.5 > 331.2; epinomectin 914.5 > 186.2; moxidectin 640.3 > 528.3 |           |           |


#### Sample preparation

##### Initial Extraction (QuEChERS)

Place 8 g ground beef (80% lean) and 2 mL water into a 50 mL centrifuge tube. Add 10 mL acetonitrile and shake the tube vigorously for 1 minute. Add the contents of DisQuE Pouch salts for European Committee for Standardization (CEN) QuEChERS and shake vigorously for 1 minute. Centrifuge for 15 minutes at 4000 rpm and take a 1 mL aliquot of the supernatant (top layer) for d-SPE cleanup.

##### d-SPE Cleanup

Transfer the 1 mL aliquot of supernatant to a 2-mL d-SPE cleanup tube that contains 150 mg magnesium sulfate and 50 mg C<sub>18</sub> sorbent and shake vigorously for 1 minute. Centrifuge for 5 minutes at 12,000 rpm and take a 0.5 mL aliquot sample for LC-MS/MS analysis.



#### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XSelect CSH C <sub>18</sub> <b>XP</b> , 2.5 μm, 2.1 x 100 mm Column | <a href="#">186005275</a>   |
| DisQuE QuEChERS Pouch   | <a href="#">186006813</a>   |
| DisQuE QuEChERS 50 mL Centrifuge Tube                               | <a href="#">186004837</a>   |
| Waters LCMS Certified Maximum Recovery Vial w/ Preslit Septa        | <a href="#">600000670CV</a> |

For complete experimental details, refer to full application note [720004440EN](#) at waters.com

## Analysis of Avermectins in Milk

### EXPERIMENTAL

#### LC conditions

|                   |  |    |    |
|-------------------|--|----|----|
| System:           | ACQUITY UPLC with Xevo TQ-S Mass Spectrometer  |    |    |
| Column:           | XSelect CSH C <sub>18</sub> XP, 2.5 μm, 2.1 x 100 mm   |    |    |
| Mobile phase A:   | 5 mM ammonium acetate in water   |    |    |
| Mobile phase B:   | 5 mM ammonium acetate in methanol  |    |    |
| Gradient:         | Time   | %A | %B |
|                   | 0.00   | 30 | 70 |
|                   | 5.00   | 3  | 97 |
|                   | 8.00   | 3  | 97 |
|                   | 8.10   | 30 | 70 |
|                   | 10.00  | 30 | 70 |
| Flow rate:        | 0.40 mL/min  |    |    |
| Column temp.:     | 35 °C  |    |    |
| Injection volume: | 5 μL   |    |    |
| Ionization mode:  | ESI+   |    |    |
| Acquisition mode: | MRM (m/z): abamectin 890.5 > 305.5; ivermectin 892.5 > 307.5; doramectin 916.5 > 331.2; eprinomectin 914.5 > 186.2; moxidectin 640.3 > 528.3 |    |    |


#### Sample preparation

##### Initial Extraction (QuEChERS)

Place 10 mL whole milk (pasteurized) into a 50 mL centrifuge tube. Add 10 mL acetonitrile and shake the tube vigorously for 1 minute. Add the contents of DisQuE Pouch salts for European Committee for Standardization (CEN) QuEChERS and shake vigorously for 1 minute. Centrifuge for 15 minutes at 4000 rpm and take a 1 mL aliquot of the supernatant (top layer) for d-SPE cleanup.

##### d-SPE Cleanup

Transfer the 1 mL aliquot of supernatant to a 2-mL d-SPE cleanup tube that contains 150 mg magnesium sulfate and 50 mg C18 sorbent and shake vigorously for 1 minute. Centrifuge for 5 minutes at 12,000 rpm and take a 0.5 mL aliquot sample for LC-MS/MS analysis.



Top trace is the low level spiked sample, bottom trace is a ground beef blank.

### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| XSelect CSH C <sub>18</sub> XP, 2.5 μm, 2.1 x 100 mm Column  | <a href="#">186005275</a>   |
| DisQuE QuEChERS Pouch  | <a href="#">186006813</a>   |
| DisQuE QuEChERS 50 mL Centrifuge Tube                        | <a href="#">186004837</a>   |
| Waters LCMS Certified Maximum Recovery Vial w/ Preslit Septa | <a href="#">600000670CV</a> |

For complete experimental details, refer to full application note [720002825EN](#) at waters.com

## Analysis of Basic Compounds

### EXPERIMENTAL

#### LC conditions

System: Alliance 2695 with

2998 PDA detector

Column: SunFire C<sub>18</sub>, 2.5 μm, 4.6 x 75 mm

Mobile phase A: 10 mM ammonium formate, pH 3

Mobile phase B: 100% acetonitrile


| Gradient: | Time  | %A | %B |
|-----------|-------|----|----|
|           | 0.00  | 85 | 15 |
|           | 13.00 | 35 | 65 |
|           | 15.00 | 35 | 65 |
|           | 15.10 | 85 | 15 |
|           | 24.00 | 85 | 15 |

Flow rate: 1 mL/min

Column temp.: 30 °C

Injection volume: 10 μL

UV detection: 260 nm



#### Sample preparation

Standard mixture of basic compounds (1) uracil, (2) pindolol, (3) quinine, (4) labetalol, (5) prednisone, (6) diltiazem, (7) amitriptyline.

#### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| SunFire C <sub>18</sub> , 2.5 μm,<br>4.6 x 75 mm Column | <a href="#">186003419</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa         | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [WA60707](#) at waters.com

## Analysis of Basic Drugs in River Water

### EXPERIMENTAL

#### LC conditions

|                   |  |                  |    |    |
|-------------------|--|------------------|----|----|
| System:           | ACQUITY UPLC H-Class with Xevo TQD Mass Spectrometer           |                  |    |    |
| Column:           | CORTECS HILIC, 2.7 µm, 2.1 x 100 mm                            |                  |    |    |
| Mobile phase A:   | Water + 0.1% acetic acid/ammonium acetate buffer (1 g/L water) |                  |    |    |
| Mobile phase B:   | Acetonitrile   |                  |    |    |
| Gradient:         | <u>Time</u>  | <u>Flow Rate</u> |    |    |
|                   |  | (mL/min)         | %A | %B |
| Initial           | 0.280  | 2                | 98 | —  |
| 4.50              | 0.280  | 30               | 70 | 6  |
| 10.80             | 0.280  | 30               | 70 | 6  |
| 11.25             | 0.280  | 2                | 98 | 6  |
| 14.40             | 0.280  | 2                | 98 | 6  |
| 14.50             | 0.280  | 2                | 98 | 6  |
| Flow rate:        | 0.28 mL/min  |                  |    |    |
| Column temp.:     | 45 °C  |                  |    |    |
| Ionization mode:  | ESI+   |                  |    |    |
| Acquisition mode: | MRM  |                  |    |    |


#### Sample preparation

Sample: Basic drugs from river water

Two hundred milliliters river water (pH 5.0 with acetic acid) prepared using Oasis MCX 6 cc Vac Cartridge, 150 mg sorbent per cartridge, 30 µm particle size.

### ORDERING INFORMATION

| Description                                  | P/N                         |
|--|-----------------------------|
| CORTECS HILIC, 2.7 µm, 2.1 x 100 mm Column   | <a href="#">186007382</a>   |
| Oasis MCX 6 cc Vac Cartridge                 | <a href="#">186000256</a>   |
| TruView LCMS Certified Vial w/ Preslit Septa | <a href="#">186005666CV</a> |



For complete experimental details, refer to full application note [WA64694](#) at waters.com

## Analysis of Basic Impurities


### EXPERIMENTAL

#### LC conditions

|                   |   |           |           |              |
|-------------------|---|-----------|-----------|--------------|
| System:           | Alliance HPLC with 2998 PDA detector            |           |           |              |
| Column:           | CORTECS C <sub>18</sub> +, 2.7 μm, 4.6 x 150 mm |           |           |              |
| Mobile phase A:   | 0.1% formic acid in water                       |           |           |              |
| Mobile phase B:   | 0.1% formic acid in acetonitrile                |           |           |              |
| Gradient:         | <u>Time</u>                                     | <u>%A</u> | <u>%B</u> | <u>Curve</u> |
|                   | 0.0   | 75        | 25        | -            |
|                   | 11.3  | 65        | 35        | 6            |
|                   | 12.0  | 65        | 35        | 6            |
|                   | 12.1  | 75        | 25        | 6            |
|                   | 15.0  | 75        | 25        | 6            |
| Flow rate:        | 1.5 mL/min                                      |           |           |              |
| Column temp.:     | 30 °C   |           |           |              |
| Injection volume: | 36 μL   |           |           |              |
| UV detection:     | 254 nm  |           |           |              |

#### Sample preparation

|         |   |
|---------|---|
| Sample: | Imipramine (0.5 mg/mL), with various concentrations of amitriptyline (10 μg/mL, 5 μg/mL, and 0.5 μg/mL) prepared in water |
|---------|---|



#### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| CORTECS C <sub>18</sub> +, 2.7 μm,<br>4.6 x 150 mm Column | <a href="#">186007408</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa           | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [720005062EN](#) at waters.com

## Analysis of Basic Impurities (*Solid-Core Technology Comparison*)

### EXPERIMENTAL

#### LC conditions

System: ACQUITY UPLC with PDA detector and TQD mass spectrometer

Columns: CORTECS C<sub>18</sub>+, 2.7 μm, 3.0 x 50 mm;  
Competitor solid-core C<sub>18</sub>, 2.6 μm,  
3.0 x 50 mm

Mobile phase A: 0.1% formic acid in water

Mobile phase B: 0.1% formic acid in acetonitrile

| Gradient: | Time | %A | %B |
|-----------|------|----|----|
|           | 0.00 | 75 | 25 |
|           | 3.00 | 65 | 35 |
|           | 3.10 | 75 | 25 |
|           | 4.10 | 75 | 25 |

Flow rate: 0.8 mL/min

Column temp.: 30 °C

Injection volume: 10.0 μL


UV detection: 254 nm

Ionization mode: ESI+

Acquisition mode: SIR (m/z) 278.4

#### Sample preparation

0.5 mg/mL imipramine and 0.5 μg/mL amitriptyline aqueous solution.



### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| CORTECS C <sub>18</sub> +, 2.7 μm,<br>3.0 x 50 mm Column | <a href="#">186007400</a>   |
| Waters LCMS Certified<br>Max Recovery Vial               | <a href="#">600000749CV</a> |

For complete experimental details, refer to full application note [XBRIDGE17](#) at waters.com

## Analysis of Beta Blockers


### EXPERIMENTAL

#### LC conditions

|                   |  |           |           |           |
|-------------------|--|-----------|-----------|-----------|
| System:           | Alliance 2695 with 2996 PDA detector             |           |           |           |
| Column:           | XBridge BEH Shield RP18,<br>3.5 µm, 4.6 x 100 mm |           |           |           |
| Mobile phase A:   | Water  |           |           |           |
| Mobile phase B:   | Methanol   |           |           |           |
| Mobile phase C:   | 100 mM ammonium bicarbonate, pH 9.0              |           |           |           |
| Gradient:         | <u>Time</u>                                      | <u>%A</u> | <u>%B</u> | <u>%C</u> |
|                   | 0.00   | 85        | 5         | 10        |
|                   | 3.00   | 55        | 35        | 10        |
|                   | 10.00  | 55        | 35        | 10        |
|                   | 11.00  | 85        | 5         | 10        |
|                   | 15.00  | 85        | 5         | 10        |
| Flow rate:        | 1.0 mL/min                                       |           |           |           |
| Column temp.:     | 30 °C  |           |           |           |
| Injection volume: | 10 µL  |           |           |           |
| UV detection:     | 280 nm   |           |           |           |

#### Sample preparation

Sample concentration and Diluent: 10 µg/mL in H<sub>2</sub>O



### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH Shield RP18, 3.5 µm,<br>4.6 x 100 mm Column | <a href="#">186003044</a>   |
| TruView LCMS Certified Vial<br>w/ PreSlit Septa         | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [720004129EN](#) at waters.com

## Anaysis of Budesonide Nasal Spray


### EXPERIMENTAL

#### LC conditions

|                   |  |
|-------------------|--|
| System:           | Alliance HPLC with 2489 UV/Visible detector  |
| Column:           | XBridge BEH C <sub>18</sub> , 5 µm, 4.6 x 150 mm   |
| Mobile phase:     | Acetonitrile and Solution A (32:68)  |
| Solution A:       | 3.17 mg/mL of monobasic sodium phosphate and 0.23 mg/mL of phosphoric acid; pH 3.2 +/- 0.1 |
| Separation mode:  | Isocratic  |
| Flow rate:        | 1.5 mL/min   |
| Injection volume: | 20 µL  |
| UV detection:     | 254 nm   |

#### Sample preparation

An amount equivalent to 1.0 g of Rhinocort AQUA (budesonide) nasal spray was accurately weighed and transferred to a 50-mL volumetric flask. Sixteen milliliters of acetonitrile was added to this flask. This mixture was mechanically shaken in the Burrell Wrist-Action shaker, Model 75 for 15 minutes. The mixture was diluted with Solution A to volume and mechanically shaken for an additional 10 minutes. This mixture was then subjected to centrifugation at 3220 rcf (4000 rpm) for 15 minutes. The supernatant was aliquoted into a 2-mL Waters Certified Glass Screw Cap Vial with bonded pre-slit PTFE/silicone septum (p/n [186000307C](#)). Final concentration of the working sample was 12.8 µg/mL.



#### ORDERING INFORMATION

| Description   | P/N                        |
|---|----------------------------|
| XBridge BEH C <sub>18</sub> , 5 µm, 4.6 x 150 mm Column | <a href="#">186003116</a>  |
| Waters LCGC Certified Vial w/ Preslit Septa             | <a href="#">186000307C</a> |

For complete experimental details, refer to full application note [WA64077](#) at waters.com

## Analysis of Buprenorphine and Buprenorphine Glucuronide

### EXPERIMENTAL


#### LC conditions

|                   |   |      |      |
|-------------------|---|------|------|
| System:           | ACQUITY UPLC with TQD detector  |      |      |
| Column:           | XBridge BEH HILIC, 3.5 $\mu$ m, 2.1 x 100 mm                                    |      |      |
| Mobile phase A:   | 10 mM ammonium formate in water, 0.125% formic acid in 50:50 acetonitrile:water |      |      |
| Mobile phase B:   | 10 mM ammonium formate in water, 0.125% formic acid in 90:10 acetonitrile:water |      |      |
| Gradient:         | Time  | %A   | %B   |
|                   | 0.00  | 0.1  | 99.9 |
|                   | 1.05  | 0.1  | 99.9 |
|                   | 4.35  | 99.9 | 0.1  |
|                   | 5.00  | 99.9 | 0.1  |
|                   | 5.01  | 0.1  | 99.9 |
|                   | 6.00  | 0.1  | 99.9 |
| Flow rate:        | 0.3 mL/min  |      |      |
| Column temp.:     | 30 °C   |      |      |
| Injection volume: | 5 $\mu$ L   |      |      |
| Acquisition mode: | MRM (m/z): buprenorphine 468.3 > 54.7; buprenorphine glucuronide 644.3 > 468.3  |      |      |

#### Sample preparation

Sample concentration: 50 ng/mL each

Sample diluent: 75:25 ACN:MeOH with 0.2% HCOOH



### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH HILIC, 3.5 $\mu$ m, 2.1 x 100 mm Column | <a href="#">186004433</a>   |
| TruView LCMS Certified Vial w/ Preslit Septa        | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [XBRIDGE6](#) at waters.com

## Analysis of Caffeine and Metabolites Using XBridge BEH C<sub>18</sub> Columns

### EXPERIMENTAL

#### LC conditions

System: Alliance 2695 with 2996 PDA detector

Column: XBridge BEH C<sub>18</sub>, 5 µm, 4.6 x 150 mm

Mobile phase A: 5 mM ammonium acetate, pH 7.5

Mobile phase B: Acetonitrile

| Gradient: | Time  | %A | %B |
|-----------|-------|----|----|
|           | 0.00  | 98 | 2  |
|           | 15.00 | 80 | 20 |
|           | 18.00 | 80 | 20 |
|           | 19.00 | 98 | 2  |
|           | 25.00 | 98 | 2  |

Flow rate: 1.0 mL/min

Column temp.: 25 °C

Injection volume: 10 µL


UV detection: 273 nm

#### Sample preparation


Sample concentration: 20 µg/mL in water

#### ORDERING INFORMATION


| Description  | P/N                         |
|--|-----------------------------|
| XBridge BEH C <sub>18</sub> , 5 µm,<br>4.6 x 150 mm Column | <a href="#">186003116</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa            | <a href="#">186005666CV</a> |




1. Xanthine




2. Theobromine



3. Theophylline



4. Caffeine



For complete experimental details, refer to full application note [XBRIDGE11](#) at waters.com

## Analysis of Caffeine Metabolites Using XBridge BEH Phenyl Columns


### EXPERIMENTAL

#### LC conditions

|                   |   |    |    |    |
|-------------------|---|----|----|----|
| System:           | Alliance 2695 with 2996 PDA detector        |    |    |    |
| Columns:          | XBridge BEH Phenyl,<br>3.5 µm, 4.6 x 100 mm |    |    |    |
| Mobile phase A:   | Water                                       |    |    |    |
| Mobile phase B:   | Acetonitrile                                |    |    |    |
| Mobile phase C:   | 100 mM ammonium bicarbonate                 |    |    |    |
| Gradient:         | Time  | %A | %B | %C |
|                   | 0.00  | 89 | 1  | 10 |
|                   | 9.00  | 66 | 24 | 10 |
|                   | 10.00                                       | 89 | 1  | 10 |
|                   | 20.00                                       | 89 | 1  | 10 |
| Flow rate:        | 1.0 mL /min                                 |    |    |    |
| Column temp.:     | 30 °C                                       |    |    |    |
| Injection volume: | 10 µL                                       |    |    |    |
| UV detection:     | 280 nm                                      |    |    |    |

#### Sample preparation

|               |  |
|---------------|--|
| Sample:       | Caffeine (10 µg/mL),<br>Theobromine (10 µg/mL),<br>1-Methylxanthine (10 µg/mL),<br>1,3-Dimethyluric acid (10 µg/mL),<br>1,7-Dimethylxanthine (10 µg/mL),<br>1,7-Dimethyluric acid (10 µg/mL)<br>in H <sub>2</sub> O/NH <sub>4</sub> HCO <sub>3</sub> (90/10) |
| Sample temp.: | 15 °C  |



#### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| XBridge BEH Phenyl, 3.5 µm,<br>4.6 x 100 mm Column | <a href="#">186003334</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa    | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [720002732EN](#) at waters.com

## Analysis of Carbonyl Compounds in Drinking Water


### EXPERIMENTAL

#### LC conditions

|                 |   |      |    |    |       |
|-----------------|---|------|----|----|-------|
| System:         | Alliance HPLC with UV detection   |      |    |    |       |
| Column:         | XBridge BEH Phenyl,<br>3.5 $\mu$ m, 4.6 x 150 mm  |      |    |    |       |
| Mobile phase A: | Water/tetrahydrofuran (THF) 90:10   |      |    |    |       |
| Mobile phase B: | Acetonitrile  |      |    |    |       |
| Gradient:       | Eluent gradient for EPA methods 554 and 8315 Option 1.  |      |    |    |       |
|                 | Time  | Flow | %A | %B | Curve |
|                 | Initial   | 1.5  | 70 | 30 | -     |
|                 | 20.0  | 1.5  | 36 | 64 | 6     |
|                 | 22.0  | 1.5  | 36 | 64 | 6     |
|                 | 22.1  | 1.5  | 70 | 30 | 6     |
|                 | Eluent gradient for EPA methods TO11 and 8315 Option 2  |      |    |    |       |
|                 | Time  | Flow | %A | %B | Curve |
|                 | Initial   | 1.5  | 70 | 30 | -     |
|                 | 16.0  | 1.5  | 53 | 47 | 6     |
|                 | 21.0  | 1.5  | 53 | 47 | 6     |
|                 | 21.1  | 1.5  | 70 | 30 | 6     |
| Flow rate:      | 1.5 mL/min  |      |    |    |       |
| Column temp.:   | 35 °C   |      |    |    |       |
| Injection:      | 20 $\mu$ L each of AccuStandard mix (M- 8315-R1- DNPH and M- 8315-R2- DNPH) diluted 1:5 in 40:60 water/acetonitrile |      |    |    |       |
| UV detection:   | 360 nm  |      |    |    |       |

#### Sample preparation

DNPH reagent added to 100 mL sample, extract with Oasis HLB or use methylene chloride extraction option.



#### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| XBridge BEH Phenyl, 3.5 $\mu$ m, 4.6 x 150 mm Column | <a href="#">186003335</a>   |
| Oasis HLB, 3 cc, 60 mg Cartridge                     | <a href="#">WAT094226</a>   |
| TruView LCMS Certified Vial w/ Preslit Septa         | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [XBRIDGE14](#) at [waters.com](#)

## Analysis of Catechins

### EXPERIMENTAL

#### LC conditions

System: Alliance 2695 with 2996 PDA detector

Columns: XBridge BEH Phenyl,  
3.5  $\mu$ m, 4.6 x 150 mm

Mobile phase A: Water

Mobile phase B: Methanol

Mobile phase C: 0.2% formic acid in water

| Gradient: | Time  | %A | %B | %C |
|-----------|-------|----|----|----|
|           | 0.00  | 84 | 15 | 1  |
|           | 8.00  | 84 | 15 | 1  |
|           | 15.00 | 62 | 37 | 1  |
|           | 20.00 | 62 | 37 | 1  |
|           | 26.00 | 84 | 15 | 1  |
|           | 30.00 | 84 | 15 | 1  |

Flow rate: 0.8 mL/min

Column temp.: 30 °C


Injection volume: 20  $\mu$ L

UV detection: 280 nm

#### Sample preparation

Sample: Gallic acid (10  $\mu$ g/mL),  
Epigallocatechin (50  $\mu$ g/mL),  
Catechin (50  $\mu$ g/mL), Caffeine (10  $\mu$ g/mL),  
Epigallocatechin gallate (50  $\mu$ g/mL),  
Gallocatechin gallate (50  $\mu$ g/mL),  
Epicatechin gallate (10  $\mu$ g/mL),  
Catechin gallate (50  $\mu$ g/mL),  
in H<sub>2</sub>O/ MeOH (85/15)

Sample temp.: 15 °C



#### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| XBridge BEH Phenyl , 3.5 $\mu$ m,<br>4.6 x 150 mm Column | <a href="#">186003335</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa          | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [XBRIDGEZ](#) at waters.com

## Analysis of Catecholamines Using XBridge BEH C<sub>18</sub> Columns

### EXPERIMENTAL

#### LC conditions


|                   |  |
|-------------------|--|
| System:           | Alliance 2695 with 2996 PDA detector                     |
| Column:           | XBridge BEH C <sub>18</sub> , 5 µm, 4.6 x 150 mm         |
| Mobile phase:     | 20 mM sodium phosphate buffer,<br>pH 2.5/methanol (97/3) |
| Separation mode:  | Isocratic  |
| Flow rate:        | 1.5 mL/min   |
| Column temp.:     | 25 °C  |
| Injection volume: | 10 µL  |
| UV detection:     | 210 nm   |

#### Sample preparation


Sample concentration: 20 µg/mL in water

### ORDERING INFORMATION


| Description  | P/N                         |
|--|-----------------------------|
| XBridge BEH C <sub>18</sub> , 5 µm,<br>4.6 x 150 mm Column | <a href="#">186003116</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa            | <a href="#">186005666CV</a> |




1. Norepinephrine




2. Epinephrine



3. Normetanephrine



4. Dopamine



For complete experimental details, refer to full application note [XBRIDGE18](#) at waters.com

## Analysis of Catecholamines Using XBridge BEH Shield RP18 Columns

### EXPERIMENTAL

#### LC conditions

System: Alliance 2695 with 2996 PDA detector

Column: XBridge BEH Shield RP18,  
3.5 µm, 4.6 x 100 mm

Mobile phase A: Water

Mobile phase B: Acetonitrile

Mobile phase C: 100 mM ammonium formate, pH 3.0

| Gradient: | Time  | %A | %B | %C |
|-----------|-------|----|----|----|
|           | 0.00  | 90 | 0  | 10 |
|           | 5.00  | 90 | 0  | 10 |
|           | 15.00 | 65 | 25 | 10 |
|           | 16.00 | 65 | 25 | 10 |
|           | 17.00 | 90 | 0  | 10 |
|           | 20.00 | 90 | 0  | 10 |

Flow rate: 1.0 mL /min

Column temp.: 30 °C


Injection volume: 10 µL

UV detection: 280 nm

#### Sample preparation

Sample concentration

and diluent: 10 µg/mL in H<sub>2</sub>O



#### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH Shield RP18, 3.5 µm,<br>4.6 x 100 mm Column | <a href="#">186003044</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa         | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [WA64102](#) at waters.com

## Analysis of Cellulosic Hydrolysates by ELSD

### EXPERIMENTAL

#### LC conditions

System: Alliance HPLC with 2424 ELSD

Column: XBridge BEH Amide,  
3.5 µm, 4.6 x 250 mm

Mobile phase A: 80/20 acetonitrile/water with  
0.2 % triethylamine

Mobile phase B: 30/70 acetonitrile/water with  
0.2 % triethylamine

| Gradient: | <u>Time</u> | <u>%A</u> | <u>%B</u> |
|-----------|-------------|-----------|-----------|
|           | 0.00        | 100       | 0         |
|           | 21.00       | 40        | 60        |
|           | 21.01       | 100       | 0         |
|           | 33.00       | 100       | 0         |

Flow rate: 1.0 mL/min

Column temp.: 35 °C

Injection volume: 15.0 µL

ELSD pressure: 30 psi

Drift tube temp.: 50 °C


#### Sample preparation

Sample was diluted with 50:50 acetonitrile/water and filtered using 0.45 µm PVDF syringe filter.

Sample concentration: 0.8 mg/mL each

### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH Amide, 3.5 µm,<br>4.6 x 250 mm Column         | <a href="#">186004870</a>   |
| Acrodisc, Syringe Filter, PVDF, 13<br>mm, 0.45 µm, 100/pk | <a href="#">WAT200512</a>   |
| Waters LCMS Certified Vial                                | <a href="#">600000751CV</a> |



For complete experimental details, refer to full application note [XBRIDGE2](#) at waters.com

## Analysis of Cephalosporin Antibiotics

### EXPERIMENTAL

#### LC conditions



|                   |  |
|-------------------|--|
| System:           | Alliance 2695 with 2996 PDA detector             |
| Column:           | XBridge BEH C <sub>18</sub> , 5 µm, 4.6 x 150 mm |
| Mobile phase:     | 0.5% acetic acid/acetonitrile (85/15)            |
| Separation mode:  | Isocratic  |
| Flow rate:        | 1.0 mL/min                                       |
| Column temp.:     | 25 °C  |
| Injection volume: | 10 µL  |
| UV detection:     | 254 nm   |

#### Sample preparation

Sample concentration: 20 µg/mL in water

### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| XBridge BEH C <sub>18</sub> , 5 µm,<br>4.6 x 150 mm Column | <a href="#">186003116</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa            | <a href="#">186005666CV</a> |



For complete experimental details, refer to full application note [720004461EN](#) at waters.com

## Analysis of Clarithromycin


### EXPERIMENTAL

#### LC conditions

|                   |   |
|-------------------|---|
| System:           | Alliance 2695   |
| Column:           | XSelect CSH C <sub>18</sub> XP, 2.5 µm, 4.6 x 75 mm                             |
| Mobile phase:     | 65:35 methanol:67 mM monobasic potassium phosphate, pH 4.0 with phosphoric acid |
| Separation mode:  | Isocratic   |
| Flow rate:        | 1.0 mL/min  |
| Column temp.:     | 50 °C   |
| Injection volume: | 10 µL   |
| UV detection:     | 210 nm  |

#### Sample preparation

Clarithromycin sample: clarithromycin and clarithromycin related compound A USP standards were prepared in the mobile phase to a concentration of 0.5 mg/mL. The sample was placed in a TruView Maximum Recovery Vial for injection.



### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| XSelect CSH C <sub>18</sub> XP, 2.5 µm, 4.6 x 75 mm Column | <a href="#">186006110</a>   |
| TruView LCMS Certified Vial w/ Preslit Septa               | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [WA64080](#) at waters.com

## Analysis of Cytosine, 5-Fluorocytosine, and Uracil


### EXPERIMENTAL

#### LC conditions

|                   |  |    |    |       |
|-------------------|--|----|----|-------|
| System:           | ACQUITY UPLC with TUV detector                                 |    |    |       |
| Column:           | XBridge BEH HILIC, 3.5 $\mu$ m, 2.1 x 50 mm                    |    |    |       |
| Mobile phase A:   | 95:5 acetonitrile:water with<br>10 mM ammonium acetate pH 5.5  |    |    |       |
| Mobile phase B:   | 50:50 acetonitrile:water with<br>10 mM ammonium acetate pH 5.5 |    |    |       |
| Gradient:         | Time   | %A | %B | Curve |
|                   | 0.00   | 99 | 1  | 6     |
|                   | 2.00   | 1  | 99 | 6     |
|                   | 2.10   | 99 | 1  | 6     |
|                   | 2.50   | 99 | 1  | 6     |
| Flow rate:        | 0.5 mL/min   |    |    |       |
| Column temp.:     | 30 °C  |    |    |       |
| Injection volume: | 2.0 $\mu$ L  |    |    |       |
| UV detection:     | 254 nm   |    |    |       |

#### Sample preparation

Sample diluent: 75:25 acetonitrile:methanol



### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH HILIC, 3.5 $\mu$ m,<br>2.1 x 50 mm Column | <a href="#">186004432</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa       | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [XBRIDGE20](#) at waters.com

## Analysis of Dextromethorphan, Tetracaine, Triprolidine, and Warfarin


### EXPERIMENTAL

#### LC conditions

|                   |  |    |    |
|-------------------|--|----|----|
| System:           | Alliance 2695 with 2996 PDA detector                 |    |    |
| Column:           | XBridge BEH Shield RP18,<br>3.5 $\mu$ m, 4.6 x 50 mm |    |    |
| Mobile phase A:   | 25 mM monopotassium phosphate, pH 7                  |    |    |
| Mobile phase B:   | Methanol   |    |    |
| Gradient:         | Time   | %A | %B |
|                   | 0.00   | 60 | 40 |
|                   | 7.00   | 20 | 80 |
|                   | 7.50   | 60 | 40 |
|                   | 10.00  | 60 | 40 |
| Flow rate:        | 1.0 mL/min   |    |    |
| Column temp.:     | 30 °C  |    |    |
| Injection volume: | 10 $\mu$ L   |    |    |
| UV detection:     | 280 nm   |    |    |

#### Sample preparation

Sample concentration  
and diluent: 10  $\mu$ g/mL in  $H_2O$



#### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH Shield RP18, 3.5 $\mu$ m,<br>4.6 x 50 mm Column | <a href="#">186003042</a>   |
| TruView LCMS Certified Vial<br>w/ PreSlit Septa             | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [720005552EN](#) at waters.com

## Analysis of Disperse Dyes

### EXPERIMENTAL

#### LC conditions

System: ACQUITY Arc with ACQUITY QDa Detector

Column: XBridge BEH C<sub>18</sub>, 5 μm, 2.1 x 150 mm

Mobile phase A: Ammonium acetate 10 mmol pH 3.6

Mobile phase B: Acetonitrile

| Gradient: | Time  | %A | %B |
|-----------|-------|----|----|
|           | 0.00  | 60 | 40 |
|           | 7.00  | 40 | 60 |
|           | 17.00 | 2  | 98 |
|           | 24.00 | 2  | 98 |
|           | 24.10 | 60 | 40 |

Flow rate: 0.30 mL/min

Column temp.: 30 °C

Injection volume: 5 μL

UV detection: 210 to 800 nm

Ionization mode: ESI+



Acquisition mode: Full scan 100-600 m/z and SIR

#### Sample preparation

Dye standards were dissolved in methanol and sequentially diluted in preparation for sample analysis.

#### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| XBridge BEH C <sub>18</sub> , 5 μm,<br>2.1 x 150 mm Column | <a href="#">186003110</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa            | <a href="#">186005666CV</a> |



For complete experimental details, refer to full application note [XBRIDGE10](#) at [waters.com](#)

## Analysis of DNPH Derivatives

### EXPERIMENTAL

#### LC conditions

System: Alliance 2695 with 2996 PDA detector

Columns: XBridge BEH Phenyl,  
3.5 µm, 4.6 x 100 mm

Mobile phase A: Water

Mobile phase B: Acetonitrile

Mobile phase C: 0.2% formic acid in water

| Gradient: | Time  | %A | %B | %C |
|-----------|-------|----|----|----|
|           | 0.00  | 40 | 50 | 10 |
|           | 2.67  | 40 | 50 | 10 |
|           | 6.67  | 0  | 90 | 10 |
|           | 7.33  | 40 | 50 | 10 |
|           | 11.00 | 40 | 50 | 10 |

Flow rate: 1.2 mL /min

Column temp.: 30 °C


Injection volume: 10 µL

UV detection: 254 nm

#### Sample preparation

Sample: Acetaldehyde-DNPH (10 µg/mL),  
Acetone-DNPH (10 µg/mL),  
Cyclohexanone-DNPH (10 µg/mL),  
Formaldehyde-DNPH (10 µg/mL),  
Crotonaldehyde-DNPH (10 µg/mL) in  
H<sub>2</sub>O/ACN (60/40)

Sample temp.: 15 °C



#### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| XBridge BEH Phenyl, 3.5 µm,<br>4.6 x 100 mm Column | <a href="#">186003334</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa    | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [720005666EN](#) at waters.com

## Analysis of Dofetilide and Related Compounds

### EXPERIMENTAL

#### LC conditions

Systems: Alliance HPLC and ACQUITY UPLC H-Class

Column: Nova-Pak C<sub>8</sub>, 60Å, 4 µm, 3.9 x 150 mm

CORTECS C<sub>8</sub>, 90Å, 2.7 µm, 3.0 x 100 mm

CORTECS C<sub>8</sub>, 90Å, 2.7 µm, 3.0 x 75 mm

CORTECS C<sub>8</sub>, 90Å, 2.7 µm, 3.0 x 50 mm

Mobile phase: Acetonitrile:buffer solution (1:3)

Buffer solution: 1.36 g monobasic potassium phosphate and 5 mg ascorbic acid in 1 L water, adjusted with 0.01 M potassium hydroxide solution to pH 7.0

Separation mode: Isocratic

Flow rate: 1.00 mL/min (4 µm column), 0.88 mL/min (2.7 µm column)

Column temp.: 30 °C

Injection volume: 50 µL (150 mm column), 19.8 µL (100 mm column), 14.8 µL (75 mm column), 9.9 µL (50 mm column)


UV detection: 230 nm

#### Sample preparation

A sample containing dofetilide (25 µg/mL) and dofetilide related compound A (0.5 µg/mL) was prepared with mobile phase as the diluent.

### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| Nova-Pak C <sub>8</sub> , 4 µm, 3.9 x 150 mm Column  | <a href="#">WAT035876</a>   |
| CORTECS C <sub>8</sub> , 2.7 µm, 3.0 x 100 mm Column | <a href="#">186008361</a>   |
| CORTECS C <sub>8</sub> , 2.7 µm, 3.0 x 75 mm Column  | <a href="#">186008360</a>   |
| CORTECS C <sub>8</sub> , 2.7 µm, 3.0 x 50 mm Column  | <a href="#">186008359</a>   |
| TruView LCMS Certified Vial w/ Preslit Septa         | <a href="#">186005666CV</a> |



For complete experimental details, refer to full application note [720004261EN](#) at waters.com

## Analysis of Donepezil Tablets

### EXPERIMENTAL


#### LC conditions

|                   |  |    |    |
|-------------------|--|----|----|
| System:           | Alliance 2695  |    |    |
| Column:           | XBridge BEH C <sub>18</sub> , 5 µm, 4.6 x 250 mm                   |    |    |
| Mobile phase A:   | 0.1% phosphoric acid in water, adjust to pH 6.5 with triethylamine |    |    |
| Mobile phase B:   | Acetonitrile   |    |    |
| Gradient:         | Time   | %A | %B |
|                   | 0.00   | 75 | 25 |
|                   | 10.00  | 40 | 60 |
|                   | 40.00  | 40 | 60 |
|                   | 41.00  | 75 | 25 |
|                   | 50.00  | 75 | 25 |
| Flow rate:        | 1.5 mL/min   |    |    |
| Column temp.:     | 50 °C  |    |    |
| Injection volume: | 20 µL  |    |    |
| UV detection:     | 286 nm   |    |    |

#### Sample preparation

Donepezil (1 mg/mL) in diluent: Waters Analytical Standard

Donepezil Tablets (1 mg/mL): Crushed tablets were weighed in a 50-mL volumetric flask and 25-mL diluent was added. The sample was sonicated for 15 minutes and made up to volume with diluent. The sample was mixed well, filtered through a 0.2 µm PTFE filter, and centrifuged at 12,000 rpm for 5 minutes.



#### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| XBridge BEH C <sub>18</sub> , 5 µm,<br>4.6 x 250 mm Column | <a href="#">186003117</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa            | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [720004453EN](#) at waters.com

## Analysis of Drugs and Metabolites

### EXPERIMENTAL

#### LC conditions

System: ACQUITY UPLC with Xevo TQ-S Detector

Column: XBridge BEH C<sub>18</sub> XP, 2.5 μm, 2.1 x 50 mm

Mobile phase A: Water with 0.1% formic acid

Mobile phase B: Acetonitrile with 0.1% formic acid

| Gradient: | Time | %A | %B |
|-----------|------|----|----|
|           | 0.00 | 95 | 5  |
|           | 1.50 | 2  | 98 |
|           | 2.00 | 2  | 98 |
|           | 2.10 | 95 | 5  |
|           | 2.50 | 95 | 5  |

Flow rate: 500 μL/min

Column temp.: 30 °C

Injection volume: 5 μL

Ionization mode: ESI+

Acquisition mode: MRM

#### Sample preparation


Plasma samples containing parent drugs and metabolites were prepared by adding 20 μL each of working solutions of parent drugs and metabolites to 1 mL of plasma. All parent drugs were spiked at a concentration of 20 ng/mL, with the exception of testosterone, which was spiked at 100 ng/mL. Metabolites were spiked at 100%, 30%, 10%, and 0% of parent drug concentrations.

Sample temp.: 10 °C


#### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH C <sub>18</sub> XP, 2.5 μm,<br>2.1 x 50 mm Column | <a href="#">186006029</a>   |
| 96-well Plate with Deactivated<br>700 μL Glass Inserts        | <a href="#">186000349DV</a> |

A



B



For complete experimental details, refer to full application note [XBRIDGE19](#) at waters.com

## Analysis of Drugs of Abuse

### EXPERIMENTAL

#### LC conditions



|                   |  |    |    |    |
|-------------------|--|----|----|----|
| System:           | Alliance 2695 with 2996 PDA detector             |    |    |    |
| Column:           | XBridge BEH Shield RP18,<br>3.5 µm, 4.6 x 100 mm |    |    |    |
| Mobile phase A:   | Water  |    |    |    |
| Mobile phase B:   | Acetonitrile                                     |    |    |    |
| Mobile phase C:   | 100 mM ammonium bicarbonate, pH 9.6              |    |    |    |
| Gradient:         | Time   | %A | %B | %C |
|                   | 0.00   | 63 | 32 | 5  |
|                   | 3.00   | 63 | 32 | 5  |
|                   | 7.00   | 45 | 50 | 5  |
|                   | 9.00   | 45 | 50 | 5  |
|                   | 10.00  | 63 | 32 | 5  |
|                   | 12.00  | 63 | 32 | 5  |
| Flow rate:        | 0.6 mL/min                                       |    |    |    |
| Column temp.:     | 40 °C  |    |    |    |
| Injection volume: | 10 µL  |    |    |    |
| UV detection:     | 210 nm   |    |    |    |

#### Sample preparation

Sample concentration  
and diluent: 10 µg/mL in water

#### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH Shield RP18, 3.5 µm,<br>4.6 x 100 mm Column | <a href="#">186003044</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa         | <a href="#">186005666CV</a> |



For complete experimental details, refer to full application note [XBRIDGE1](#) at waters.com

## Analysis of Estradiol

### EXPERIMENTAL

#### LC conditions


|                   |  |
|-------------------|--|
| System:           | Alliance 2695 with 2996 PDA detector             |
| Column:           | XBridge BEH C <sub>18</sub> , 5 µm, 4.6 x 150 mm |
| Mobile phase:     | Water/acetonitrile (45/55)                       |
| Separation mode:  | Isocratic  |
| Flow rate:        | 1.0 mL/min                                       |
| Column temp.:     | 25 °C  |
| Injection volume: | 10 µL  |
| UV detection:     | 205 nm   |

#### Sample preparation


Sample concentration: 20 µg/mL in water/acetonitrile (50/50)

### ORDERING INFORMATION


| Description  | P/N                         |
|--|-----------------------------|
| XBridge BEH C <sub>18</sub> , 5 µm,<br>4.6 x 150 mm Column | <a href="#">186003116</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa            | <a href="#">186005666CV</a> |




1. Ethylparaben



2. Estradiol



3. Estrone



For complete experimental details, refer to full application note [WA60197](#) at waters.com

## Analysis of Flavonoids in Fruit Juice

### EXPERIMENTAL

#### LC conditions

System: Alliance 2695 with 996 PDA detector

Columns: XBridge BEH Shield RP18,  
5 µm, 4.6 x 150 mm  
XBridge BEH C<sub>8</sub>, 5 µm, 4.6 x 150 mm

Mobile phase A: 2% acetic acid

Mobile phase B: Acetonitrile

| Gradient: | Time  | %A | %B |
|-----------|-------|----|----|
|           | 0.00  | 90 | 10 |
|           | 15.00 | 86 | 14 |
|           | 20.00 | 82 | 18 |
|           | 30.00 | 75 | 25 |
|           | 55.00 | 45 | 55 |
|           | 67.00 | 5  | 95 |
|           | 80.00 | 5  | 95 |
|           | 85.00 | 90 | 10 |

Flow rate: 0.75 mL/min



Column temp.: Ambient

Injection: 20 µL

UV detection: 310 nm

### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH Shield RP18, 5 µm,<br>4.6 x 150 mm Column     | <a href="#">186003009</a>   |
| XBridge BEH C <sub>8</sub> , 5 µm,<br>4.6 x 150 mm Column | <a href="#">186003017</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa           | <a href="#">186005666CV</a> |



For complete experimental details, refer to full application note [WA64113](#) at waters.com

## Analysis of 5-Fluorouracil

### EXPERIMENTAL


#### LC conditions

|                   |  |
|-------------------|--|
| System:           | Alliance HPLC with 2998 PDA detector   |
| Column:           | XBridge Amide, 3.5 µm, 4.6 x 250 mm  |
| Mobile phase:     | 95/2.5/2.5 acetonitrile/<br>isopropyl alcohol/water with<br>5 mM ammonium acetate,<br>pH 9.0 |
| Separation mode:  | Isocratic  |
| Flow rate:        | 0.5 mL/min   |
| Column temp.:     | 25 °C  |
| Injection volume: | 50.0 µL  |
| UV detection:     | 265 nm   |

#### Sample preparation

Sample was diluted with 50:50 acetonitrile/water and filtered using 0.45 µm PVDF syringe filter.

Sample concentration: 100 µg/mL



### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH Amide, 3.5 µm,<br>4.6 x 250 mm Column         | <a href="#">186004870</a>   |
| Acrodisc, Syringe Filter,<br>PVDF, 13 mm, 0.45 µm, 100/pk | <a href="#">WAT200512</a>   |
| Waters LCMS Certified Vial                                | <a href="#">600000751CV</a> |

For complete experimental details, refer to full application note [XBRIDGE16](#) at waters.com

## Analysis of Food Additives and Preservatives


### EXPERIMENTAL

#### LC conditions

|                       |  |
|-----------------------|--|
| System:               | Alliance 2695 with 2996 PDA detector           |
| Columns:              | XBridge BEH Phenyl,<br>3.5 µm, 4.6 x 100 mm    |
| Mobile phase A:       | 20 mM KH <sub>2</sub> PO <sub>4</sub> , pH 2.5 |
| Mobile phase B:       | Acetonitrile                                   |
| Isocratic conditions: | 75% A; 25% B                                   |
| Flow rate:            | 1.0 mL/min                                     |
| Column temp.:         | 30 °C  |
| Injection volume:     | 10 µL  |
| UV detection:         | 240 nm   |

#### Sample preparation

|               |  |
|---------------|--|
| Sample:       | Saccharin (100 µg/mL),<br>P-hydroxybenzoic acid (10 µg/mL),<br>Dehydroacetic acid (100 µg/mL),<br>Methylparaben (25 µg/mL),<br>Sorbic acid (10 µg/mL) in<br>KH <sub>2</sub> PO <sub>4</sub> /ACN (75/25) |
| Sample temp.: | 15 °C  |



### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| XBridge BEH Phenyl, 3.5 µm,<br>4.6 x 100 mm Column | <a href="#">186003334</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa    | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [WA64094](#) at waters.com

## Analysis of Food Sugars in Sports Drink


### EXPERIMENTAL

#### LC conditions

|                       |   |
|-----------------------|---|
| System:               | Alliance HPLC with 2424 ELSD                              |
| Column:               | XBridge BEH Amide,<br>3.5 µm, 4.6 x 250 mm                |
| Mobile phase A:       | 80/20 acetonitrile/water<br>with 0.2% triethylamine       |
| Mobile phase B:       | 30/70 acetonitrile/water<br>with 0.2% triethylamine       |
| Isocratic conditions: | 90% A/10% B (75% acetonitrile<br>with 0.2% triethylamine) |
| Flow rate:            | 1.0 mL/min  |
| Column temp.:         | 35 °C   |
| Injection volume:     | 15.0 µL   |
| ELSD pressure:        | 30 psi  |
| Drift tube temp.:     | 50 °C   |

#### Sample preparation

Sample was diluted with 50:50 acetonitrile/water and filtered using 0.45 µm PVDF syringe filter.



### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH Amide, 3.5 µm,<br>4.6 x 250 mm Column         | <a href="#">186004870</a>   |
| Acrodisc, Syringe Filter,<br>PVDF, 13 mm, 0.45 µm, 100/pk | <a href="#">WAT200512</a>   |
| Waters LCMS Certified Vial                                | <a href="#">600000751CV</a> |

For complete experimental details, refer to full application note [WA64089](#) at waters.com

## Analysis of Food Sugars in Bran with Raisin Cereal


### EXPERIMENTAL

#### LC conditions

|                       |   |
|-----------------------|---|
| System:               | Alliance HPLC with 2424 ELSD                              |
| Column:               | XBridge BEH Amide,<br>3.5 $\mu$ m, 4.6 x 250 mm           |
| Mobile phase A:       | 80/20 acetonitrile/water<br>with 0.2% triethylamine       |
| Mobile phase B:       | 30/70 acetonitrile/water<br>with 0.2% triethylamine       |
| Isocratic conditions: | 90% A/10% B (75% acetonitrile<br>with 0.2% triethylamine) |
| Flow rate:            | 1.0 mL/min  |
| Column temp.:         | 35 °C   |
| Injection volume:     | 15.0 $\mu$ L  |
| ELSD pressure:        | 30 psi  |
| Drift tube temp.:     | 50 °C   |

#### Sample preparation

Add 25 mL of 50:50 acetonitrile/water to ~3 g sample, homogenize, centrifuge at 3200 rpm for 30 minutes, collect supernatant and filter using 0.45  $\mu$ m PVDF syringe filter.



### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH Amide, 3.5 $\mu$ m, 4.6 x 250 mm Column         | <a href="#">186004870</a>   |
| Acrodisc, Syringe Filter, PVDF, 13 mm, 0.45 $\mu$ m, 100/pk | <a href="#">WAT200512</a>   |
| Waters LCMS Certified Vial                                  | <a href="#">600000751CV</a> |

For complete experimental details, refer to full application note [WA64090](#) at waters.com

## Analysis of Food Sugars in Ketchup


### EXPERIMENTAL

#### LC conditions

|                       |   |
|-----------------------|---|
| System:               | Alliance HPLC with 2424 ELSD                              |
| Column:               | XBridge BEH Amide,<br>3.5 µm, 4.6 x 250 mm                |
| Mobile phase A:       | 80/20 acetonitrile/water<br>with 0.2% triethylamine       |
| Mobile phase B:       | 30/70 acetonitrile/water<br>with 0.2% triethylamine       |
| Isocratic conditions: | 90% A/10% B (75% acetonitrile<br>with 0.2% triethylamine) |
| Flow rate:            | 1.0 mL/min  |
| Column temp.:         | 35 °C   |
| Injection volume:     | 15.0 µL   |
| ELSD pressure:        | 30 psi  |
| Drift tube temp.:     | 50 °C   |

#### Sample preparation

Add 25 mL of 50:50 acetonitrile/water to ~3 g sample, homogenize, centrifuge at 3200 rpm for 30 minutes, collect supernatant and filter using 0.45 µm PVDF syringe filter.



### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH Amide, 3.5 µm,<br>4.6 x 250 mm Column         | <a href="#">186004870</a>   |
| Acrodisc, Syringe Filter,<br>PVDF, 13 mm, 0.45 µm, 100/pk | <a href="#">WAT200512</a>   |
| Waters LCMS Certified Vial                                | <a href="#">600000751CV</a> |

For complete experimental details, refer to full application note [WA64091](#) at waters.com

## Analysis of Food Sugars in Milk


### EXPERIMENTAL

#### LC conditions

|                       |   |
|-----------------------|---|
| System:               | Alliance HPLC with 2424 ELSD                              |
| Column:               | XBridge BEH Amide,<br>3.5 µm, 4.6 x 250 mm                |
| Mobile phase A:       | 80/20 acetonitrile/water<br>with 0.2% triethylamine       |
| Mobile phase B:       | 30/70 acetonitrile/water<br>with 0.2% triethylamine       |
| Isocratic conditions: | 90% A/10% B (75% acetonitrile<br>with 0.2% triethylamine) |
| Flow rate:            | 1.0 mL/min  |
| Column temp.:         | 35 °C   |
| Injection volume:     | 15.0 µL   |
| ELSD pressure:        | 30 psi  |
| Drift tube temp.:     | 50 °C   |

#### Sample preparation

Sample was diluted with 50:50 acetonitrile/water and filtered using 0.45 µm PVDF syringe filter.



### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH Amide, 3.5 µm,<br>4.6 x 250 mm Column         | <a href="#">186004870</a>   |
| Acrodisc, Syringe Filter,<br>PVDF, 13 mm, 0.45 µm, 100/pk | <a href="#">WAT200512</a>   |
| Waters LCMS Certified Vial                                | <a href="#">600000751CV</a> |

For complete experimental details, refer to full application note [WA64092](#) at waters.com

## Analysis of Food Sugars in Molasses


### EXPERIMENTAL

#### LC conditions

|                       |   |
|-----------------------|---|
| System:               | Alliance HPLC with 2424 ELSD                              |
| Column:               | XBridge BEH Amide,<br>3.5 µm, 4.6 x 250 mm                |
| Mobile phase A:       | 80/20 acetonitrile/water<br>with 0.2% triethylamine       |
| Mobile phase B:       | 30/70 acetonitrile/water<br>with 0.2% triethylamine       |
| Isocratic conditions: | 90% A/10% B (75% acetonitrile<br>with 0.2% triethylamine) |
| Flow rate:            | 1.0 mL/min  |
| Column temp.:         | 35 °C   |
| Injection volume:     | 15.0 µL   |
| ELSD pressure:        | 30 psi  |
| Drift tube temp.:     | 50 °C   |

#### Sample preparation

Sample was diluted with 50:50 acetonitrile/water and filtered using 0.45 µm PVDF syringe filter.



### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH Amide, 3.5 µm,<br>4.6 x 250 mm Column         | <a href="#">186004870</a>   |
| Acrodisc, Syringe Filter,<br>PVDF, 13 mm, 0.45 µm, 100/pk | <a href="#">WAT200512</a>   |
| Waters LCMS Certified Vial                                | <a href="#">600000751CV</a> |

For complete experimental details, refer to full application note [WA64096](#) at waters.com

## Analysis of Food Sugars in Potato Chips


### EXPERIMENTAL

#### LC conditions

|                       |   |
|-----------------------|---|
| System:               | Alliance HPLC with 2424 ELSD                              |
| Column:               | XBridge BEH Amide,<br>3.5 µm, 4.6 x 250 mm                |
| Mobile phase A:       | 80/20 acetonitrile/water<br>with 0.2% triethylamine       |
| Mobile phase B:       | 30/70 acetonitrile/water<br>with 0.2% triethylamine       |
| Isocratic conditions: | 90% A/10% B (75% acetonitrile<br>with 0.2% triethylamine) |
| Flow rate:            | 1.0 mL/min  |
| Column temp.:         | 35 °C   |
| Injection volume:     | 15.0 µL   |
| ELSD pressure:        | 30 psi  |
| Drift tube temp.:     | 50 °C   |

#### Sample preparation

Add 25 mL of 50:50 acetonitrile/water to ~3 g sample, homogenize, centrifuge at 3200 rpm for 30 minutes, collect supernatant and filter using 0.45 µm PVDF syringe filter.



### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH Amide, 3.5 µm,<br>4.6 x 250 mm Column         | <a href="#">186004870</a>   |
| Acrodisc, Syringe Filter,<br>PVDF, 13 mm, 0.45 µm, 100/pk | <a href="#">WAT200512</a>   |
| Waters LCMS Certified Vial                                | <a href="#">600000751CV</a> |

For complete experimental details, refer to full application note [WA64093](#) at waters.com

## Analysis of Food Sugars in Prepared Foods


### EXPERIMENTAL

#### LC conditions

|                       |   |
|-----------------------|---|
| System:               | Alliance HPLC with 2424 ELSD                              |
| Column:               | XBridge BEH Amide,<br>3.5 µm, 4.6 x 250 mm                |
| Mobile phase A:       | 80/20 acetonitrile/water<br>with 0.2% triethylamine       |
| Mobile phase B:       | 30/70 acetonitrile/water<br>with 0.2% triethylamine       |
| Isocratic conditions: | 90% A/10% B (75% acetonitrile<br>with 0.2% triethylamine) |
| Flow rate:            | 1.0 mL/min  |
| Column temp.:         | 35 °C   |
| Injection volume:     | 15.0 µL   |
| ELSD pressure:        | 30 psi  |
| Drift tube temp.:     | 50 °C   |

#### Sample preparation

Add 25 mL of 50:50 acetonitrile/water to ~3 g sample, homogenize, centrifuge at 3200 rpm for 30 minutes, collect supernatant and filter using 0.45 µm PVDF syringe filter.



### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH Amide, 3.5 µm,<br>4.6 x 250 mm Column         | <a href="#">186004870</a>   |
| Acrodisc, Syringe Filter,<br>PVDF, 13 mm, 0.45 µm, 100/pk | <a href="#">WAT200512</a>   |
| Waters LCMS Certified Vial                                | <a href="#">600000751CV</a> |

For complete experimental details, refer to full application note [WA64095](#) at waters.com

## Analysis of Food Sugars in Wine


### EXPERIMENTAL

#### LC conditions

|                       |   |
|-----------------------|---|
| System:               | Alliance HPLC with 2424 ELSD                              |
| Column:               | XBridge BEH Amide,<br>3.5 µm, 4.6 x 250 mm                |
| Mobile phase A:       | 80/20 acetonitrile/water<br>with 0.2% triethylamine       |
| Mobile phase B:       | 30/70 acetonitrile/water<br>with 0.2% triethylamine       |
| Isocratic conditions: | 90% A/10% B (75% acetonitrile<br>with 0.2% triethylamine) |
| Flow rate:            | 1.0 mL/min  |
| Column temp.:         | 35 °C   |
| Injection volume:     | 15.0 µL   |
| ELSD pressure:        | 30 psi  |
| Drift tube temp.:     | 50 °C   |

#### Sample preparation

Sample was diluted with 50:50 acetonitrile/water and filtered using 0.45 µm PVDF syringe filter.



### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH Amide, 3.5 µm,<br>4.6 x 250 mm Column         | <a href="#">186004870</a>   |
| Acrodisc, Syringe Filter,<br>PVDF, 13 mm, 0.45 µm, 100/pk | <a href="#">WAT200512</a>   |
| Waters LCMS Certified Vial                                | <a href="#">600000751CV</a> |

For complete experimental details, refer to full application note [WA64088](#) at waters.com

## Analysis of Food Sugars Standard


### EXPERIMENTAL

#### LC conditions

|                       |   |
|-----------------------|---|
| System:               | Alliance HPLC with 2424 ELSD                              |
| Column:               | XBridge BEH Amide,<br>3.5 µm, 4.6 x 250 mm                |
| Mobile phase A:       | 80/20 acetonitrile/water<br>with 0.2% triethylamine       |
| Mobile phase B:       | 30/70 acetonitrile/water<br>with 0.2% triethylamine       |
| Isocratic conditions: | 90% A/10% B (75% acetonitrile<br>with 0.2% triethylamine) |
| Flow rate:            | 1.0 mL/min  |
| Column temp.:         | 35 °C   |
| Injection volume:     | 15.0 µL   |
| ELSD pressure:        | 30 psi  |
| Drift tube temp.:     | 50 °C   |

#### Sample preparation

Sample concentration: 1 mg/mL each



### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH Amide, 3.5 µm,<br>4.6 x 250 mm Column         | <a href="#">186004870</a>   |
| Acrodisc, Syringe Filter,<br>PVDF, 13 mm, 0.45 µm, 100/pk | <a href="#">WAT200512</a>   |
| Waters LCMS Certified Vial                                | <a href="#">600000751CV</a> |

For complete experimental details, refer to full application note [WA64101](#) at waters.com

## Analysis of Food Sugars/Saccharides in Beer by ELSD

### EXPERIMENTAL

#### LC conditions

System: Alliance HPLC with 2424 ELSD

Column: XBridge BEH Amide,  
3.5 µm, 4.6 x 250 mm

Mobile phase A: 80/20 acetonitrile/water  
with 0.2% triethylamine

Mobile phase B: 30/70 acetonitrile/water  
with 0.2% triethylamine

| Gradient: | Time  | %A | %B |
|-----------|-------|----|----|
|           | 0.00  | 90 | 10 |
|           | 16.00 | 30 | 70 |
|           | 16.01 | 90 | 10 |
|           | 30.00 | 90 | 10 |

Flow rate: 1.0 mL/min

Column temp.: 35 °C

Injection volume: 10.0 µL

ELSD pressure: 30 psi


Drift tube temp.: 50 °C

#### Sample preparation

Sample was diluted with 50:50 acetonitrile/water and filtered using 0.45 µm PVDF syringe filter.

### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH Amide, 3.5 µm<br>4.6 x 250 mm Column          | <a href="#">186004870</a>   |
| Acrodisc, Syringe Filter,<br>PVDF, 13 mm, 0.45 µm, 100/pk | <a href="#">WAT200512</a>   |
| Waters LCMS Certified Vial                                | <a href="#">600000751CV</a> |



For complete experimental details, refer to full application note [WA64105](#) at waters.com

## Analysis of Food Sugars/Saccharides in Beer by MS


### EXPERIMENTAL

#### LC conditions

|                   |   |           |           |
|-------------------|---|-----------|-----------|
| System:           | ACQUITY UPLC with 30-cm column cooler/heater and ACQUITY TQD                            |           |           |
| Column:           | XBridge BEH Amide,<br>3.5 $\mu$ m, 4.6 x 250 mm   |           |           |
| Mobile phase A:   | 80/20 acetonitrile/water with 0.1% ammonium hydroxide                                   |           |           |
| Mobile phase B:   | 30/70 acetonitrile/water with 0.1% ammonium hydroxide                                   |           |           |
| Gradient:         | <u>Time</u>   | <u>%A</u> | <u>%B</u> |
|                   | 0.00  | 90        | 10        |
|                   | 16.00   | 30        | 70        |
|                   | 16.01   | 90        | 10        |
|                   | 30.00   | 90        | 10        |
| Flow rate:        | 1.0 mL/min  |           |           |
| Column temp.:     | 35 °C   |           |           |
| Injection volume: | 20.0 $\mu$ L  |           |           |
| Ionization mode:  | ESI-  |           |           |
| Acquisition mode: | SIR ( $m/z$ ): 179.2 (fructose, glucose); 341.3 (sucrose, maltose); 503.4 (maltotriose) |           |           |

#### Sample preparation

Sample was diluted with 50:50 acetonitrile/water and filtered using 0.45  $\mu$ m PVDF syringe filter.



### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH Amide, 3.5 $\mu$ m, 4.6 x 250 mm Column         | <a href="#">186004870</a>   |
| Acrodisc, Syringe Filter, PVDF, 13 mm, 0.45 $\mu$ m, 100/pk | <a href="#">WAT200512</a>   |
| Waters LCMS Certified Vial w/ Preslit Septa                 | <a href="#">600000668CV</a> |

For complete experimental details, refer to full application note [WA64098](#) at waters.com

## Analysis of Food Sugars/Saccharides in Cough Syrup

### EXPERIMENTAL

#### LC conditions

System: Alliance HPLC with 2424 ELSD

Column: XBridge BEH Amide,  
3.5  $\mu$ m, 4.6 x 250 mm

Mobile phase A: 80/20 acetonitrile/water  
with 0.2% triethylamine

Mobile phase B: 30/70 acetonitrile/water  
with 0.2% triethylamine

| Gradient: | Time  | %A | %B |
|-----------|-------|----|----|
|           | 0.00  | 90 | 10 |
|           | 16.00 | 30 | 70 |
|           | 16.01 | 90 | 10 |
|           | 30.00 | 90 | 10 |

Flow rate: 1.0 mL/min

Column temp.: 35 °C

Injection volume: 10.0  $\mu$ L

ELSD pressure: 30 psi


Drift tube temp.: 50 °C

#### Sample preparation

Sample was diluted with 50:50 acetonitrile/water and filtered using 0.45  $\mu$ m PVDF syringe filter.

### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| XBridge BEH Amide, 3.5 $\mu$ m,<br>4.6 x 250 mm Column         | <a href="#">186004870</a>   |
| Acrodisc, Syringe Filter,<br>PVDF, 13 mm, 0.45 $\mu$ m, 100/pk | <a href="#">WAT200512</a>   |
| Waters LCMS Certified Vial                                     | <a href="#">600000751CV</a> |



For complete experimental details, refer to full application note [WA64099](#) at waters.com

## Analysis of Food Sugars/Saccharides in Honey

### EXPERIMENTAL

#### LC conditions

System: Alliance HPLC with 2424 ELSD

Column: XBridge BEH Amide,  
3.5  $\mu$ m, 4.6 x 250 mm

Mobile phase A: 80/20 acetonitrile/water with  
0.2% triethylamine

Mobile phase B: 30/70 acetonitrile/water with  
0.2% triethylamine

| Gradient: | <u>Time</u> | <u>%A</u> | <u>%B</u> |
|-----------|-------------|-----------|-----------|
|           | 0.00        | 90        | 10        |
|           | 16.00       | 30        | 70        |
|           | 16.01       | 90        | 10        |
|           | 30.00       | 90        | 10        |

Flow rate: 1.0 mL/min

Column temp.: 35 °C

Injection volume: 10.0  $\mu$ L

ELSD pressure: 30 psi


Drift tube temp.: 50 °C

#### Sample preparation

Sample was diluted with 50:50 acetonitrile/water and filtered using 0.45  $\mu$ m PVDF syringe filter.

### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| XBridge BEH Amide, 3.5 $\mu$ m,<br>4.6 x 250 mm Column         | <a href="#">186004870</a>   |
| Acrodisc, Syringe Filter,<br>PVDF, 13 mm, 0.45 $\mu$ m, 100/pk | <a href="#">WAT200512</a>   |
| Waters LCMS Certified Vial                                     | <a href="#">600000751CV</a> |



For complete experimental details, refer to full application note [WA64100](#) at waters.com

## Analysis of Food Sugars/Saccharides in Maple Syrup

### EXPERIMENTAL

#### LC conditions

System: Alliance HPLC with 2424 ELSD

Column: XBridge BEH Amide,  
3.5  $\mu$ m, 4.6 x 250 mm

Mobile phase A: 80/20 acetonitrile/water with  
0.2% triethylamine

Mobile phase B: 30/70 acetonitrile/water with  
0.2% triethylamine

| Gradient: | Time  | %A | %B |
|-----------|-------|----|----|
|           | 0.00  | 90 | 10 |
|           | 16.00 | 30 | 70 |
|           | 16.01 | 90 | 10 |
|           | 30.00 | 90 | 10 |

Flow rate: 1.0 mL/min

Column temp.: 35 °C

Injection volume: 10.0  $\mu$ L

ELSD pressure: 30 psi


Drift tube temp.: 50 °C

#### Sample preparation

Sample was diluted with 50:50 acetonitrile/water and filtered using 0.45  $\mu$ m PVDF syringe filter.

### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| XBridge BEH Amide, 3.5 $\mu$ m,<br>4.6 x 250 mm Column         | <a href="#">186004870</a>   |
| Acrodisc, Syringe Filter,<br>PVDF, 13 mm, 0.45 $\mu$ m, 100/pk | <a href="#">WAT200512</a>   |
| Waters LCMS Certified Vial                                     | <a href="#">600000751CV</a> |



For complete experimental details, refer to full application note [WA64097](#) at waters.com

## Analysis of Food Sugars/Saccharide Standards by ELSD

### EXPERIMENTAL

#### LC conditions

System: Alliance HPLC with 2424 ELSD

Column: XBridge BEH Amide,  
3.5 µm, 4.6 x 250 mm

Mobile phase A: 80/20 acetonitrile/water  
with 0.2% triethylamine

Mobile phase B: 30/70 acetonitrile/water  
with 0.2% triethylamine

| Gradient: | <u>Time</u> | <u>%A</u> | <u>%B</u> |
|-----------|-------------|-----------|-----------|
|           | 0.00        | 90        | 10        |
|           | 16.00       | 30        | 70        |
|           | 16.01       | 90        | 10        |
|           | 30.00       | 90        | 10        |

Flow rate: 1.0 mL/min

Column temp.: 35 °C


Injection volume: 10.0 µL

ELSD pressure: 30 psi

Drift tube temp.: 50 °C

#### Sample preparation

Sample concentration: 1 mg/mL each



### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH Amide, 3.5 µm,<br>4.6 x 250 mm Column         | <a href="#">186004870</a>   |
| Acrodisc, Syringe Filter,<br>PVDF, 13 mm, 0.45 µm, 100/pk | <a href="#">WAT200512</a>   |
| Waters LCMS Certified Vial                                | <a href="#">600000751CV</a> |

For complete experimental details, refer to full application note [WA64104](#) at waters.com

## Analysis of Food Sugars/Saccharide Standards by MS

### EXPERIMENTAL

#### LC conditions

|                 |  |           |           |
|-----------------|--|-----------|-----------|
| System:         | ACQUITY UPLC with ACQUITY TQD                            |           |           |
| Column:         | XBridge BEH Amide,<br>3.5 µm, 4.6 x 150 mm               |           |           |
| Mobile phase A: | 80/20 acetonitrile/water<br>with 0.1% ammonium hydroxide |           |           |
| Mobile phase B: | 30/70 acetonitrile/water<br>with 0.1% ammonium hydroxide |           |           |
| Gradient:       | <u>Time</u>  | <u>%A</u> | <u>%B</u> |
|                 | 0.00   | 100       | 0         |
|                 | 30.60  | 40        | 60        |
|                 | 30.61  | 100       | 0         |
|                 | 52.00  | 100       | 0         |

Flow rate: 0.4 mL/min

Column temp.: 35 °C


Injection volume: 10.0 µL

Ionization mode: ESI-

Acquisition mode: SIR (m/z): 178.96 (fructose, glucose);  
341.04 (sucrose, maltose); 503.08  
(maltotriose); 665.10 (maltotetraose);  
827.22 (maltopentaose); 989.21  
(maltohexaose); 1151.29 (maltoheptaose)

#### Sample preparation

Sample concentrations: 10 µg/mL each



#### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH Amide, 3.5 µm,<br>4.6 x 150 mm Column         | <a href="#">186004869</a>   |
| Acrodisc, Syringe Filter,<br>PVDF, 13 mm, 0.45 µm, 100/pk | <a href="#">WAT200512</a>   |
| Waters LCMS Certified Vial<br>w/ Preslit Septa            | <a href="#">600000668CV</a> |

For complete experimental details, refer to full application note [720002738EN](#) at waters.com

## Analysis of Formaldehyde in Ambient Air

### EXPERIMENTAL

#### LC conditions

System: Alliance HPLC with UV detection  
 Column: XBridge BEH Phenyl, 3.5 µm, 4.6 x 150 mm  
 Mobile phase A: 90% water, 10% tetrahydrofuran (THF)  
 Mobile phase B: Acetonitrile  
 Gradient: Eluent gradient for EPA methods 554 and 8315 Option 1.

| Time    | Flow | %A | %B | Curve |
|---------|------|----|----|-------|
| Initial | 1.5  | 70 | 30 | -     |
| 20.0    | 1.5  | 36 | 64 | 6     |
| 22.0    | 1.5  | 36 | 64 | 6     |
| 22.1    | 1.5  | 70 | 30 | 6     |


Eluent gradient for EPA Methods TO11 and 8315 Option 2.

| Time    | Flow | %A | %B | Curve |
|---------|------|----|----|-------|
| Initial | 1.5  | 70 | 30 | -     |
| 16.0    | 1.5  | 53 | 47 | 6     |
| 21.0    | 1.5  | 53 | 47 | 6     |
| 21.1    | 1.5  | 70 | 30 | 6     |

Flow rate: 1.5 mL/min  
 Column temp.: 35 °C  
 Injection: 20 µL each  
 UV detection: 360 nm

#### Sample preparation

AccuStandard mix (M- 8315-R1- DNPH and M- 8315-R2- DNPH) diluted 1:5 in 40:60 water/acetonitrile. Online derivatization carried out on Sep-Pak DNPH Silica Cartridge, backflush cartridge with acetonitrile.



#### ORDERING INFORMATION

| Description                                     | P/N                         |
|---|-----------------------------|
| XBridge BEH Phenyl, 3.5 µm, 4.6 x 150 mm Column | <a href="#">186003335</a>   |
| Sep-Pak DNPH-Silica Cartridge                   | <a href="#">WAT037500</a>   |
| TruView LCMS Certified Vial w/ Preslit Septa    | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [WA60198](#) at waters.com

## Analysis of Furanocoumarins in Fruit Juice


### EXPERIMENTAL

#### LC conditions

|                 |  |    |    |
|-----------------|--|----|----|
| System:         | Alliance 2695 with 996 PDA detector  |    |    |
| Columns:        | XBridge BEH Shield RP18,<br>5 µm, 4.6 x 150 mm;<br>XBridge BEH C <sub>8</sub> , 5 µm, 4.6 x 150 mm |    |    |
| Mobile phase A: | 2% acetic acid   |    |    |
| Mobile phase B: | Acetonitrile   |    |    |
| Gradient:       | Time   | %A | %B |
|                 | 0.0  | 90 | 10 |
|                 | 15.0   | 80 | 20 |
|                 | 20.0   | 75 | 25 |
|                 | 30.0   | 60 | 40 |
|                 | 55.0   | 30 | 70 |
|                 | 67.0   | 5  | 95 |
|                 | 80.0   | 5  | 95 |
|                 | 85.0   | 90 | 10 |
|                 | 95.0   | 90 | 10 |
| Flow rate:      | 0.75 mL/min  |    |    |
| Column temp.:   | Ambient  |    |    |
| Injection:      | 20 µL  |    |    |
| UV detection:   | 310 nm   |    |    |

#### Sample preparation

The juice samples were obtained from white grapefruit. Samples were centrifuged and the furanocoumarins then extracted into ethyl acetate.



#### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH Shield RP18, 5 µm,<br>4.6 x 150 mm Column     | <a href="#">186003009</a>   |
| XBridge BEH C <sub>8</sub> , 5 µm,<br>4.6 x 150 mm Column | <a href="#">186003017</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa           | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [720003721EN](#) at waters.com

## Analysis of Galantamine and Related Substances


### EXPERIMENTAL

#### LC conditions

|                   |   |     |    |
|-------------------|---|-----|----|
| System:           | Alliance 2695   |     |    |
| Column:           | XBridge BEH C <sub>18</sub> , 3.5 μm, 4.6 x 100 mm  |     |    |
| Mobile phase A:   | 95% phosphate buffer solution:<br>5% methanol   |     |    |
| Buffer:           | Dissolve 0.79 g of dibasic sodium phosphate dihydrate and 2.46 g of monobasic sodium phosphate anhydrous in 1 L of water. |     |    |
| Mobile phase B:   | Acetonitrile  |     |    |
| Gradient:         | Time  | %A  | %B |
|                   | 0.00  | 100 | 0  |
|                   | 6.00  | 100 | 0  |
|                   | 20.00   | 95  | 5  |
|                   | 35.00   | 85  | 15 |
|                   | 50.00   | 80  | 20 |
|                   | 51.00   | 40  | 60 |
|                   | 55.00   | 40  | 60 |
|                   | 56.00   | 100 | 0  |
|                   | 60.00   | 100 | 0  |
| Flow rate:        | 1.5 mL/min  |     |    |
| Column temp.:     | 55 °C   |     |    |
| Injection volume: | 20 μL   |     |    |
| UV detection:     | 230 nm  |     |    |

#### Sample preparation

United States Pharmacopeia reference standards: USP Galantamine Hydrobromide RS and USP Galantamine Hydrobromide Related Compounds Mixture RS.



#### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| XBridge BEH C <sub>18</sub> , 3.5 μm,<br>4.6 x 100 mm Column | <a href="#">186003033</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa              | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [WA64086](#) at waters.com

## Analysis of Ginsenoside Rb1 in Ginseng Root Powder Extract


### EXPERIMENTAL

#### LC conditions

|                   |  |
|-------------------|--|
| System:           | Alliance HPLC with 2998 PDA detector       |
| Column:           | XBridge BEH Amide,<br>3.5 µm, 4.6 x 150 mm |
| Mobile phase:     | 80:20 acetonitrile/water                   |
| Separation mode:  | Isocratic                                  |
| Flow rate:        | 1.4 mL/min                                 |
| Column temp.:     | 60 °C                                      |
| Injection volume: | 11.5 µL                                    |
| UV detection:     | 203 nm                                     |

#### Sample preparation

1. Weigh 200 mg ginseng root powder into an extraction vessel.
2. Add 1 mL 80% methanol, sonicate for 5 minutes.
3. Centrifuge at 10,000 rpm for 5 minutes.
4. Collect the supernatant.
5. Repeat steps 2-4 two more times.
6. Combine the extracts, mix well.
7. Filter through 13 mm nylon 0.2 µm filter for injection.



### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH Amide, 3.5 µm,<br>4.6 x 150 mm Column         | <a href="#">186004869</a>   |
| Acrodisc, Syringe Filter,<br>Nylon, 13 mm, 0.2 µm, 100/pk | <a href="#">WAT200524</a>   |
| Waters LCMS Certified Vial                                | <a href="#">600000751CV</a> |



For complete experimental details, refer to full application note [WA64087](#) at waters.com

## Analysis of Ginsenoside Rb1 in Herbal Medicine Extract

### EXPERIMENTAL

#### LC conditions

|                   |  |
|-------------------|--|
| System:           | Alliance HPLC with 2998 PDA detector       |
| Column:           | XBridge BEH Amide,<br>3.5 µm, 4.6 x 250 mm |
| Mobile phase:     | 80:20 acetonitrile/water                   |
| Separation mode:  | Isocratic                                  |
| Flow rate:        | 0.8 mL/min                                 |
| Column temp.:     | 60 °C                                      |
| Injection volume: | 20 µL                                      |
| UV detection:     | 203 nm                                     |



#### Sample preparation

##### Pretreatment

1. Weigh 2 g of herbal medicine powder into a centrifuge tube.
2. Add 30 mL of 60% methanol/40% water.
3. Shake for 15 minutes.
4. Centrifuge at 4000 rpm for 10 minutes.
5. Obtain the supernatant.
6. Repeat steps 2-5 with the residue using 15 mL of 60% methanol/40% water.
7. Combine the supernatant, and make exactly 50 mL by adding 60% methanol/40% water.
8. Take 10 mL of this solution and add 3 mL of sodium hydroxide test solution (1 mol/L).
9. Let stand for 30 minutes.
10. Add 3 mL of HCl test solution (1 mol/L).
11. Add 60% methanol/40% water to make exactly 20 mL.

#### Solid-Phase Extraction Procedure

1. Condition Sep-Pak Plus C<sub>18</sub> Cartridge, 360 mg (55-105 µm) with 2 mL methanol.
2. Equilibrate with 2 mL of 30% methanol/70% water just before loading.
3. Load 5 mL of the solution from step 11 in the pretreatment stage.
4. Wash with 2 mL of 30% methanol/70% water.
5. Wash with 1 mL of sodium carbonate test solution (1 mol/L).
6. Wash with 10 mL of 30% methanol/70% water.
7. Elute with 5 mL methanol (this is the injection solution).

### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH Amide, 3.5 µm,<br>4.6 x 250 mm Column         | <a href="#">186004870</a>   |
| Sep-Pak C <sub>18</sub> Plus Short Cartridge              | <a href="#">WAT020515</a>   |
| Acrodisc, Syringe Filter,<br>PVDF, 13 mm, 0.45 µm, 100/pk | <a href="#">WAT200512</a>   |
| Waters LCMS Certified Vial                                | <a href="#">600000751CV</a> |

For complete experimental details, refer to full application note [720005229EN](#) at waters.com

## Analysis of Goldenseal

### EXPERIMENTAL

#### LC conditions

|                   |  |    |    |
|-------------------|--|----|----|
| System:           | Alliance HPLC with<br>ACQUITY QDa Detector     |    |    |
| Column:           | CORTECS C <sub>18</sub> +, 2.7 μm, 3.0 x 50 mm |    |    |
| Mobile phase A:   | 0.1% formic acid in water                      |    |    |
| Mobile phase B:   | 0.1% formic acid in acetonitrile               |    |    |
| Gradient:         | Time   | %A | %B |
|                   | 0.00   | 93 | 7  |
|                   | 5.00   | 70 | 30 |
|                   | 5.01   | 93 | 7  |
|                   | 6.01   | 93 | 7  |
| Flow rate:        | 1.0 mL/min                                     |    |    |
| Column temp.:     | 30 °C  |    |    |
| Injection volume: | 1.0 μL   |    |    |
| UV detection:     | 300 nm   |    |    |
| Ionization mode:  | ESI+   |    |    |
| Acquisition mode: | Full scan 150–1250 m/z                         |    |    |


#### Sample preparation

Capsule samples: Add 2.5 mL of 90:10 methanol/water with 0.1% acetic acid to 20 mg sample, sonicate 15 minutes, centrifuge at 4000 rpm for 5 minutes. Remove supernatant and repeat extraction three additional times. Combine extracted liquid and filter through a 0.1 μm nylon syringe filter.

Liquid sample: Two drops of liquid Goldenseal was added to 10 mL of 90:10 methanol/water with 0.1% acetic acid and filter through.

### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| CORTECS C <sub>18</sub> +, 2.7 μm,<br>3.0 x 50 mm Column    | <a href="#">186007400</a>   |
| Waters LCMS Certified Max<br>Recovery Vial w/ Preslit Septa | <a href="#">600000670CV</a> |



For complete experimental details, refer to full application note [WA64109](#) at waters.com

## Analysis of Histidine Dipeptides


### EXPERIMENTAL

#### LC conditions

|                   |   |           |           |
|-------------------|---|-----------|-----------|
| System:           | ACQUITY UPLC with 30-cm column cooler/heater and TQD detector                                   |           |           |
| Column:           | XBridge BEH Amide,<br>3.5 µm, 4.6 x 250 mm  |           |           |
| Mobile phase A:   | 50/50 acetonitrile/water with<br>10 mM ammonium acetate and<br>0.04% ammonium hydroxide, pH 9.0 |           |           |
| Mobile phase B:   | 95/5 acetonitrile/water with<br>10 mM ammonium acetate and<br>0.04% ammonium hydroxide, pH 9.0  |           |           |
| Gradient:         | <u>Time</u>   | <u>%A</u> | <u>%B</u> |
|                   | 0.00  | 90        | 10        |
|                   | 16.00   | 30        | 70        |
|                   | 16.01   | 90        | 10        |
|                   | 30.00   | 90        | 10        |
| Flow rate:        | 1.0 mL/min  |           |           |
| Column temp.:     | 65 °C   |           |           |
| Injection volume: | 15.0 µL   |           |           |
| Ionization mode:  | ESI+  |           |           |
| Acquisition mode: | SIR   |           |           |

#### Sample preparation

Add 25 mL of 50:50 acetonitrile/water to ~3 g sample, homogenize, centrifuge at 3200 rpm for 30 minutes, collect supernatant and filter using 0.45 µm PVDF syringe filter.



#### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH Amide, 3.5 µm,<br>4.6 x 250 mm Column         | <a href="#">186004870</a>   |
| Acrodisc, Syringe Filter,<br>PVDF, 13 mm, 0.45 µm, 100/pk | <a href="#">WAT200512</a>   |
| Waters LCMS Certified Vial<br>w/ Preslit Septa            | <a href="#">600000668CV</a> |

For complete experimental details, refer to full application note [720004130EN](#) at waters.com

## Analysis of Irbesartan Tablets


### EXPERIMENTAL

#### LC conditions

|                   |  |
|-------------------|--|
| System:           | Alliance HPLC with<br>2489 UV/Visible detector   |
| Column:           | XSelect HSS T3, 5 µm, 4.6 x 250 mm   |
| Mobile phase:     | Acetonitrile and buffer solution (40:60);<br><br>Buffer solution:<br>0.55% phosphoric acid in water adjusted<br>to pH 3.0 with triethylamine |
| Separation mode:  | Isocratic  |
| Flow rate:        | 1.0 mL/min   |
| Column temp.:     | 30 °C  |
| Injection volume: | 10 µL  |
| UV detection:     | 220 nm   |

#### Sample preparation

The concentration of the working standard and sample specified in the USP monograph is 0.15 mg/mL. The sample was prepared from AVAPRO (irbesartan) tablets as specified in the USP Monograph for Irbesartan: USP34-NF29. Five tablets of irbesartan were weighed and finely powdered. An equivalent of 15 mg of this powder was weighed and transferred to a 100-mL volumetric flask. Seventy-five milliliters of methanol was added to the flask and this solution was sonicated for 15 minutes, with stirring at 5-minute intervals. Methanol was added to make up the volume to 100 mL and this solution was passed through a 0.45-µm porous glass microfiber membrane filter.



#### ORDERING INFORMATION

| Description                                     | P/N                         |
|---|-----------------------------|
| XSelect HSS T3, 5 µm,<br>4.6 x 250 mm Column    | <a href="#">186004793</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [720004132EN](#) at waters.com

## Analysis of Lamotrigine and Related Compounds

### EXPERIMENTAL

#### LC conditions

|         | Column |      |    |         |
|---------|--------|------|----|---------|
|         | Time   | %A   | %B | Volumes |
| Initial | 76.5   | 23.5 |    | -       |
| 4.00    | 76.5   | 23.5 |    | 2.43    |
| 14.00   | 20.0   | 80.0 |    | 6.08    |
| 15.00   | 76.5   | 23.5 |    | 0.61    |
| 19.00   | 76.5   | 23.5 |    | 2.43    |

| Gradient: | Time | %A   | %B | Volumes |
|-----------|------|------|----|---------|
| Initial   | 76.5 | 23.5 |    | -       |
| 4.00      | 76.5 | 23.5 |    | 2.43    |
| 14.00     | 20.0 | 80.0 |    | 6.08    |
| 15.00     | 76.5 | 23.5 |    | 0.61    |
| 19.00     | 76.5 | 23.5 |    | 2.43    |

Flow rate: 1.0 mL/min

Column temp.: 35 °C

Injection volume: 10 µL


UV detection: 270 nm

#### Sample preparation

The samples were prepared by transferring an appropriate pooled number of tablets to a 1 L volumetric flask to obtain a concentration equivalent to 1.0 mg/mL lamotrigine. Tablets were dissolved in 200 mL water and 800 mL methanol. This solution was mechanically shaken for 20 minutes followed by centrifugation at 4000 rpm for 20 minutes. Aliquots from the dissolved tablet sample solution were diluted with diluent (0.1 M hydrochloric acid) to obtain a working sample concentration of 0.2 mg/mL.

#### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| XBridge BEH C <sub>18</sub> , 5 µm,<br>4.6 x 150 mm Column | <a href="#">186003116</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa            | <a href="#">186005666CV</a> |



For complete experimental details, refer to full application note [720005407EN](#) at waters.com

## Analysis of Levonorgestrel and Ethynodiol Tablets


### EXPERIMENTAL

#### LC conditions

|                   |   |
|-------------------|---|
| System:           | Alliance 2695                                   |
| Column:           | XBridge BEH C <sub>8</sub> , 5 µm, 4.6 x 150 mm |
| Mobile phase:     | 7:3:9 acetonitrile:methanol:water               |
| Separation mode:  | Isocratic                                       |
| Flow rate:        | 1 mL/min  |
| Injection volume: | 50 µL   |
| UV detection:     | 215 nm  |

#### Sample preparation

Dissolve levonorgestrel and ethynodiol commercially-available tablets in mobile phase to a final concentration of 15 µg/mL levonorgestrel and 3 µg/mL ethynodiol. Sonicate for 5 minutes, shake mechanically for 20 minutes. Centrifuge at 4000 rpm for 10 minutes. Collect supernatant and re-centrifuge at 12,000 rpm for 30 minutes, pipet clear supernatant for injection.



### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH C <sub>8</sub> , 5 µm,<br>4.6 x 150 mm Column | <a href="#">186003017</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa           | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [720005786EN](#) at waters.com

## Analysis of Lipid Soluble Antioxidants Using Atlantis T3, 3 µm Columns

### EXPERIMENTAL

#### LC conditions

System: ACQUITY Arc with 2998 PDA detector

Column: Atlantis T3, 3 µm, 3.0 x 75 mm

Mobile phase A: Water

Mobile phase B: Acetonitrile

Mobile phase C: Methanol

Mobile phase D: 2% formic acid in water  
(autoblended to 0.1% formic acid)

| Gradient: | Time  | %A | %B   | %C   | %D |
|-----------|-------|----|------|------|----|
|           | 0.00  | 60 | 17.5 | 17.5 | 5  |
|           | 2.00  | 40 | 27.5 | 27.5 | 5  |
|           | 3.00  | 14 | 40.0 | 41.0 | 5  |
|           | 7.50  | 14 | 40.0 | 41.0 | 5  |
|           | 8.00  | 60 | 17.5 | 17.5 | 5  |
|           | 10.00 | 60 | 17.5 | 17.5 | 5  |

Flow rate: 0.85 mL/min

Column temp.: 30 °C

Injection volume: 2.1 µL

UV detection: 280 nm

#### Sample preparation

Sample diluted to the described concentrations using 65:35 water:methanol.

Propyl gallate (0.05 mg/mL)

2,4,5-Trihydroxybutyrophenone (0.05 mg/mL)

Tert-butylhydroquinone (0.1 mg/mL)


Butylated hydroxyanisole (0.1 mg/mL)

2,6-Di-tert-butyl-4-hydroxymethylphenol (0.1 mg/mL)

Octyl gallate (0.05 mg/mL)

#### ORDERING INFORMATION

| Description                                     | P/N                         |
|---|-----------------------------|
| Atlantis T3, 3 µm,<br>3.0 x 75 mm Column        | <a href="#">186005653</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa | <a href="#">186005666CV</a> |



For complete experimental details, refer to full application note [720005786EN](#) at waters.com

## Analysis of Lipid Soluble Antioxidants Using CORTECS T3, 2.7 $\mu\text{m}$ Columns

### EXPERIMENTAL

#### LC conditions

|                 |  |    |      |      |    |
|-----------------|--|----|------|------|----|
| System:         | ACQUITY Arc with 2998 PDA detector                           |    |      |      |    |
| Column:         | CORTECS T3, 2.7 $\mu\text{m}$ , 3.0 x 75 mm                  |    |      |      |    |
| Mobile phase A: | Water  |    |      |      |    |
| Mobile phase B: | Acetonitrile   |    |      |      |    |
| Mobile phase C: | Methanol   |    |      |      |    |
| Mobile phase D: | 2% formic acid in water<br>(autoblended to 0.1% formic acid) |    |      |      |    |
| Gradient:       | Time   | %A | %B   | %C   | %D |
|                 | 0.00   | 60 | 17.5 | 17.5 | 5  |
|                 | 2.00   | 40 | 27.5 | 27.5 | 5  |
|                 | 3.00   | 14 | 40.0 | 41.0 | 5  |
|                 | 7.50   | 14 | 40.0 | 41.0 | 5  |
|                 | 8.00   | 60 | 17.5 | 17.5 | 5  |
|                 | 10.00  | 60 | 17.5 | 17.5 | 5  |

Flow rate: 0.85 mL/min

Column temp.: 30 °C

Injection volume: 2.1  $\mu\text{L}$

UV detection: 280 nm

#### Sample preparation

Sample diluted to the described concentrations using 65:35 water:methanol.

Propyl gallate (0.05 mg/mL)

2,4,5-Trihydroxybutyrophenone (0.05 mg/mL)

Tert-butylhydroquinone (0.1 mg/mL)


Butylated hydroxyanisole (0.1 mg/mL)

2,6-Di-tert-butyl-4-hydroxymethylphenol (0.1 mg/mL)

Octyl gallate (0.05 mg/mL)

#### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| CORTECS T3, 2.7 $\mu\text{m}$ ,<br>3.0 x 75 mm Column | <a href="#">186008488</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa       | <a href="#">186005666CV</a> |



For complete experimental details, refer to full application note [XBRIDGE5](#) at waters.com

## Analysis of Local Anesthetics

### EXPERIMENTAL

#### LC conditions


|                   |  |
|-------------------|--|
| System:           | Alliance 2695 with 2996 PDA detector                       |
| Column:           | XBridge BEH C <sub>18</sub> , 5 μm, 4.6 x 150 mm           |
| Mobile phase:     | 10 mM ammonium bicarbonate,<br>pH 10.5/acetonitrile (50/5) |
| Separation mode:  | Isocratic  |
| Flow rate:        | 1.0 mL/min   |
| Column temp.:     | 25 °C  |
| Injection volume: | 10 μL  |
| UV detection:     | 210 nm   |

#### Sample preparation


Sample concentration: 20 μg/mL in water/acetonitrile (50/50)

### ORDERING INFORMATION


| Description  | P/N                         |
|--|-----------------------------|
| XBridge BEH C <sub>18</sub> , 5 μm,<br>4.6 x 150 mm Column | <a href="#">186003116</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa            | <a href="#">186005666CV</a> |




1. Procaine



2. Lidocaine



3. Tetracaine



For complete experimental details, refer to full application note [720003721EN](#) at waters.com

## Analysis of Loratadine Using XBridge BEH C<sub>18</sub> Columns

### EXPERIMENTAL

#### LC conditions

System: Alliance 2695

Column: XBridge BEH C<sub>18</sub>, 5 µm, 4.6 x 250 mm

Mobile phase A: 0.96 g of 1-pentaesulfonic acid in 1 L water adjusted to pH 3.00 ± 0.05 with 10% phosphoric acid

Mobile phase B: Acetonitrile


| Gradient: | Time  | %A | %B |
|-----------|-------|----|----|
|           | 0.00  | 75 | 25 |
|           | 20.00 | 50 | 50 |
|           | 30.00 | 40 | 60 |
|           | 35.00 | 30 | 70 |
|           | 45.00 | 30 | 70 |
|           | 50.00 | 75 | 25 |

Flow rate: 1.2 mL/min

Column temp.: 35 °C

Injection volume: 20 µL

UV detection: 254 nm



### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH C <sub>18</sub> , 3.5 µm, 4.6 x 100 mm Column | <a href="#">186003033</a>   |
| TruView LCMS Certified Vial w/ Preslit Septa              | <a href="#">186005666CV</a> |

### Sample preparation

United States Pharmacopeia reference standards: USP Loratadine RS, USP Loratadine Related Compound A RS, and USP Loratadine Compound B RS, Claritin.

For complete experimental details, refer to full application note [720005579EN](#) at waters.com

## Analysis of Loratadine Using XBridge BEH C<sub>8</sub> Columns


### EXPERIMENTAL

#### LC conditions

|                   |   |
|-------------------|---|
| System:           | ACQUITY UPLC H-Class  |
| Column:           | XBridge BEH C <sub>8</sub> , 5 $\mu$ m, 4.6 x 150 mm  |
| Mobile phase:     | Acetonitrile:methanol:0.01 M dibasic potassium phosphate (6:6:7) adjusted with phosphoric acid to an apparent pH of 7.2 |
| Separation mode:  | Isocratic   |
| Flow rate:        | 1.0 mL/min  |
| Column temp.:     | 30 °C   |
| Injection volume: | 15.0 $\mu$ L  |
| UV detection:     | 254 nm  |

#### Sample preparation

A sample containing loratadine (40  $\mu$ g/mL), loratadine related compound A (10  $\mu$ g/mL), and loratadine related compound B (10  $\mu$ g/mL) was created using the 260:260:400:80 acetonitrile:methanol:0.05 N HCl:0.6M dibasic potassium phosphate.



### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| XBridge BEH C <sub>8</sub> , 5 $\mu$ m,<br>4.6 x 150 mm Column | <a href="#">186003017</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa                | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [720005579EN](#) at waters.com

## Analysis of Loratadine Using CORTECS C<sub>8</sub> Columns


### EXPERIMENTAL

#### LC conditions

|                   |   |
|-------------------|---|
| System:           | ACQUITY UPLC H-Class  |
| Column:           | CORTECS C <sub>8</sub> , 2.7 µm, 3 x 100 mm   |
| Mobile phase:     | Acetonitrile:methanol:0.01 M dibasic potassium phosphate (6:6:7) adjusted with phosphoric acid to an apparent pH of 7.2 |
| Separation mode:  | Isocratic   |
| Flow rate:        | 0.8 mL/min  |
| Column temp.:     | 30 °C   |
| Injection volume: | 4.3 µL  |
| UV detection:     | 254 nm  |

#### Sample preparation

A sample containing loratadine (40 µg/mL), loratadine related compound A (10 µg/mL), and loratadine related compound B (10 µg/mL) was created using the 260:260:400:80 acetonitrile:methanol: 0.05 N HCl:0.6M dibasic potassium phosphate.



### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| CORTECS C <sub>8</sub> , 2.7 µm,<br>3.0 x 100 mm Column | <a href="#">186008361</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa         | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [720005200EN](#) at waters.com

## Analysis of 2- and 4-Methylimidazole in Beverages


### EXPERIMENTAL

#### LC conditions

|                   |  |      |      |
|-------------------|--|------|------|
| System:           | Alliance HPLC with ACQUITY QDa detector        |      |      |
| Column:           | CORTECS HILIC, 2.7 $\mu$ m, 2.1 x 100 mm       |      |      |
| Mobile phase A:   | 10 mM ammonium formate pH-4 with formic acid   |      |      |
| Mobile phase B:   | Acetonitrile (0.1% formic acid)                |      |      |
| Gradient:         | Time   | %A   | %B   |
|                   | 0.00   | 7.5  | 92.5 |
|                   | 8.50   | 7.5  | 92.5 |
|                   | 9.00   | 60.0 | 40.0 |
|                   | 11.00  | 60.0 | 40.0 |
|                   | 11.50  | 7.5  | 92.5 |
|                   | 20.50  | 7.5  | 92.5 |
| Flow rate:        | 0.4 mL/min                                     |      |      |
| Injection volume: | 5 $\mu$ L                                      |      |      |
| Ionization mode:  | ESI+   |      |      |
| Acquisition mode: | SIR ( $m/z$ ) imidazole 69.1; 2 and 4-MEI 83.1 |      |      |

#### Sample preparation

Soft drink samples were sonicated to remove carbonation. Each of the six samples was fortified with 100 ppb imidazole as an internal standard. Separate portions of each sample were fortified with 100 ppb 2-MEI and 4-MEI to determine recovery.



#### ORDERING INFORMATION

| Description                                     | P/N                         |
|---|-----------------------------|
| CORTECS HILIC, 2.7 $\mu$ m, 2.1 x 100 mm Column | <a href="#">186007382</a>   |
| TruView LCMS Certified Vial w/ Preslit Septa    | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [720005558EN](#) at waters.com

## Analysis of Metoclopramide Using an HPLC 5 µm Column

### EXPERIMENTAL

#### LC conditions


|                   |   |    |    |
|-------------------|---|----|----|
| System:           | ACQUITY Arc with 2998 PDA and ACQUITY QDa detectors |    |    |
| Column:           | XSelect CSH C <sub>18</sub> , 5 µm, 4.6 x 150 mm    |    |    |
| Mobile phase A:   | 0.1% formic acid in water                           |    |    |
| Mobile phase B:   | 0.1% formic acid in methanol                        |    |    |
| Gradient:         | Time  | %A | %B |
|                   | 0.00  | 95 | 5  |
|                   | 15.00   | 40 | 60 |
|                   | 16.50   | 40 | 60 |
|                   | 16.80   | 95 | 5  |
|                   | 21.00   | 95 | 5  |
| Flow rate:        | 2.9 mL/min  |    |    |
| Injection volume: | 10.0 µL   |    |    |
| UV detection:     | 270 nm  |    |    |
| Ionization mode:  | ESI+, ESI-  |    |    |
| Acquisition mode: | Full scan 100–440 m/z                               |    |    |

#### Sample preparation

The related compounds of metoclopramide HCl used in this study are listed in Table 1 of the full application note (p/n [720005558EN](#)). Separate stock solutions were prepared in methanol at 1.0 mg/mL. A metoclopramide stock solution was diluted with water to 0.5 mg/mL and spiked with related substances at 1.0% level.

#### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| XSelect CSH C <sub>18</sub> , 5 µm,<br>4.6 x 150 mm Column | <a href="#">186005290</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa            | <a href="#">186005666CV</a> |



For complete experimental details, refer to full application note [720005558EN](#) at waters.com

## Analysis of Metoclopramide Using an HPLC 3.5 $\mu$ m Column

### EXPERIMENTAL

#### LC conditions


|                   |   |    |    |
|-------------------|---|----|----|
| System:           | ACQUITY Arc with 2998 PDA and ACQUITY QDa detectors     |    |    |
| Column:           | XSelect CSH C <sub>18</sub> , 3.5 $\mu$ m, 3.0 x 100 mm |    |    |
| Mobile phase A:   | 0.1% formic acid in water                               |    |    |
| Mobile phase B:   | 0.1% formic acid in methanol                            |    |    |
| Gradient:         | Time  | %A | %B |
|                   | 0.00  | 95 | 5  |
|                   | 10.00   | 40 | 60 |
|                   | 11.00   | 40 | 60 |
|                   | 11.20   | 95 | 5  |
|                   | 14.00   | 95 | 5  |
| Flow rate:        | 1.2 mL/min  |    |    |
| Injection volume: | 2.8 $\mu$ L   |    |    |
| UV detection:     | 270 nm  |    |    |
| Ionization mode:  | ESI+, ESI-  |    |    |
| Acquisition mode: | Full scan 100–440 m/z                                   |    |    |

#### Sample preparation

The related compounds of metoclopramide HCl used in this study are listed in Table 1 of the full application note (p/n [720005558EN](#)). Separate stock solutions were prepared in methanol at 1.0 mg/mL. A metoclopramide stock solution was diluted with water to 0.5 mg/mL and spiked with related substances at 1.0% level.

#### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| XSelect CSH C <sub>18</sub> , 3.5 $\mu$ m<br>3.0 x 100 mm Column | <a href="#">186005262</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa                  | <a href="#">186005666CV</a> |



For complete experimental details, refer to full application note [720005558EN](#) at waters.com

## Analysis of Metoclopramide Using an HPLC 2.5 µm Column

### EXPERIMENTAL

#### LC conditions


|                   |   |    |    |
|-------------------|---|----|----|
| System:           | ACQUITY Arc with 2998 PDA and ACQUITY QDa detectors |    |    |
| Column:           | XSelect CSH C <sub>18</sub> , 2.5 µm, 3.0 x 75 mm   |    |    |
| Mobile phase A:   | 0.1% formic acid in water                           |    |    |
| Mobile phase B:   | 0.1% formic acid in methanol                        |    |    |
| Gradient:         | Time  | %A | %B |
|                   | 0.00  | 95 | 5  |
|                   | 7.50  | 40 | 60 |
|                   | 8.25  | 40 | 60 |
|                   | 8.40  | 95 | 5  |
|                   | 10.50   | 95 | 5  |
| Flow rate:        | 1.2 mL/min  |    |    |
| Injection volume: | 2.1 µL  |    |    |
| UV detection:     | 270 nm  |    |    |
| Ionization mode:  | ESI+, ESI-  |    |    |
| Acquisition mode: | Full scan 100–440 m/z                               |    |    |

#### Sample preparation

The related compounds of metoclopramide HCl used in this study are listed in Table 1 of the full application note (p/n [720005558EN](#)). Separate stock solutions were prepared in methanol at 1.0 mg/mL. A metoclopramide stock solution was diluted with water to 0.5 mg/mL and spiked with related substances at 1.0% level.

#### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XSelect CSH C <sub>18</sub> , 2.5 µm,<br>3.0 x 75 mm Column | <a href="#">186006106</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa             | <a href="#">186005666CV</a> |



For complete experimental details, refer to full application note [720005622EN](#) at waters.com

## Analysis of Miconazole Nitrate Cream Using XBridge BEH Phenyl Columns


### EXPERIMENTAL

#### LC conditions

|                   |   |
|-------------------|---|
| System:           | Alliance e2695 with<br>2489 UV/Visible detector                                       |
| Column:           | XBridge BEH Phenyl,<br>5 µm, 4.6 x 250 mm   |
| Mobile phase:     | Methanol/acetonitrile/tetrahydrofuran/<br>1% triethylamine, pH 2.5 (25/20/15/40, v/v) |
| Separation mode:  | Isocratic   |
| Flow rate:        | 1.50 mL/min   |
| Column temp.:     | 45 °C   |
| Injection volume: | 10 µL   |
| UV detection:     | 225 nm  |

#### Sample preparation

A standard solution of 0.28 mg/mL of miconazole nitrate and 0.02 mg/mL of benzoic acid were prepared in mobile phase. A sample solution with a concentration of 0.28 mg/mL of miconazole nitrate and 0.02 mg/mL of benzoic acid was prepared by dispersing one applicator of an OTC (over-the-counter) cream preparation containing 100 mg of micronazole per dose in 357 mLs of mobile phase. The solution was heated for one hour at 40–45 °C in an ultrasonic bath, and then allowed to cool to room temperature. Twenty milliliters was filtered through a 0.45 µm PTFE filter, and a 2 mL aliquot was transferred to a TruView LCMS Clear Glass Vial for analysis.



### ORDERING INFORMATION

| Description                                      | P/N                         |
|--|-----------------------------|
| XBridge BEH Phenyl, 5 µm,<br>4.6 x 250 mm Column | <a href="#">186003353</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa  | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [720005622EN](#) at waters.com

## Analysis of Miconazole Nitrate Cream Using CORTECS Phenyl Columns


### EXPERIMENTAL

#### LC conditions

|                   |  |
|-------------------|--|
| System:           | ACQUITY UPLC with PDA detector   |
| Column:           | CORTECS Phenyl, 2.7 µm, 3.0 x 100 mm   |
| Mobile phase:     | Methanol/acetonitrile/tetrahydrofuran/1% triethylamine, pH2.5 (25/20/15/40, v/v) |
| Separation mode:  | Isocratic  |
| Flow rate:        | 0.64 mL/min  |
| Column temp.:     | 45 °C  |
| Injection volume: | 1.7 µL   |
| UV detection:     | 225 nm   |

#### Sample preparation

A standard solution of 0.28 mg/mL of miconazole nitrate and 0.02 mg/mL of benzoic acid were prepared in mobile phase. A sample solution with a concentration of 0.28 mg/mL of miconazole nitrate and 0.02 mg/mL of benzoic acid was prepared by dispersing one applicator of an OTC (over-the-counter) cream preparation containing 100 mg of miconazole per dose in 357 mLs of mobile phase. The solution was heated for one hour at 40-45 °C in an ultrasonic bath, and then allowed to cool to room temperature. Twenty milliliters was filtered through a 0.45 µm PTFE filter, and a 2 mL aliquot was transferred to a TruView LCMS Clear Glass Vial for analysis.



### ORDERING INFORMATION

| Description                                  | P/N                         |
|--|-----------------------------|
| CORTECS Phenyl, 2.7 µm, 3.0 x 100 mm Column  | <a href="#">186008331</a>   |
| TruView LCMS Certified Vial w/ Preslit Septa | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [720004147EN](#) at waters.com

## Analysis of Mometasone Furoate Ointment

### EXPERIMENTAL


#### LC conditions

|                   |  |    |    |
|-------------------|--|----|----|
| System:           | Alliance HPLC with<br>2489 UV/Visible detector |    |    |
| Column:           | XBridge Shield RP18, 5 µm, 4.6 x 250 mm        |    |    |
| Mobile phase A:   | 100% water                                     |    |    |
| Mobile phase B:   | 100% acetonitrile                              |    |    |
| Gradient:         | Time   | %A | %B |
|                   | Initial  | 70 | 30 |
|                   | 2  | 70 | 30 |
|                   | 45   | 45 | 55 |
|                   | 46   | 70 | 30 |
|                   | 50   | 70 | 30 |
| Flow rate:        | 2.0 mL/min                                     |    |    |
| Column temp.:     | 25 °C  |    |    |
| Injection volume: | 20 µL  |    |    |
| UV detection:     | 254 nm   |    |    |

#### Sample preparation

Mometasone furoate stock standard was prepared by dissolving an accurate amount of mometasone furoate reference material in Diluent A (100:1 tetrahydrofuran:acetic acid) to make a solution at approximately 0.2 mg/mL concentration. Internal standard and mometasone furoate stock were diluted with Diluent B (50:50:1 acetonitrile:water:acetic acid) to obtain a working standard of approximately 0.05 mg/mL of mometasone furoate and 0.35 mg/mL of diethyl phthalate, respectively.

Sample temp.: 15 °C



#### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH Shield RP18, 5 µm,<br>4.6 x 250 mm Column | <a href="#">186003010</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa       | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [720005609EN](#) at waters.com

## Analysis of Mono- and Disaccharides and Selected Alditols in Juice, Beer, Wine, and Whiskey

### EXPERIMENTAL

#### LC conditions

System: ACQUITY Arc with ACQUITY QDa Detector

Column: XBridge BEH Amide **XP**, 2.5  $\mu$ m, 3.0 x 150 mm

Mobile phase A: 90% acetonitrile: 5% IPA: 5% water\*

Mobile phase B: 80% acetonitrile: 20% water\*

\*Both containing 500 ppb guanidine hydrochloride and 0.05% diethylamine.

| Gradient: | Time  | %A  | %B  |
|-----------|-------|-----|-----|
|           | 0.00  | 100 | 0   |
|           | 4.50  | 100 | 0   |
|           | 18.00 | 0   | 100 |
|           | 25.00 | 0   | 100 |
|           | 25.10 | 100 | 0   |
|           | 40.00 | 100 | 0   |

Flow rate: 0.8 mL/min

Column temp.: 85 °C

Injection volume: 1  $\mu$ L

Ionization mode: ESI-


Acquisition mode: SIR ( $m/z$ ) ([M+Cl]<sup>-</sup> ion): 185 (arabinose); 215 (fructose); 215 (glucose); 215 (inositol); 217 (sorbitol); 217 (mannitol); 377 (sucrose); 377 (maltose); 539 (maltotriose)

#### Sample preparation

A 100 mg/L stock of the nine saccharides listed below was prepared in 1:1 acetonitrile-water.

#### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| XBridge BEH Amide <b>XP</b> , 2.5 $\mu$ m, 3.0 x 150 mm Column | <a href="#">186006725</a>   |
| TruView LCMS Certified Vial w/ Preslit Septa                   | <a href="#">186005666CV</a> |



For complete experimental details, refer to full application note [720004389EN](#) at waters.com

## Analysis of Monoamine Neurotransmitters

### EXPERIMENTAL

#### LC conditions

System: ACQUITY UPLC with Xevo TQ-S detector

Column: XBridge BEH Amide **XP**,  
2.5  $\mu$ m, 2.1 x 75 mm

Mobile phase A: 95:5 water:acetonitrile containing  
100 mM ammonium formate, pH 3.0

Mobile phase B: 85:15 acetonitrile:water containing  
30 mM ammonium formate, pH 3.0


| Gradient: | Time | %A | %B  |
|-----------|------|----|-----|
|           | 0.00 | 0  | 100 |
|           | 2.50 | 30 | 70  |
|           | 2.60 | 0  | 100 |
|           | 4.00 | 0  | 100 |

Column temp.: 30 °C

Injection volume: 20  $\mu$ L

Ionization mode: ESI+

Acquisition mode: MRM (m/z): NMS 191.1 > 160;  
5-HT 177.0 > 160; DA 154 > 137;  
EP 184 > 166; NE 152 > 107



### Sample preparation

Combined stock standards of dopamine, norepinephrine, epinephrine, serotonin, and N-methyl serotonin (NMS) were prepared in methanol containing 0.1% ascorbic acid and 2.5% 1N HCl to prevent oxidation. Working standards of 100 ng/mL DA, NE, EP, 5-HT, and 10 ng/mL NMS were prepared fresh each day in starting mobile-phase conditions.

Sample temp.: 5 °C

### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| XBridge BEH Amide <b>XP</b> , 2.5 $\mu$ m,<br>2.1 x 75 mm Column | <a href="#">186006090</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa                  | <a href="#">186005666CV</a> |


For complete experimental details, refer to full application note [720005255EN](#) at waters.com

## Analysis of Monosaccharides

### EXPERIMENTAL

#### LC conditions

|                         |  |
|-------------------------|--|
| System:                 | ACQUITY UPLC H-Class Bio with FLR detector   |
| Columns:                | XBridge BEH C <sub>18</sub> , 5 µm, 4.6 x 100 mm<br>XBridge BEH C <sub>18</sub> , 3.5 µm, 2.1 x 100 mm<br>XBridge BEH C <sub>18</sub> <b>XP</b> , 2.5 µm, 2.1 x 100 mm |
| Mobile phase A:         | 0.2% N-butylamine, 0.5% phosphoric acid, and 1% THF in water   |
| Mobile phase B:         | 50% mobile phase A in acetonitrile   |
| Gradient and flow rate: | See table  |
| Column temp.:           | 30 °C  |
| Injection volume:       | 4.6 x 100 mm format, 4.8 µL;<br>2.1 x 100 mm format, 1 µL  |
| FLR detection:          | Excitation wavelength = 360 nm;<br>Emission wavelength = 425 nm  |



#### Sample preparation

Monosaccharides from bovine fetuin were released by acid hydrolysis using 2 M TFA with hydrolysis occurring for 3 h at 100 °C. Resulting hydrolysates were then dried by centrifugal evaporation followed by reconstitution in 5 µL of 80 mg/mL sodium acetate trihydrate. A 2AA labeling solution was prepared by dissolving 30 mg of 2AA in 1 mL of 2% (w/v) boric acid in methanol. This suspension was then used to dissolve 30 mg of sodium cyanoborohydride. Of this preparation, 10 µL was added to each of the monosaccharide mixtures. Monosaccharides were labeled at 80 °C for 60 minutes. Upon completion of labeling, serial dilutions were performed to generate a 1000-fold dilution of the labeled material. For preparation of monosaccharide standards, labeling was performed as outlined above with the omission of acid hydrolysis.

| Step | %B  | Method details (flow rate and time) |            |                              |            |                              |            |
|------|-----|-------------------------------------|------------|------------------------------|------------|------------------------------|------------|
|      |     | 5 µm                                |            | 3.5 µm                       |            | 2.5 µm                       |            |
|      |     | Flow (mL min <sup>-1</sup> )        | Time (min) | Flow (mL min <sup>-1</sup> ) | Time (min) | Flow (mL min <sup>-1</sup> ) | Time (min) |
| 1    | 7   | 0.480                               | 0.00       | 0.685                        | 0.00       | 0.200                        | 0.00       |
| 2    | 7   | 0.480                               | 7.78       | 0.685                        | 5.45       | 0.200                        | 3.89       |
| 3    | 17  | 0.480                               | 27.78      | 0.685                        | 19.47      | 0.200                        | 13.88      |
| 4    | 100 | 0.480                               | 28.89      | 0.685                        | 20.24      | 0.200                        | 14.43      |
| 5    | 100 | 0.480                               | 40.00      | 0.685                        | 28.03      | 0.200                        | 19.99      |
| 6    | 7   | 0.480                               | 41.11      | 0.685                        | 28.81      | 0.200                        | 20.54      |
| 7    | 7   | 0.480                               | 50.00      | 0.685                        | 35.04      | 0.200                        | 24.98      |

#### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH C <sub>18</sub> , 5 µm, 4.6 x 100 mm Column             | <a href="#">186003115</a>   |
| XBridge BEH C <sub>18</sub> , 3.5 µm, 2.1 x 100 mm Column           | <a href="#">186003033</a>   |
| XBridge BEH C <sub>18</sub> <b>XP</b> , 2.5 µm, 2.1 x 100 mm Column | <a href="#">186006031</a>   |
| TruView LCMS Certified Vial w/ Preslit Septa                        | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [WA6411](#) at waters.com

## Analysis of Morphine and Related Compounds


### EXPERIMENTAL

#### LC conditions

|                   |   |           |           |
|-------------------|---|-----------|-----------|
| System:           | ACQUITY UPLC with 30-cm column cooler/heater and TQD detector         |           |           |
| Column:           | XBridge BEH Amide,<br>3.5 µm, 4.6 x 250 mm                            |           |           |
| Mobile phase A:   | 50/50 acetonitrile/water with<br>10 mM ammonium formate, pH 3.0       |           |           |
| Mobile phase B:   | 90/10 acetonitrile/water with<br>10 mM ammonium formate, pH 3.0       |           |           |
| Gradient:         | <u>Time</u>   | <u>%A</u> | <u>%B</u> |
|                   | 0.00  | 0.1       | 99.9      |
|                   | 15.00   | 0.1       | 99.9      |
|                   | 62.50   | 99.9      | 0.1       |
|                   | 62.60   | 0.1       | 99.9      |
|                   | 75.00   | 0.1       | 99.9      |
| Flow rate:        | 1.0 mL/min  |           |           |
| Column temp.:     | 30 °C   |           |           |
| Injection volume: | 15.0 µL   |           |           |
| Ionization mode:  | ESI-  |           |           |
| Acquisition mode: | SIR (m/z): 287.5 (morphine);<br>329.5 (6-acetylmorphine); 463.6 (M3G) |           |           |

#### Sample preparation

Sample was diluted with 50:50 acetonitrile/water and filtered using 0.45 µm PVDF syringe filter.



### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH Amide, 3.5 µm,<br>4.6 x 250 mm Column         | <a href="#">186004870</a>   |
| Acrodisc, Syringe Filter,<br>PVDF, 13 mm, 0.45 µm, 100/pk | <a href="#">WAT200512</a>   |
| Waters LCMS Certified Vial<br>w/ Preslit Septa            | <a href="#">600000668CV</a> |

For complete experimental details, refer to full application note [WA64079](#) at waters.com

## Analysis of Morphine and Metabolites Using XBridge BEH HILIC Columns

### EXPERIMENTAL

#### LC conditions

|                   |   |           |           |
|-------------------|---|-----------|-----------|
| System:           | ACQUITY UPLC with PDA detector  |           |           |
| Column:           | XBridge BEH HILIC, 3.5 µm, 2.1 x 50 mm  |           |           |
| Mobile phase A:   | 10 mM ammonium formate in water, 0.125% formic acid in 50:50 acetonitrile/water |           |           |
| Mobile phase B:   | 10 mM ammonium formate in water, 0.125% formic acid in 90:10 acetonitrile/water |           |           |
| Gradient:         | <u>Time</u>   | <u>%A</u> | <u>%B</u> |
|                   | 0.00  | 0.1       | 99.9      |
|                   | 1.05  | 0.1       | 99.9      |
|                   | 4.35  | 99.9      | 0.1       |
|                   | 4.50  | 0.1       | 99.9      |
|                   | 6.00  | 0.1       | 99.9      |
| Flow rate:        | 0.6 mL/min  |           |           |
| Column temp.:     | 30 °C   |           |           |
| Injection volume: | 5 µL  |           |           |
| UV detection:     | 280 nm  |           |           |


#### Sample preparation

Sample concentration: 25 µg/mL each

Sample diluent: 75:25 ACN:MeOH with 0.2% HCOOH

### ORDERING INFORMATION

| Description                                   | P/N                         |
|---|-----------------------------|
| XBridge BEH HILIC, 3.5 µm, 2.1 x 50 mm Column | <a href="#">186004432</a>   |
| TruView LCMS Certified Vial w/ Preslit Septa  | <a href="#">186005666CV</a> |



For complete experimental details, refer to full application note [WA64701](#) at waters.com

## Analysis of Morphine and Metabolites Using CORTECS 2.7 $\mu$ m Columns

### EXPERIMENTAL

#### LC conditions

|                 |   |           |           |
|-----------------|---|-----------|-----------|
| System:         | Alliance HPLC with 2998 PDA detector  |           |           |
| Column:         | CORTECS HILIC, 2.7 $\mu$ m, 4.6 x 150 mm  |           |           |
| Mobile phase A: | 10 mM ammonium formate in<br>50% acetonitrile/49.875%<br>water/0.125% formic acid |           |           |
| Mobile phase B: | 10 mM ammonium formate<br>in 90% acetonitrile/9.875%<br>water/0.125% formic acid  |           |           |
| Gradient:       | <u>Time</u>   | <u>%A</u> | <u>%B</u> |
|                 | Initial   | 0.1       | 99.9      |
|                 | 4.42  | 0.1       | 99.9      |
|                 | 18.29   | 99.9      | 0.1       |
|                 | 18.99   | 0.1       | 99.9      |
|                 | 26.01   | 0.1       | 99.9      |

Curve

Flow rate: 1.99 mL/min

Column temp.: 30 °C

Injection volume: 14.4  $\mu$ L


UV detection: 280 nm

#### Sample preparation

|                 |                      |
|-----------------|----------------------|
| Sample:         | Morphine metabolites |
| Sample diluent: | Mobile phase B       |

#### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| CORTECS HILIC, 2.7 $\mu$ m,<br>4.6 x 150 mm Column | <a href="#">186007393</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa    | <a href="#">186005666CV</a> |



For complete experimental details, refer to full application note [WA60184](#) at waters.com

## Analysis of Mouthwash

### EXPERIMENTAL

#### LC conditions

System: Alliance 2695 with 2996 PDA detector

Column: XBridge BEH Shield RP18,  
3.5  $\mu$ m, 4.6 x 100 mm

Mobile phase A: 0.1 mM ammonium acetate, pH 5.4

Mobile phase B: Acetonitrile

| Gradient: | Time  | %A | %B |
|-----------|-------|----|----|
|           | 0.00  | 95 | 5  |
|           | 2.00  | 85 | 15 |
|           | 7.00  | 5  | 95 |
|           | 8.00  | 5  | 95 |
|           | 9.00  | 95 | 5  |
|           | 12.00 | 95 | 5  |

Flow rate: 1.2 mL/min

Column temp.: 30 °C


Injection volume: 20  $\mu$ L

UV detection: 262 nm

#### Sample preparation

Sample: Sodium saccharin (50  $\mu$ g/mL),  
Domiphen bromide (50  $\mu$ g/mL),  
Cetylpyridinium chloride (10  $\mu$ g/mL)  
in ACN/CH<sub>3</sub>COONH<sub>4</sub> (5/95)

Sample temp.: 20 °C



### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| XBridge BEH Shield RP18, 3.5 $\mu$ m,<br>4.6 x 100 mm Column | <a href="#">186003044</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa              | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [WA60199](#) at waters.com

## Analysis of Nerve Agent Degradation Products in Drinking Water


### EXPERIMENTAL

#### LC conditions

|                   |  |           |           |
|-------------------|--|-----------|-----------|
| System:           | Alliance 2690                                      |           |           |
| Column:           | XBridge BEH C <sub>18</sub> , 3.5 μm, 2.1 x 150 mm |           |           |
| Mobile phase A:   | 10 mM ammonium formate in water                    |           |           |
| Mobile phase B:   | 10 mM ammonium formate in methanol                 |           |           |
| Gradient:         | <u>Time</u>  | <u>%A</u> | <u>%B</u> |
|                   | 0.00   | 99        | 1         |
|                   | 2.00   | 99        | 1         |
|                   | 17.00  | 30        | 70        |
|                   | 25.00  | 30        | 70        |
| Flow rate:        | 0.2 mL/min   |           |           |
| Injection volume: | 5 μL   |           |           |
| Ionization mode:  | ESI-   |           |           |

#### Sample preparation

Five milliliters of water sample was spiked with solutions of GB, GD, GF, VX and RVX in methanol to the appropriate concentration and then stored at room temperature for 5 days prior to analysis (ensuring that hydrolysis occurred). The water sample was filtered through a 0.2 μm membrane filter and then analyzed by LC-MS.



### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| XBridge BEH C <sub>18</sub> , 3.5 μm,<br>2.1 x 150 mm Column | <a href="#">186003023</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa              | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [WA64076](#) at waters.com

## Analysis of Neurotransmitters

### EXPERIMENTAL


#### LC conditions

|                       |  |
|-----------------------|--|
| System:               | ACQUITY UPLC with TQD detector   |
| Column:               | XBridge BEH HILIC, 3.5 $\mu$ m, 2.1 x 50 mm  |
| Mobile phase A:       | 10 mM ammonium formate with 0.125% formic acid in water                              |
| Mobile phase B:       | 10 mM ammonium formate with 0.125% formic acid in 90/5/5 acetonitrile/methanol/water |
| Isocratic conditions: | 10% A; 90% B   |
| Flow rate:            | 0.5 mL/min   |
| Column temp.:         | 30 °C  |
| Injection volume:     | 10.0 $\mu$ L   |
| Ionization mode:      | ESI+   |
| Acquisition mode:     | SIR (m/z): 146.1 (acetylcholine); 104.0 (choline)                                    |

#### Sample preparation

Sample diluent: 75/25 acetonitrile/methanol with 0.2% formic acid

Sample concentration: 5 ng/mL each



#### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| XBridge BEH HILIC, 3.5 $\mu$ m, 2.1 x 50 mm Column | <a href="#">186004432</a>   |
| TruView LCMS Certified Vial w/ Preslit Septa       | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [XBRIDGE8](#) at waters.com

## Analysis of Nimodipine

### EXPERIMENTAL

#### LC conditions


|                 |  |    |    |
|-----------------|--|----|----|
| System:         | Alliance 2695 with 2996 PDA detector             |    |    |
| Column:         | XBridge BEH Shield RP18,<br>3.5 µm, 4.6 x 100 mm |    |    |
| Mobile phase A: | 200 mM ammonium formate pH 3                     |    |    |
| Mobile phase B: | Acetonitrile                                     |    |    |
| Mobile phase C: | Water  |    |    |
| Gradient:       | Time   | %A | %B |
|                 | 0.00   | 10 | 30 |
|                 | 50.00  | 10 | 60 |
| Flow rate:      | 1.4 mL/min                                       |    |    |
| Column temp.:   | 30 °C  |    |    |
| Injection:      | 100 µL   |    |    |
| UV detection:   | 254 nm   |    |    |

#### Sample preparation

Sample concentration: 30 mg/mL in DMSO

#### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH Shield RP18, 3.5 µm,<br>4.6 x 100 mm Column | <a href="#">186003044</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa         | <a href="#">186005666CV</a> |



For complete experimental details, refer to full application note [720005580EN](#) at waters.com

## Analysis of Nitroaromatic Compounds


### EXPERIMENTAL

#### LC conditions

|                   |  |
|-------------------|--|
| System:           | ACQUITY UPLC   |
| Column:           | CORTECS Phenyl, 2.7 $\mu$ m, 2.1 x 100 mm;<br>CORTECS C <sub>8</sub> , 2.7 $\mu$ m, 2.1 x 100 mm |
| Mobile phase:     | 45:55 methanol:water   |
| Separation mode:  | Isocratic  |
| Flow rate:        | 0.5 mL/min   |
| Column temp.:     | 40 °C  |
| Injection volume: | 1.0 $\mu$ L  |
| UV detection:     | 254 nm   |

#### Sample preparation

The nitroaromatic compounds were prepared as 10  $\mu$ g/mL solutions in 100% methanol.



### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| CORTECS Phenyl, 2.7 $\mu$ m,<br>2.1 x 100 mm Column          | <a href="#">186008321</a>   |
| CORTECS C <sub>8</sub> , 2.7 $\mu$ m,<br>2.1 x 100 mm Column | <a href="#">186008351</a>   |
| TruView LCMS Certified<br>Max Recovery Vial                  | <a href="#">186005662CV</a> |
| Neutrals QC Reference Material                               | <a href="#">186006360</a>   |

For complete experimental details, refer to full application note [XBRIDGE9](#) at waters.com

## Analysis of Non-Steroidal Inflammatory Drugs (NSAIDS)

### EXPERIMENTAL

#### LC conditions

System: Alliance 2695 with 2996 PDA detector

Column: XBridge BEH Phenyl,  
3.5  $\mu$ m, 4.6 x 100 mm

Mobile phase A: Water

Mobile phase B: Methanol

Mobile phase C: 0.2% formic acid in water

| Gradient: | Time  | %A | %B | C% |
|-----------|-------|----|----|----|
|           | 0.00  | 40 | 50 | 10 |
|           | 13.33 | 25 | 65 | 10 |
|           | 16.67 | 25 | 65 | 10 |
|           | 17.33 | 40 | 50 | 10 |
|           | 20.00 | 40 | 50 | 10 |

Flow rate: 1.0 mL/min

Column temp.: 30 °C


Injection volume: 15  $\mu$ L

UV detection: 254 nm

#### Sample preparation

Sample: Fenoprofen (20  $\mu$ g/mL),  
Ibuprofen (20  $\mu$ g/mL),  
Diclofenac (10  $\mu$ g/mL),  
Tolmetin (10  $\mu$ g/mL),  
Suprofen (10  $\mu$ g/mL),  
Naproxen (10  $\mu$ g/mL)  
in  $H_2O$ /MeOH (60/40)

Sample temp.: 15 °C



#### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH Phenyl, 3.5 $\mu$ m,<br>4.6 x 100 mm Column | <a href="#">186003334</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa         | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [WA64116](#) at waters.com

## Analysis of Nucleobases

### EXPERIMENTAL


#### LC conditions

|                   |   |           |           |
|-------------------|---|-----------|-----------|
| System:           | Alliance HPLC with 2998 PDA detector                            |           |           |
| Column:           | XBridge BEH Amide,<br>3.5 µm, 4.6 x 250 mm                      |           |           |
| Mobile phase A:   | 50/50 acetonitrile/water with<br>10 mM ammonium formate, pH 3.0 |           |           |
| Mobile phase B:   | 95/5 acetonitrile/water with<br>10 mM ammonium formate, pH 3.0  |           |           |
| Gradient:         | <u>Time</u>   | <u>%A</u> | <u>%B</u> |
|                   | 0.00  | 1         | 99        |
|                   | 50.00   | 50        | 50        |
|                   | 50.10   | 1         | 99        |
|                   | 60.00   | 1         | 99        |
| Flow rate:        | 1.2 mL/min  |           |           |
| Column temp.:     | 30 °C   |           |           |
| Injection volume: | 60.0 µL   |           |           |
| UV detection:     | 260 nm  |           |           |

#### Sample preparation

Sample was diluted with 50:50 acetonitrile/water and filtered using 0.45 µm PVDF syringe filter.

Sample concentration: 20 µg/mL



### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH Amide, 3.5 µm,<br>4.6 x 250 mm Column         | <a href="#">186004870</a>   |
| Acrodisc, Syringe Filter,<br>PVDF, 13 mm, 0.45 µm, 100/pk | <a href="#">WAT200512</a>   |
| Waters LCMS Certified Vial                                | <a href="#">600000751CV</a> |

For complete experimental details, refer to full application note [WA64121](#) at waters.com

## Analysis of Nucleotide Phosphates

### EXPERIMENTAL


#### LC conditions

|                   |   |
|-------------------|---|
| System:           | Alliance HPLC with 2998 PDA detector                          |
| Column:           | XBridge BEH Amide,<br>3.5 µm, 4.6 x 250 mm                    |
| Mobile phase:     | 80/20 acetonitrile/water with<br>2 mM monopotassium phosphate |
| Separation mode:  | Isocratic   |
| Flow rate:        | 1.2 mL/min  |
| Column temp.:     | 25 °C   |
| Injection volume: | 40.0 µL   |
| UV detection:     | 254 nm  |

#### Sample preparation

Sample was diluted with 50:50 acetonitrile/water and filtered using 0.45 µm PVDF syringe filter.

Sample concentration: 10 µg/mL



### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH Amide, 3.5 µm,<br>4.6 x 250 mm Column         | <a href="#">186004870</a>   |
| Acrodisc, Syringe Filter,<br>PVDF, 13 mm, 0.45 µm, 100/pk | <a href="#">WAT200512</a>   |
| Waters LCMS Certified Vial                                | <a href="#">600000751CV</a> |

For complete experimental details, refer to full application note [WA64075](#) at waters.com

## Analysis of Nutrients

### EXPERIMENTAL


#### LC conditions

|                   |   |      |      |
|-------------------|---|------|------|
| System:           | ACQUITY UPLC with PDA detector  |      |      |
| Column:           | XBridge BEH HILIC, 3.5 µm, 2.1 x 50 mm  |      |      |
| Mobile phase A:   | 10 mM ammonium formate in water, 0.125% formic acid in 50/50 acetonitrile/water |      |      |
| Mobile phase B:   | 10 mM ammonium formate in water, 0.125% formic acid in 90/10 acetonitrile/water |      |      |
| Gradient:         | Time  | %A   | %B   |
|                   | 0.00  | 0.1  | 99.9 |
|                   | 1.05  | 0.1  | 99.9 |
|                   | 4.35  | 99.9 | 0.1  |
|                   | 4.50  | 0.1  | 99.9 |
|                   | 6.00  | 0.1  | 99.9 |
| Flow rate:        | 0.6 mL/min  |      |      |
| Column temp.:     | 30 °C   |      |      |
| Injection volume: | 5 µL  |      |      |
| UV detection:     | 268 nm  |      |      |

#### Sample preparation

Sample diluent: 75/25 acetonitrile/methonal with 0.2% formic acid

Sample concentration: 25 µg/mL each



#### ORDERING INFORMATION

| Description                                   | P/N                         |
|---|-----------------------------|
| XBridge BEH HILIC, 3.5 µm, 2.1 x 50 mm Column | <a href="#">186004432</a>   |
| TruView LCMS Certified Vial w/ Preslit Septa  | <a href="#">186005666CV</a> |


For complete experimental details, refer to full application note [720002376EN](#) at waters.com

## Analysis of Oligonucleotides

### EXPERIMENTAL

#### LC conditions

|                 |   |
|-----------------|---|
| System:         | Alliance 2796 Bioseparations System with 2996 PDA detector        |
| Column:         | XBridge Oligonucleotide BEH C <sub>18</sub> , 2.5 µm, 2.1 x 50 mm |
| Mobile phase A: | 100 mM TEAA, pH 7   |
| Mobile phase B: | 80% A, 20% acetonitrile   |
| Gradient:       | 40 to 62.5% B in 30 min   |
| Flow rate:      | 0.2 mL/min  |
| Column temp.:   | 60 °C   |
| UV detection:   | 260 nm  |



### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| XBridge Oligonucleotide BEH C <sub>18</sub> , 2.5 µm, 2.1 x 50 mm Column | <a href="#">186003952</a>   |
| TruView LCMS Certified Vial w/ Preslit Septa                             | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [720005103EN](#) at [waters.com](#)

## Analysis of Omeprazole


### EXPERIMENTAL

#### LC conditions

|                   |   |    |    |
|-------------------|---|----|----|
| System:           | Alliance 2695 with 2998 PDA and ACQUITY QDa detectors |    |    |
| Column:           | CORTECS C <sub>18</sub> +, 2.7 µm, 4.6 x 150 mm       |    |    |
| Mobile phase A:   | 0.1% formic acid in water                             |    |    |
| Mobile phase B:   | 0.1% formic acid in acetonitrile                      |    |    |
| Gradient:         | Time  | %A | %B |
|                   | 0.00  | 90 | 10 |
|                   | 16.50   | 22 | 78 |
|                   | 16.60   | 90 | 10 |
|                   | 20.00   | 90 | 10 |
| Flow rate:        | 1.2 mL/min  |    |    |
| Column temp.:     | 30 °C   |    |    |
| Injection volume: | 9.6 µL  |    |    |
| UV detection:     | 280 nm  |    |    |
| Ionization mode:  | ESI+  |    |    |
| Acquisition mode: | Full scan 120–420 m/z                                 |    |    |

#### Sample preparation

Two Omeprazole tablets (20 mg Omeprazole) were separately crushed with a mortar and pestle and transferred to two 100 mL volumetric flasks. To one flask (A), 25 mL 0.1 N HCl was added and the solution was left at room temperature for 1.5 hours. Twenty-five milliliters 0.1 N NaOH was added to neutralize the solution. Methanol was added to the flask to bring the sample up to 100 mL. The other solution (B) was diluted to 100 mL with 50:50 methanol:water. Both solutions were then filtered through a 0.2 µm filter. To create the sample for injection 0.66 mL of solution A and 0.34 mL of solution B were combined in an LCMS Certified Max Recovery Vial.



#### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| CORTECS C <sub>18</sub> +, 2.7 µm, 4.6 x 150 mm Column | <a href="#">186007408</a>   |
| Waters LCMS Certified Max Recovery Vial                | <a href="#">600000749CV</a> |

For complete experimental details, refer to full application note [WA6410](#) at waters.com

## Analysis of Organic Acids


### EXPERIMENTAL

#### LC conditions

|                   |  |      |      |
|-------------------|--|------|------|
| System:           | ACQUITY UPLC with 30-cm column cooler/heater and ACQUITY TQD Detector  |      |      |
| Column:           | XBridge BEH Amide,<br>3.5 $\mu$ m, 4.6 x 250 mm  |      |      |
| Mobile phase A:   | 50/50 acetonitrile/water with<br>10 mM ammonium acetate and<br>0.04% ammonium hydroxide, pH 9.0  |      |      |
| Mobile phase B:   | 95/5 acetonitrile/water with<br>10 mM ammonium acetate and<br>0.04% ammonium hydroxide, pH 9.0   |      |      |
| Gradient:         | Time   | %A   | %B   |
|                   | 0.00   | 0.1  | 99.9 |
|                   | 3.00   | 0.1  | 99.9 |
|                   | 3.10   | 40.0 | 60.0 |
|                   | 14.00  | 70.0 | 30.0 |
|                   | 14.10  | 0.1  | 99.9 |
|                   | 26.00  | 0.1  | 99.9 |
| Flow rate:        | 1.0 mL/min   |      |      |
| Column temp.:     | 50 °C  |      |      |
| Injection volume: | 15.0 $\mu$ L   |      |      |
| Ionization mode:  | ESI-   |      |      |
| Acquisition mode: | MRM (m/z): pyruvic acid 86.92 > 42.9;<br>lactic acid 88.92 > 42.9; succinic acid<br>116.93 > 72.9; maleic acid and fumaric<br>acid 114.88 > 70.9 |      |      |

#### Sample preparation

Sample was diluted with 50:50 acetonitrile/water and filtered using 0.45  $\mu$ m PVDF syringe filter.



#### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| XBridge BEH Amide, 3.5 $\mu$ m,<br>4.6 x 250 mm Column         | <a href="#">186004870</a>   |
| Acrodisc, Syringe Filter,<br>PVDF, 13 mm, 0.45 $\mu$ m, 100/pk | <a href="#">WAT200512</a>   |
| Waters LCMS Certified Vial<br>w/ Preslit Septa                 | <a href="#">600000668CV</a> |

For complete experimental details, refer to full application note [WA43181](#) at waters.com

## Analysis of Organic Acids and Bases

### EXPERIMENTAL

#### LC conditions

System: Alliance 2695 with 2996 PDA detector

#### Stability Testing

Column: XBridge BEH C<sub>18</sub>, 5 µm, 4.6 x 150 mm

Mobile phase A: 200 mM potassium phosphate (pH 12):acetonitrile (80:20)

Mobile phase B: Water

Mobile phase C: Acetonitrile

Isocratic conditions: 10% A; 37% B; 53% C

Flow rate: 1.0 mL/min

Injection volume: 10 µL of 440 µg/mL (total concentration)

UV detection

wavelength: 254 nm

#### Selectivity Study

Column: XBridge C<sub>18</sub>, 3.5 µm, 4.6 x 100 mm

Mobile phase A1: 30 mM potassium phosphate, pH 2

Mobile phase A2: 30 mM potassium phosphate, pH 7

Mobile phase A2: 30 mM potassium phosphate, pH 12

Mobile phase B: Acetonitrile

Gradient:

| Time | %A | %B |
|------|----|----|
| 0.0  | 90 | 10 |
| 7.0  | 20 | 80 |
| 8.0  | 20 | 80 |

Flow rate: 1.4 mL/min



Column temp.: 30 °C

Injection volume: 20 µL of 5 µg/mL (each) standard

UV detection: 210 nm (pH 2, 7); 220 nm (pH 12)

### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH C <sub>18</sub> , 5 µm, 4.6 x 150 mm Column   | <a href="#">186003116</a>   |
| XBridge BEH C <sub>18</sub> , 3.5 µm, 4.6 x 100 mm Column | <a href="#">186003033</a>   |
| TruView LCMS Certified Vial w/ Preslit Septa              | <a href="#">186005666CV</a> |



For complete experimental details, refer to full application note [WA64108](#) at waters.com

## Analysis of Organophosphonic Acids by Isocratic MS

### EXPERIMENTAL


#### LC conditions

|                   |   |
|-------------------|---|
| System:           | ACQUITY UPLC with 30-cm column cooler/heater and ACQUITY TQD detector                           |
| Column:           | XBridge BEH Amide,<br>3.5 $\mu$ m, 4.6 x 250 mm   |
| Mobile phase:     | 90/10 acetonitrile/water with<br>10 mM ammonium acetate and<br>0.04% ammonium hydroxide, pH 9.0 |
| Separation mode:  | Isocratic   |
| Flow rate:        | 1.0 mL/min  |
| Column temp.:     | 65 °C   |
| Injection volume: | 15.0 $\mu$ L  |
| Ionization mode:  | ESI-  |
| Acquisition mode: | SIR (m/z): 122.9 (EMPA); 136.95 (IMPA);<br>150.95 (MMPA); 177.0 (CMPA);<br>179.0 (PPMA)         |

#### Sample preparation

Sample was diluted with 50:50 acetonitrile/water and filtered using 0.45  $\mu$ m PVDF syringe filter.

Sample concentration: 10  $\mu$ g/mL each



### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| XBridge BEH Amide, 3.5 $\mu$ m,<br>4.6 x 250 mm Column         | <a href="#">186004870</a>   |
| Acrodisc, Syringe Filter,<br>PVDF, 13 mm, 0.45 $\mu$ m, 100/pk | <a href="#">WAT200512</a>   |
| Waters LCMS Certified Vial<br>w/ Preslit Septa                 | <a href="#">600000668CV</a> |

For complete experimental details, refer to full application note [WA64107](#) at waters.com

## Analysis of Organophosphonic Acids by MS

### EXPERIMENTAL


#### LC conditions

|                   |   |     |      |
|-------------------|---|-----|------|
| System:           | ACQUITY UPLC with 30-cm column cooler/heater and ACQUITY TQD detector                     |     |      |
| Column:           | XBridge BEH Amide, 3.5 µm, 4.6 x 250 mm   |     |      |
| Mobile phase A:   | 50/50 acetonitrile/water with 10 mM ammonium acetate and 0.04% ammonium hydroxide, pH 9.0 |     |      |
| Mobile phase B:   | 95/5 acetonitrile/water with 10 mM ammonium acetate and 0.04% ammonium hydroxide, pH 9.0  |     |      |
| Gradient:         | Time  | %A  | %B   |
|                   | 0.00  | 0.1 | 99.9 |
|                   | 60.00   | 10  | 90.0 |
|                   | 60.01   | 0.1 | 99.9 |
|                   | 72.00   | 0.1 | 99.9 |
| Flow rate:        | 1.0 mL/min  |     |      |
| Column temp.:     | 65 °C   |     |      |
| Injection volume: | 15.0 µL   |     |      |
| Ionization mode:  | ESI-  |     |      |
| Acquisition mode: | SIR (m/z): 122.9 (EMPA); 136.95 (IMPA); 150.95 (MMPA); 177.0 (CMPA); 179.0 (PMPA)         |     |      |

#### Sample preparation

Sample was diluted with 50:50 acetonitrile/water and filtered using 0.45 µm PVDF syringe filter.

Sample concentration: 10 µg/mL each



#### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| XBridge BEH Amide, 3.5 µm, 4.6 x 250 mm Column         | <a href="#">186004870</a>   |
| Acrodisc, Syringe Filter, PVDF, 13 mm, 0.45 µm, 100/pk | <a href="#">WAT200512</a>   |
| Waters LCMS Certified Vial w/ Preslit Septa            | <a href="#">600000668CV</a> |

For complete experimental details, refer to full application note [720005185EN](#) at waters.com

## Analysis of a Comprehensive Panel of Pain Management Drugs Using XBridge BEH Phenyl Columns

### EXPERIMENTAL

#### LC conditions

System: ACQUITY UPLC I-Class, Fixed Loop (FL) with Column Manager (CMA), Xevo TQD Mass Spectrometer

Columns: XBridge BEH Phenyl **XP**, 2.5 µm, 3.0 x 50 mm

Mobile phase A: Water with 0.1% formic acid

Mobile phase B: Acetonitrile with 0.1% formic acid

| Gradient: | <u>Time</u> | <u>%A</u> | <u>%B</u> |
|-----------|-------------|-----------|-----------|
|           | 0.0         | 95        | 5         |
|           | 4.0         | 40        | 60        |
|           | 4.1         | 95        | 5         |
|           | 5.0         | 95        | 5         |

Flow rate: 0.6 mL/min

Column temp.: 30 °C

Injection volume: 10 µL

Ionization mode: ESI+

Acquisition mode: MRM


#### Sample preparation

Panel of 35 common pain management compounds including opioids, benzodiazepines, stimulants, enzyoletecgonine (BZE), and phencyclidine (PCP). Stock solutions were prepared in methanol. Working solutions were prepared in 5% acetonitrile containing 0.1% formic acid.

Sample temp.: 10 °C

### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH Phenyl <b>XP</b> , 2.5 µm, 3.0 x 50 mm Column | <a href="#">186006069</a>   |
| TruView LCMS Certified Vial w/ Preslit Septa              | <a href="#">186005666CV</a> |



For complete experimental details, refer to full application note [720005185EN](#) at [waters.com](#)

## Analysis of a Comprehensive Panel of Pain Management Drugs Using CORTECS C<sub>18</sub> Columns

### EXPERIMENTAL

#### LC conditions

System: ACQUITY UPLC I-Class, Fixed Loop (FL) with Column Manager (CMA), Xevo TQD Mass Spectrometer

Columns: CORTECS C<sub>18</sub>, 2.7 μm, 3.0 x 50 mm

Mobile phase A: Water with 0.1% formic acid

Mobile phase B: Acetonitrile with 0.1% formic acid

| Gradient: | Time | %A | %B |
|-----------|------|----|----|
|           | 0.0  | 95 | 5  |
|           | 4.0  | 40 | 60 |
|           | 4.1  | 95 | 5  |
|           | 5.0  | 95 | 5  |

Flow rate: 0.6 mL/min

Column temp.: 30 °C

Injection volume: 10 μL

Ionization mode: ESI+

Acquisition mode: MRM


#### Sample preparation

Panel of 35 common pain management compounds, including opioids, benzodiazepines, stimulants, enzyoletconine (BZE), and phencyclidine (PCP). Stock solutions were prepared in methanol. Working solutions were prepared in 5% acetonitrile containing 0.1% formic acid.

Sample temp.: 10 °C

### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| CORTECS C <sub>18</sub> , 2.7 μm, 3.0 x 50 mm Column | <a href="#">186007370</a>   |
| TruView LCMS Certified Vial w/ Preslit Septa         | <a href="#">186005666CV</a> |



For complete experimental details, refer to full application note [720004672EN](#) at waters.com

## Analysis of Peppermint Extract


### EXPERIMENTAL

#### LC conditions

|                 |   |           |
|-----------------|---|-----------|
| System:         | AutoPurification  |           |
| Columns:        | XSelect CSH C <sub>18</sub> , 5 µm, 4.6 x 100 mm;<br>XSelect CSH Phenyl-Hexyl,<br>5 µm, 4.6 x 100 mm;<br>XSelect CSH Fluoro-Phenyl,<br>5 µm, 4.6 x 100 mm |           |
| Mobile phase A: | 0.1% trifluoroacetic acid (TFA) in water  |           |
| Mobile phase B: | 0.1% TFA in acetonitrile  |           |
| Gradient:       | <u>Time</u>   | <u>%B</u> |
|                 | 0.0   | 5.0       |
|                 | 1.0   | 17.4      |
|                 | 11.7  | 25.4      |
|                 | 12.2  | 95.0      |
|                 | 17.2  | 95.0      |
|                 | 17.4  | 5.0       |
|                 | 25.4  | 5.0       |
| Flow rate:      | 1.46 mL/min   |           |
| UV detection:   | 220 nm  |           |

#### Sample preparation

A total of 3.3 g dried peppermint was extracted with a 20 mL 80:20 methanol/water mixture for six hours at room temperature. The supernatant was filtered with an Acrodisc Syringe Filter with GHP Membrane, 25 mm, 0.45 µm.



### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| XSelect CSH C <sub>18</sub> , 5 µm,<br>4.6 x 100 mm Column | <a href="#">186005289</a>   |
| XSelect CSH Phenyl-Hexyl, 5 µm,<br>4.6 x 100 mm Column     | <a href="#">186005399</a>   |
| XSelect CSH Fluoro-Phenyl, 5 µm,<br>4.6 x 100 mm Column    | <a href="#">186005344</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa            | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [720005588EN](#) at waters.com

## Analysis of Peptides

### EXPERIMENTAL

#### LC conditions

|                 |  |  |
|-----------------|--|--|
| Systems:        | ACQUITY Arc with 2489 UV/Visible detector and ACQUITY QDa Mass Spectrometer, flow path 1 |  |
|                 |  | Agilent 1100 Series HPLC with quaternary pump and DAD detector |
| Columns:        | XBridge BEH C <sub>18</sub> , 3.5 μm, 4.6 x 100 mm                                       |  |
| Mobile phase A: | Water with 0.1% (v/v) TFA  |  |
| Mobile phase B: | Acetonitrile with 0.1% (v/v) TFA   |  |
| Gradient:       | Time   | %A   |
|                 | Initial  | 95   |
|                 | 5.00   | 95   |
|                 | 45.00  | 50   |
|                 | 47.50  | 5  |
|                 | 52.50  | 5  |
|                 | 52.60  | 95   |
|                 | 60.00  | 95   |
| Flow rate:      | 0.5 mL/min   |  |

Column temp.: 40 °C

Injection volume: 75 μL

UV detection: 214 nm


#### Sample preparation

A 90-μL aliquot of infliximab at 10 mg/mL was reduced with dithiothreitol and alkylated with iodoacetamide. Samples were then digested with trypsin at a 1:20 enzyme to substrate ratio and incubated at 37 °C for 18 hours. Neat TFA was added to deactivate the trypsin. Digested samples had an estimated final concentration of 0.4 mg/mL and were injected without any further dilution.

Sample temp.: 4 °C

### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| XBridge BEH C <sub>18</sub> , 3.5 μm,<br>4.6 x 100 mm Column | <a href="#">186003033</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa              | <a href="#">186005666CV</a> |



For complete experimental details, refer to full application note [720005663EN](#) at waters.com

## Analysis of Pesticides (AI 1, Tebuconazole)

### EXPERIMENTAL

#### LC conditions


|                   |  |    |    |
|-------------------|--|----|----|
| System:           | ACQUITY Arc with 2998 PDA detector and ACQUITY QDa Mass Spectrometer |    |    |
| Column:           | CORTECS C <sub>18</sub> +, 2.7 μm, 3.0 x 100 mm                      |    |    |
| Mobile phase A:   | Water with 0.1% formic acid  |    |    |
| Mobile phase B:   | Acetonitrile   |    |    |
| Gradient:         | Time   | %A | %B |
|                   | 0.00   | 80 | 20 |
|                   | 10.00  | 20 | 80 |
|                   | 11.00  | 10 | 90 |
|                   | 12.00  | 10 | 90 |
|                   | 12.10  | 80 | 20 |
| Flow rate:        | 0.80 mL/min  |    |    |
| Column temp.:     | 50 °C  |    |    |
| Injection volume: | 5 μL   |    |    |
| UV detection:     | 220 nm   |    |    |
| Ionization mode:  | ESI+   |    |    |
| Acquisition mode: | Full scan 100-1000 m/z   |    |    |

#### Sample preparation

Add 1 g commercially available pesticide formulation to 9 mL 50:50 (v/v) acetonitrile/water, sonicate for 20 minutes and filter using a 0.2 μm PVDF syringe filter.

### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| CORTECS C <sub>18</sub> +, 2.7 μm,<br>3.0 x 100 mm Column | <a href="#">186007402</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa           | <a href="#">186005666CV</a> |



For complete experimental details, refer to full application note [WA60205](#) at waters.com

## Analysis of Pharmaceuticals in Environmental Samples

### EXPERIMENTAL

#### LC conditions

Column: XBridge BEH C<sub>18</sub>, 5 µm, 2.1 x 50 mm

#### For ESI- method

Mobile phase A: 5 mM ammonium hydroxide

Mobile phase B: Acetonitrile

| Gradient: | <u>Time</u> | <u>%A</u> | <u>%B</u> |
|-----------|-------------|-----------|-----------|
|           | 0           | 95        | 5         |
|           | 1           | 95        | 5         |
|           | 12          | 40        | 60        |
|           | 13          | 95        | 5         |
|           | 25          | 95        | 5         |

#### For ESI+ method

Mobile phase A: 0.5% formic acid

Mobile phase B: Acetonitrile

| Gradient: | <u>Time</u> | <u>%A</u> | <u>%B</u> |
|-----------|-------------|-----------|-----------|
|           | 0           | 95        | 5         |
|           | 1           | 95        | 5         |
|           | 14          | 30        | 70        |
|           | 15          | 95        | 5         |
|           | 25          | 95        | 5         |

Flow rate: 0.2 mL/min

Column temp.: 30 °C

Injection volume: 20 µL

Ionization mode: ESI+ and ESI-

Acquisition mode: MRM

#### Sample preparation



Solid-phase extraction was used to separate the pharmaceuticals from the water component of the sample. The samples were filtered through 0.45 µm filters which were pre-washed with hexane, acetone, methanol, and water. The pH of the samples was adjusted to 2.0 using concentrated HCL. Oasis MCX 3 cc was used as the solid-phase adsorbent. The adsorbent was pre-conditioned with 2 mL of hexane, 2 mL of acetone, 10 mL of methanol, and 10 mL of non-contaminated groundwater (pH adjusted to 2.0). The samples were added to the cartridges at a flow rate of 8 mL/min. The cartridges were dried with nitrogen for 1 hour and the pharmaceuticals eluted using 4 x 1 mL of acetone. The extracts were then evaporated to 100 µL with nitrogen and 100 µL of methanol was added. Evaporation continued until the volume was 50 µL. Four hundred fifty microliters of ammonium hydroxide was added and the extracts stored at -18 °C.

|                           |  | Retention Time (min) | Ionization (ESI) | Precursor Ion (m/z) | Product Ion (m/z) |
|---------------------------|--|----------------------|------------------|---------------------|-------------------|
| Ciprofloxacin             | Antibiotic   | 9.8                  | Negative         | 331.9               | 287.9             |
| Norfloxacin               | Antibiotic   | 9.7                  | Negative         | 319.8               | 275.9             |
| Ofloxacin                 | Antibiotic   | 9.7                  | Negative         | 361.8               | 317.9             |
| Carbamazepine             | Antiepileptic  | 13.4                 | Negative         | 237.0               | 193.9             |
| Acebutolol                | Beta blocker   | 10.5                 | Negative         | 336.8               | 116.0             |
| Atenolol                  | Beta blocker   | 3.4                  | Negative         | 267.0               | 144.9             |
| Metoprolol                | Beta blocker   | 10.7                 | Negative         | 267.9               | 190.9             |
| Sotalol                   | Beta blocker   | 3.1                  | Negative         | 254.8               | 132.9             |
| Clofibric acid            | Drug metabolite  | 8.9                  | Negative         | 212.9               | 126.9             |
| Enrofloxacin (IS)         | IS for the antibiotics                                       | 10.3                 | Negative         | 359.9               | 315.9             |
| Dihydrocarbamazepine (IS) | IS for carbamazepine   | 13.5                 | Negative         | 239.0               | 193.9             |
| Alprenolol (IS)           | IS for the beta blockers                                     | 12.8                 | Negative         | 249.9               | 172.9             |
| Diclofenac                | Anti-inflammatory  | 11.5                 | Positive         | 293.8               | 249.9             |
| Ibuprofen                 | Anti-inflammatory  | 10.8                 | Positive         | 205.1               | 161.0             |
| Ketoprofen                | Anti-inflammatory  | 10.0                 | Positive         | 253.0               | 209.0             |
| Naproxen                  | Anti-inflammatory  | 9.5                  | Positive         | 229.0               | 169.9             |
| Bezafibrate               | Lipid regulator  | 10.6                 | Positive         | 360.0               | 273.9             |
| Fenoprop (IS)             | IS for the anti-inflammatory, bezafibrate and clofibric acid | 10.5                 | Positive         | 266.8               | 194.8             |

IS = internal standard

For complete experimental details, refer to full application note [WA60205](#) at waters.com

## Analysis of Pharmaceuticals in Environmental Samples *continued*



### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH C <sub>18</sub> , 5 μm,<br>2.1 x 50 mm Column | <a href="#">186003108</a>   |
| Oasis MCX 3 cc 60 mg Cartridge                            | <a href="#">186000253</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa           | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [720005576EN](#) at waters.com

## Analysis of Polyethylene Glycols (PEGs)

### EXPERIMENTAL


#### LC conditions

|                   |  |
|-------------------|--|
| System:           | ACQUITY UPLC H-Class with PDA detector and ACQUITY QDa Mass Spectrometer |
| Column:           | CORTECS C <sub>8</sub> , 2.7 μm, 3 x 100 mm                              |
| Mobile phase:     | 80:20 water/methanol with 1% glacial acetic acid                         |
| Separation mode:  | Isocratic  |
| Flow rate:        | 0.6 mL/min   |
| Column temp.:     | 30 °C  |
| Injection volume: | 1 μL   |
| UV detection:     | 280 nm   |
| Ionization mode:  | ESI+   |
| Acquisition mode: | Full scan 50-1000 m/z  |

#### Sample preparation

Acetaminophen in cough syrup.

Sample temp.: Ambient



### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| CORTECS C <sub>8</sub> , 2.7 μm,<br>3 x 100 mm Column | <a href="#">186008361</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa       | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [WA64704](#) at waters.com

## Analysis of HILIC Quality Control Reference Material


### EXPERIMENTAL

#### LC conditions

|                   |   |
|-------------------|---|
| System:           | ACQUITY UPLC with PDA detector                            |
| Column:           | CORTECS HILIC, 2.7 µm, 4.6 x 100 mm                       |
| Mobile phase:     | 90:10 acetonitrile/100 mM ammonium formate (pH 3.0) (v/v) |
| Separation:       | Isocratic   |
| Flow rate:        | 2.0 mL/min  |
| Column temp.:     | 30 °C   |
| Injection volume: | 9.6 µL  |

#### Sample preparation

|         |                             |
|---------|-----------------------------|
| Sample: | HILIC QC Reference Material |
|---------|-----------------------------|



### ORDERING INFORMATION

| Description                                     | P/N                         |
|---|-----------------------------|
| CORTECS HILIC, 2.7 µm,<br>4.6 x 100 mm Column   | <a href="#">186007392</a>   |
| HILIC QC Reference Material                     | <a href="#">186007226</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [WA64705](#) at waters.com

## Analysis of LCMS Quality Control Reference Material

### EXPERIMENTAL

#### LC conditions

System: ACQUITY UPLC with  
ACQUITY TQD Mass Spectrometer

Column: CORTECS C<sub>18</sub>, 2.7 μm, 4.6 x 100 mm

Mobile phase A: 0.1% formic acid in water

Mobile phase B: 0.1% formic acid in acetonitrile

| Gradient: | Time  | %A | %B | Curve |
|-----------|-------|----|----|-------|
|           | 0.00  | 95 | 5  | -     |
|           | 9.60  | 25 | 75 | 6     |
|           | 10.00 | 25 | 75 | 6     |
|           | 10.10 | 75 | 25 | 6     |
|           | 12.00 | 75 | 25 | 6     |

Flow rate: 2.0 mL/min


Column temp.: 40 °C

Injection volume: 9.6 μL

Ionization mode: ESI+

#### Sample preparation

Sample: LCMS QC Reference Material



### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| CORTECS C <sub>18</sub> , 2.7 μm,<br>4.6 x 100 mm Column | <a href="#">186007377</a>   |
| LCMS QC Reference Material                               | <a href="#">186006963</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa          | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [WA60706](#) at waters.com

## Analysis of Reversed-Phase Quality Control Reference Material


### EXPERIMENTAL

#### LC conditions

|                   |   |           |           |       |
|-------------------|---|-----------|-----------|-------|
| System:           | ACQUITY UPLC with PDA detector                  |           |           |       |
| Column:           | CORTECS C <sub>18</sub> +, 2.7 μm, 2.1 x 100 mm |           |           |       |
| Mobile phase A:   | 0.1% formic acid in water                       |           |           |       |
| Mobile phase B:   | 0.1% formic acid in acetonitrile                |           |           |       |
| Gradient:         | <u>Time</u>                                     | <u>%A</u> | <u>%B</u> | Curve |
|                   | Initial   | 95        | 5         | –     |
|                   | 2.70  | 5         | 95        | 6     |
|                   | 3.00  | 5         | 95        | 6     |
|                   | 3.12  | 95        | 5         | 6     |
|                   | 4.00  | 95        | 5         | 6     |
| Flow rate:        | 1.0 mL/min                                      |           |           |       |
| Column temp.:     | 30 °C   |           |           |       |
| Injection volume: | 2.0 μL  |           |           |       |

#### Sample preparation

Sample: Reversed-Phase QC Reference Material



### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| CORTECS C <sub>18</sub> +, 2.7 μm,<br>2.1 x 100 mm Column | <a href="#">186007397</a>   |
| Reversed-Phase QC<br>Reference Material                   | <a href="#">186006363</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa           | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [720005550EN](#) at waters.com

## Analysis of Sialic Acid by HPLC

### EXPERIMENTAL

#### LC conditions

|                   |   |
|-------------------|---|
| System:           | ACQUITY UPLC with fluorescence detector                         |
| Column:           | XBridge BEH C <sub>18</sub> , 3.5 μm, 4.6 x 100 mm              |
| Mobile phase:     | Acetonitrile:methanol:water (9%:7%:84%)                         |
| Separation mode:  | Isocratic   |
| Flow rate:        | 0.43 mL/min   |
| Injection volume: | 6.7 μL  |
| Column temp.:     | 30 °C   |
| FLR detection:    | Excitation wavelength = 373 nm;<br>Emission wavelength = 448 nm |

### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| XBridge BEH C <sub>18</sub> , 3.5 μm,<br>4.6 x 100 mm Column | <a href="#">186003033</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa              | <a href="#">186005666CV</a> |

#### Sample preparation


Preparation of 1,2-Diamino-4,5-methylenedioxybenzene dihydrochloride (DMB) labeling solution:

- Into a 2-mL glass vial, 436 μL of water and 38 μL of glacial acetic acid were mixed.
- 26 μL of 2-mercaptoethanol was added to the 2-mL vial and mixed.
- 440 μL of the above solution was added to a separate 2-mL glass vial containing 4 mg of sodium hyrosulfite and mixed.
- This solution was added to a 2-mL glass vial containing 0.7 mg of DMB and mixed.
- Due to the light and moisture sensitivity this DMB-labeling solution was used immediately after preparation.

DMB Labeling of Sialic Acid Reference Panel:

- 20 μL of the DMB-labeling solution was added to the vial containing the purchased sialic acid reference panel.
- The sample was incubated in the dark using a heater block set to 50 °C.
- After three hours, the reaction was stopped by adding 480 μL of water to the reaction mixture.
- This DMB-labeled sample was injected onto the ACQUITY UPLC System with injection volumes scaled appropriately for column configurations.

Sample temp.: 4 °C



For complete experimental details, refer to full application note [720005550EN](#) at waters.com

## Analysis of Sialic Acid by UHPLC

### EXPERIMENTAL

#### LC conditions

|                   |   |
|-------------------|---|
| System:           | ACQUITY UPLC with fluorescence detector                         |
| Column:           | XBridge BEH C <sub>18</sub> <b>XP</b> , 2.5 µm, 3.0 x 75 mm     |
| Mobile phase:     | Acetonitrile:methanol:water (9%:7%:84%)                         |
| Separation mode:  | Isocratic   |
| Flow rate:        | 0.26 mL/min   |
| Injection volume: | 2.0 µL  |
| Column temp.:     | 30 °C   |
| FLR detection:    | Excitation wavelength = 373 nm;<br>Emission wavelength = 448 nm |

### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| XBridge BEH C <sub>18</sub> <b>XP</b> , 2.5 µm, 3.0 x 75 mm Column | <a href="#">186006034</a>   |
| TruView LCMS Certified Vial w/ Preslit Septa                       | <a href="#">186005666CV</a> |

#### Sample preparation


Preparation of 1,2-Diamino-4,5-methylenedioxybenzene dihydrochloride (DMB) labeling solution:

- Into a 2-mL glass vial, 436 µL of water and 38 µL of glacial acetic acid and were mixed.
- 26 µL of 2-mercaptoethanol was added to the 2-mL vial and mixed.
- 440 µL of the above solution was added to a separate 2-mL glass vial containing 4 mg of sodium hydrosulfite and mixed.
- This solution was added to a 2-mL glass vial containing 0.7 mg of DMB and mixed.
- Due to the light and moisture sensitivity this DMB-labeling solution was used immediately after preparation.

DMB Labeling of Sialic Acid Reference Panel:

- 20 µL of the DMB-labeling solution was added to the vial containing the purchased sialic acid reference panel.
- The sample was incubated in the dark using a heater block set to 50 °C.
- After three hours, the reaction was stopped by adding 480 µL of water to the reaction mixture.
- This DMB-labeled sample was injected onto the ACQUITY UPLC System with injection volumes scaled appropriately for column configurations.

Sample temp.: 4 °C



For complete experimental details, refer to full application note [720001901EN](#) at waters.com

## Analysis of Simvastatin


### EXPERIMENTAL

#### LC conditions

|                   |  |
|-------------------|--|
| System:           | ACQUITY UPLC with PDA detector                   |
| Column:           | XBridge BEH C <sub>18</sub> , 5 µm, 4.6 x 250 mm |
| Mobile phase:     | 65% acetonitrile/35% phosphate buffer, pH 4.5    |
| Separation mode:  | Isocratic  |
| Flow rate:        | 1.5 mL/min                                       |
| Column temp.:     | 45 °C  |
| Injection volume: | 10 µL  |
| UV detection:     | 238 nm   |

#### Sample preparation

A standard solution of simvastatin was prepared according to the USP methodology, and then was diluted to 100 µg/mL.



### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| XBridge BEH C <sub>18</sub> , 5 µm,<br>4.6 x 250 mm Column | <a href="#">186003117</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa            | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [720004589EN](#) at waters.com

## Analysis of Soft Drink

### EXPERIMENTAL

#### LC conditions


|                   |   |
|-------------------|---|
| System:           | ACQUITY UPLC H-Class                                  |
| Column:           | XBridge BEH Phenyl <b>XP</b> ,<br>2.5 µm, 4.6 x 50 mm |
| Mobile phase:     | Waters Beverage Analysis<br>Mobile-Phase Reagent      |
| Separation mode:  | Isocratic   |
| Flow rate:        | 1.0 mL/min  |
| Column temp.:     | 35 °C   |
| Injection volume: | 5 µL  |
| UV detection:     | 214 nm  |

#### Sample preparation

One bottle of Waters Beverage Analysis Standards was poured into one bottle of Waters Beverage Analysis Standards Solid. The bottle containing this mixture was capped tightly, and shaken vigorously until the aspartame was completely dissolved.

### ORDERING INFORMATION

| Description  | P/N                       |
|--|---------------------------|
| XBridge BEH Phenyl <b>XP</b> , 2.5 µm,<br>4.6 x 50 mm Column | <a href="#">186006073</a> |
| LCGC Certified Clear Glass<br>Recovery Vial                  | <a href="#">186003270</a> |
| Waters Beverage Analysis Kit                                 | <a href="#">176002534</a> |



For complete experimental details, refer to full application note [720004253EN](#) at waters.com

## Analysis of Soy Isoflavones in Foods and Dietary Supplements by HPLC


### EXPERIMENTAL

#### LC conditions

|                   |  |    |    |
|-------------------|--|----|----|
| System:           | ACQUITY UPLC H-Class with ACQUITY SQD detector and 2998 PDA detector |    |    |
| Column:           | XSelect HSS Cyano, 5 µm, 4.6 x 150 mm                                |    |    |
| Mobile phase A:   | 0.1% formic acid in water  |    |    |
| Mobile phase B:   | 0.1% formic acid in acetonitrile                                     |    |    |
| Gradient:         | Time   | %A | %B |
|                   | 0.00   | 90 | 10 |
|                   | 3.00   | 90 | 10 |
|                   | 33.00  | 70 | 30 |
|                   | 36.00  | 70 | 30 |
|                   | 36.10  | 90 | 10 |
|                   | 51.10  | 90 | 10 |
| Flow rate:        | 1.0 mL/min   |    |    |
| Column temp.:     | 30 °C  |    |    |
| Injection volume: | 43 µL  |    |    |
| Ionization mode:  | ESI+   |    |    |

#### Sample preparation

Standard solution: Prepared from daidzin (25 ppm), glycitin (25 ppm), genistin (15 ppm), daidzein (25 ppm), glycitein (25 ppm), and genistein (15 ppm) using 10/90 acetonitrile/water diluent.



#### ORDERING INFORMATION

| Description                                  | P/N                         |
|--|-----------------------------|
| XSelect HSS Cyano, 5 µm, 4.6 x 150 mm Column | <a href="#">186005945</a>   |
| TruView LCMS Certified Vial w/ Preslit Septa | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [720004253EN](#) at waters.com

## Analysis of Soy Isoflavones in Foods and Dietary Supplements by UHPLC


### EXPERIMENTAL

#### LC conditions

|                   |  |    |    |
|-------------------|--|----|----|
| System:           | ACQUITY UPLC H-Class with ACQUITY SQD detector and 2998 PDA detector |    |    |
| Column:           | XSelect HSS Cyano, 2.5 µm, 4.6 x 75 mm                               |    |    |
| Mobile phase A:   | 0.1% formic acid in water  |    |    |
| Mobile phase B:   | 0.1% formic acid in acetonitrile                                     |    |    |
| Gradient:         | Time   | %A | %B |
|                   | 0.00   | 90 | 10 |
|                   | 0.75   | 90 | 10 |
|                   | 8.25   | 70 | 30 |
|                   | 9.00   | 70 | 30 |
|                   | 9.03   | 90 | 10 |
|                   | 12.78  | 90 | 10 |
| Flow rate:        | 2.0 mL/min   |    |    |
| Column temp.:     | 30 °C  |    |    |
| Injection volume: | 22 µL  |    |    |
| Ionization mode:  | ESI+   |    |    |

#### Sample preparation

Standard solution: Prepared from daidzin (25 ppm), glycitin (25 ppm), genistin (15 ppm), daidzein (25 ppm), glycetein (25 ppm), and genistein (15 ppm) using 10/90 acetonitrile/water diluent.



#### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| XSelect HSS Cyano <i>XP</i> , 2.5 µm, 4.6 x 75 mm Column | <a href="#">186006194</a>   |
| TruView LCMS Certified Vial w/ Preslit Septa             | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [XBRIDGE13](#) at [waters.com](#)

## Analysis of Statins

### EXPERIMENTAL

#### LC conditions

System: Alliance 2695 with 2996 PDA detector

Column: XBridge BEH Phenyl,  
3.5  $\mu$ m 4.6 x 100 mm

Mobile phase A: Water

Mobile phase B: Acetonitrile

Mobile phase C: 100 mM ammonium bicarbonate

| Gradient: | Time  | %A | %B | %C |
|-----------|-------|----|----|----|
|           | 0.00  | 65 | 15 | 20 |
|           | 20.00 | 30 | 50 | 20 |
|           | 21.00 | 65 | 15 | 20 |
|           | 25.00 | 65 | 15 | 20 |

Flow rate: 1.2 mL /min

Column temp.: 25 °C


Injection volume: 20  $\mu$ L

UV detection: 248 nm

#### Sample preparation

Sample: Atorvastatin (10  $\mu$ g/mL),  
Simvastatin (10  $\mu$ g/mL),  
Lovastatin (10  $\mu$ g/mL),  
Pravastatin sodium (10  $\mu$ g/mL)  
in  $H_2O/NH_4HCO_3$  (90/10)

Sample temp.: 15 °C



#### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH Phenyl, 3.5 $\mu$ m,<br>4.6 x 100 mm Column | <a href="#">186003334</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa         | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [WA64103](#) at waters.com

## Analysis of Stevia Related Compounds by ELSD

### EXPERIMENTAL


#### LC conditions

|                       |  |
|-----------------------|--|
| System:               | Alliance HPLC with 2424 ELSD                               |
| Column:               | XBridge BEH Amide,<br>3.5 µm, 4.6 x 250 mm                 |
| Mobile phase A:       | 80/20 acetonitrile/water<br>with 0.2% triethylamine        |
| Mobile phase B:       | 30/70 acetonitrile/water<br>with 0.2% triethylamine        |
| Isocratic conditions: | 95% A/5% B (77.5% acetonitrile<br>with 0.2% triethylamine) |
| Flow rate:            | 1.0 mL/min   |
| Column temp.:         | 35 °C  |
| Injection volume:     | 10.0 µL  |
| ELSD pressure:        | 30 psi   |
| Drift tube temp.:     | 50 °C  |

#### Sample preparation

Add 25 mL of 50:50 acetonitrile/water to ~3 g sample, homogenize, centrifuge at 3200 rpm for 30 minutes, collect supernatant and filter using 0.45 µm PVDF syringe filter.

Sample concentration: 5 mg/mL each



### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH Amide, 3.5 µm,<br>4.6 x 250 mm Column         | <a href="#">186004870</a>   |
| Acrodisc, Syringe Filter,<br>PVDF, 13 mm, 0.45 µm, 100/pk | <a href="#">WAT200512</a>   |
| Waters LCMS Certified Vial                                | <a href="#">600000751CV</a> |

For complete experimental details, refer to full application note [WA64106](#) at waters.com

## Analysis of Stevia Related Compounds by MS

### EXPERIMENTAL

#### LC conditions

|                       |   |
|-----------------------|---|
| System:               | ACQUITY UPLC with 30-cm column cooler/heater and Xevo TQD Mass Spectrometer                       |
| Column:               | XBridge BEH Amide, 3.5 $\mu$ m, 4.6 x 250 mm  |
| Mobile phase A:       | 80/20 acetonitrile/water with 0.1 % ammonium hydroxide  |
| Mobile phase B:       | 30/70 acetonitrile/water with 0.1 % ammonium hydroxide  |
| Isocratic conditions: | 95% A/5% B  |
| Flow rate:            | 1.0 mL/min  |
| Column temp.:         | 35 °C   |
| Injection volume:     | 15.0 $\mu$ L  |
| Ionization mode:      | ESI-  |
| Acquisition mode:     | SIR (m/z): 121.1 (erythritol); 803.8 (stevioside); 950.1 (rebaudioside C); 966.1 (rebaudioside A) |


#### Sample preparation

Add 25 mL of 50:50 acetonitrile/water to ~3 g sample, homogenize, centrifuge at 3200 rpm for 30 minutes, collect supernatant and filter using 0.45  $\mu$ m PVDF syringe filter.

Sample concentration: 50  $\mu$ g/mL each

### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH Amide, 3.5 $\mu$ m, 4.6 x 250 mm Column         | <a href="#">186004870</a>   |
| Acrodisc, Syringe Filter, PVDF, 13 mm, 0.45 $\mu$ m, 100/pk | <a href="#">WAT200512</a>   |
| Waters LCMS Certified Vial w/ Preslit Septa                 | <a href="#">600000668CV</a> |



For complete experimental details, refer to full application note [720005669EN](#) at waters.com

## Analysis of Sucralose


### EXPERIMENTAL

#### LC conditions

|                       |  |
|-----------------------|--|
| System:               | Alliance HPLC with 2414 Refractive Index (RI) detector |
| Column:               | CORTECS C <sub>18</sub> , 2.7 µm, 4.6 x 100 mm         |
| Mobile phase:         | 80:20 water/methanol                                   |
| Separation mode:      | Isocratic  |
| Flow rate:            | 1 mL/min   |
| Column temp.:         | 30 °C  |
| Injection volume:     | 50 µL  |
| Refractive Index (RI) |  |
| Detector temp.:       | 30 °C  |

#### Sample preparation

Sucralose reference standard 100 µg/mL.



### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| CORTECS C <sub>18</sub> , 2.7 µm,<br>4.6 x 100 mm Column | <a href="#">186007377</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa          | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [WA60708](#) at waters.com

## Analysis of Sudan Dyes

### EXPERIMENTAL

#### LC conditions

|                 |  |    |    |    |       |
|-----------------|--|----|----|----|-------|
| System:         | ACQUITY UPLC H-Class with Xevo TQD Mass Spectrometer |    |    |    |       |
| Column:         | CORTECS C <sub>18</sub> , 2.7 μm, 2.1 x 100 mm       |    |    |    |       |
| Mobile phase A: | Water + 0.1% formic acid                             |    |    |    |       |
| Mobile phase B: | Methanol + 0.1% formic acid                          |    |    |    |       |
| Mobile phase C: | Acetonitrile + 0.1% formic acid                      |    |    |    |       |
| Gradient:       | Time   | %A | %B | %C | Curve |
|                 | Initial  | 80 | 10 | 10 | -     |
|                 | 0.5  | 40 | 30 | 30 | 6     |
|                 | 5.0  | 0  | 50 | 50 | 6     |
|                 | 9.0  | 0  | 50 | 50 | 6     |
|                 | 9.1  | 80 | 10 | 10 | 6     |
|                 | 12.0   | 80 | 10 | 10 | 6     |
| Flow rate:      | 0.4 mL/min   |    |    |    |       |

Column temp.: 45 °C

Injection volume: 5 μL

Ionization mode: ESI+

Acquisition mode: MRM

#### Sample preparation



Sample: Sudan Dyes in Oleoresin

Oleoresin prepared using Certified Sep-Pak Silica 3 cc Vac Cartridge, 500 mg sorbent per cartridge, 55-105 μm particle size.

### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| CORTECS C <sub>18</sub> , 2.7 μm, 2.1 x 100 mm Column | <a href="#">186007367</a>   |
| Certified Sep-Pak Silica 3 cc Vac Cartridge           | <a href="#">186004615</a>   |
| TruView LCMS Certified Vial w/ Preslit Septa          | <a href="#">186005666CV</a> |

100ppb Spiked Sudan Dyes in Oleoresin



1. Sudan orange G
2. Sudan black B
3. Sudan red G
4. Sudan IV
5. Sudan II
6. Sudan red 7 B
7. Sudan I
8. Sudan III
9. Dimethyl yellow
10. Para red

For complete experimental details, refer to full application note [WA64698](#) at waters.com

## Analysis of Synthetic Cannabinoids

### EXPERIMENTAL

#### LC conditions

System: ACQUITY UPLC I-Class System (SM-FL),  
Column Manager (CMA) with Xevo TQD  
Mass Spectrometer

Column: CORTECS C<sub>18</sub>, 2.7 μm, 2.1 x 100 mm

Mobile phase A: 0.1% formic acid in water

Mobile phase B: 0.1% formic acid in acetonitrile

| Gradient: | Time | %A | %B | Curve |
|-----------|------|----|----|-------|
| Initial   | 70   | 30 | -  |       |
| 3.0       | 50   | 50 | 6  |       |
| 4.5       | 50   | 50 | 6  |       |
| 10.5      | 10   | 90 | 6  |       |
| 13.0      | 10   | 90 | 6  |       |
| 13.1      | 70   | 30 | 11 |       |
| 15.0      | 70   | 30 | 11 |       |

Column temp.: 30 °C

Injection volume: 5 μL

Ionization mode: ESI+

Acquisition mode: MRM

#### Sample preparation

Sample: Synthetic cannabinoid mix


Challenge Sample: Prepared plasma using Ostro Sample Preparation Plate

### ORDERING INFORMATION







| Description  | P/N                         |
|--|-----------------------------|
| CORTECS C <sub>18</sub> , 2.7 μm,<br>2.1 x 100 mm Column | <a href="#">186007367</a>   |
| Ostro Sample Preparation Plate                           | <a href="#">186005518</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa          | <a href="#">186005666CV</a> |

#### Synthetic Cannabinoids

| Peak     | Compound           | Retention Time |                |
|----------|--------------------|----------------|----------------|
|          |                    | Initial        | Injection 1000 |
| 2        | RCS-4, M10         | 1.91           | 1.90           |
| 10       | JWH-018, 4-OH met. | 4.18           | 4.18           |
| 21       | AB 001             | 10.49          | 10.48          |
| Pressure |                    | 3753           | 3749           |



7: MRM of 2 Channels ES+  
TIC (AM2233)  
4.99e6





For complete experimental details, refer to full application note [720004582EN](#) at waters.com

## Analysis of Tetracyclines in Milk

### EXPERIMENTAL

#### LC conditions

| System:           | Alliance e2690/5 with<br>2998 PDA detector   |      |    |    |      |    |    |      |    |    |       |    |    |       |    |    |       |    |    |
|-------------------|--|------|----|----|------|----|----|------|----|----|-------|----|----|-------|----|----|-------|----|----|
| Column:           | XBridge BEH C <sub>18</sub> XP, 2.5 μm,<br>100 x 4.6 mm  |      |    |    |      |    |    |      |    |    |       |    |    |       |    |    |       |    |    |
| Mobile phase A:   | 10 mM oxalic acid in water   |      |    |    |      |    |    |      |    |    |       |    |    |       |    |    |       |    |    |
| Mobile phase B:   | 10 mM oxalic acid in acetonitrile  |      |    |    |      |    |    |      |    |    |       |    |    |       |    |    |       |    |    |
| Gradient:         | <table border="1"> <thead> <tr> <th>Time</th> <th>%A</th> <th>%B</th> </tr> </thead> <tbody> <tr> <td>0.00</td> <td>85</td> <td>15</td> </tr> <tr> <td>8.00</td> <td>50</td> <td>50</td> </tr> <tr> <td>11.25</td> <td>50</td> <td>50</td> </tr> <tr> <td>11.60</td> <td>85</td> <td>15</td> </tr> <tr> <td>12.85</td> <td>85</td> <td>15</td> </tr> </tbody> </table> | Time | %A | %B | 0.00 | 85 | 15 | 8.00 | 50 | 50 | 11.25 | 50 | 50 | 11.60 | 85 | 15 | 12.85 | 85 | 15 |
| Time              | %A   | %B   |    |    |      |    |    |      |    |    |       |    |    |       |    |    |       |    |    |
| 0.00              | 85   | 15   |    |    |      |    |    |      |    |    |       |    |    |       |    |    |       |    |    |
| 8.00              | 50   | 50   |    |    |      |    |    |      |    |    |       |    |    |       |    |    |       |    |    |
| 11.25             | 50   | 50   |    |    |      |    |    |      |    |    |       |    |    |       |    |    |       |    |    |
| 11.60             | 85   | 15   |    |    |      |    |    |      |    |    |       |    |    |       |    |    |       |    |    |
| 12.85             | 85   | 15   |    |    |      |    |    |      |    |    |       |    |    |       |    |    |       |    |    |
| Flow rate:        | 1.20 mL/min  |      |    |    |      |    |    |      |    |    |       |    |    |       |    |    |       |    |    |
| Column temp.:     | 30 °C  |      |    |    |      |    |    |      |    |    |       |    |    |       |    |    |       |    |    |
| Injection volume: | 35 μL  |      |    |    |      |    |    |      |    |    |       |    |    |       |    |    |       |    |    |
| UV detection:     | 355 nm   |      |    |    |      |    |    |      |    |    |       |    |    |       |    |    |       |    |    |



#### Sample preparation

##### Sample and Buffer Preparation

- EDTA/McIlvaine Buffer: In a 1-L volumetric flask, dissolve 28.41 g anhydrous dibasic sodium phosphate in approximately 900 mL water, dilute to volume, and mix. In a separate 1-L volumetric flask, dissolve 21.01 g citric acid monohydrate in approximately 900 mL water, dilute to volume, and mix. Combine 1-L citric acid solution with 625 mL of phosphate solution. Add 60.5 g disodium EDTA, and mix well until dissolved. Prepare fresh weekly.
- Initial Extraction/Precipitation: Transfer 1.5 mL of milk to a 15-mL centrifuge tube. Add 6 mL of EDTA/McIlvaine buffer, and vortex for 30 seconds. Centrifuge at 4000 rpm for 5 minutes. Collect the supernant, and adjust to pH 10 with 0.75 mL 1 M NaOH.
- SPE Cleanup: SPE cleanup is performed using an Oasis MAX Cartridge (1 cc, 30 mg). Condition the cartridge with 2 mL of methanol, followed by 2 mL of water. Set flow rate to approximately 1 mL/min. Load pH adjusted supernatant obtained from the initial extraction. Wash with 0.5 mL of 5% ammonium hydroxide, and then with 0.5 mL of methanol. Elute with 0.5 mL 45:55 acetonitrile/75 mM aqueous oxalic acid. Dilute to 1.5 mL with reagent water prior to LC analysis.

#### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| XBridge BEH C <sub>18</sub> XP, 2.5 μm,<br>100 x 4.6 mm Column | <a href="#">186006039</a>   |
| Oasis MAX 1 cc Vac Cartridge                                   | <a href="#">186000366</a>   |
| TruView LCMS Certified Vial<br>w/ PreSlit Septa                | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [WA64114](#) at waters.com

## Analysis of Thiourea

### EXPERIMENTAL


#### LC conditions

|                   |   |
|-------------------|---|
| System:           | Alliance HPLC with 2998 PDA detector  |
| Column:           | XBridge BEH Amide,<br>3.5 µm, 4.6 x 250 mm  |
| Mobile phase:     | 95/2.5/2.5 acetonitrile/isopropyl<br>alcohol/water with 10 mM ammonium<br>acetate, pH 9.0 |
| Separation mode:  | Isocratic   |
| Flow rate:        | 0.5 mL/min  |
| Column temp.:     | 25 °C   |
| Injection volume: | 40.0 µL   |
| UV detection:     | 245 nm  |

#### Sample preparation

Sample was diluted with 50:50 acetonitrile/water and filtered using 0.45 µm PVDF syringe filter.

Sample concentration: 10 µg/mL



### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH Amide, 3.5 µm,<br>4.6 x 250 mm Column         | <a href="#">186004870</a>   |
| Acrodisc, Syringe Filter,<br>PVDF, 13 mm, 0.45 µm, 100/pk | <a href="#">WAT200512</a>   |
| Waters LCMS Certified Vial                                | <a href="#">600000751CV</a> |

For complete experimental details, refer to full application note [720004554EN](#) at waters.com

## Analysis of Tioconazole and Related Compounds


### EXPERIMENTAL

#### LC conditions

|                   |  |
|-------------------|--|
| System:           | Alliance HPLC with 2998 PDA detector   |
| Column:           | XSelect CSH C <sub>18</sub> , 5 µm, 4.6 x 250 mm;<br>XSelect CSH C <sub>18</sub> <b>XP</b> , 2.5 µm, 4.6 x 150 mm;<br>XSelect CSH C <sub>18</sub> <b>XP</b> , 2.5 µm, 4.6 x 100 mm |
| Mobile phase:     | 44:40:28 acetonitrile/methanol/water<br>with 2 mL ammonium hydroxide   |
| Separation mode:  | Isocratic  |
| Flow rate:        | 1.0 mL/min   |
| Column temp.:     | 25 °C  |
| Injection volume: | 25 µL (250-mm column),<br>12 µL (150-mm column),<br>8 µL (100-mm column)   |
| UV detection:     | 219 nm   |

#### Sample preparation

The tioconazole sample was prepared in 100% methanol to the concentrations described in the table.



### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| XSelect CSH C <sub>18</sub> , 5 µm,<br>4.6 x 250 mm Column             | <a href="#">186005291</a>   |
| XSelect CSH C <sub>18</sub> <b>XP</b> , 2.5 µm,<br>4.6 x 150 mm Column | <a href="#">186006729</a>   |
| XSelect CSH C <sub>18</sub> <b>XP</b> , 2.5 µm,<br>4.6 x 100 mm Column | <a href="#">186006111</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa                        | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [720004643EN](#) at waters.com

## Analysis of Topiramate

### EXPERIMENTAL

#### LC conditions


|                   |  |
|-------------------|--|
| System:           | Alliance HPLC with 2414 RI detector                |
| Column:           | XSelect HSS C <sub>18</sub> , 5.0 µm, 4.6 x 250 mm |
| Mobile phase:     | 1:1 (v/v) acetonitrile/water                       |
| Separation mode:  | Isocratic  |
| Flow              | 0.6 mL/min   |
| Colum temp.:      | 50 °C  |
| Injection volume: | 20 µL  |

#### Sample preparation

The standard solution used in this study was prepared according to the assay method defined in the USP Monograph for Topiramate Drug Substance.

### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| XSelect HSS C <sub>18</sub> , 5.0 µm, 4.6 x 250 mm Columns | <a href="#">186004775</a>   |
| TruView LCMS Certified Vial w/ Preslit Septa               | <a href="#">186005666CV</a> |



For complete experimental details, refer to full application note [XBRIDGE12](#) at waters.com

## Analysis of Tricyclic Antidepressants


### EXPERIMENTAL

#### LC conditions

|                       |   |
|-----------------------|---|
| System:               | Alliance 2695 with 2996 PDA detector    |
| Column:               | XBridge BEH Phenyl, 3.5 µm, 4.6 x 50 mm |
| Mobile phase A:       | Water                                   |
| Mobile phase B:       | Acetonitrile                            |
| Mobile phase C:       | 100 mM ammonium bicarbonate             |
| Isocratic conditions: | 48% A; 42% B; 10% C                     |
| Flow rate:            | 1.2 mL/min                              |
| Column temp.:         | 30 °C                                   |
| Injection volume:     | 10 µL                                   |
| UV detection:         | 254 nm                                  |

#### Sample preparation

|               |   |
|---------------|---|
| Sample:       | Nordoxepin (10 µg/mL),<br>Desipramine (10 µg/mL),<br>Doxepin (10 µg/mL),<br>Imipramine (10 µg/mL),<br>Amitriptyline (10 µg/mL)<br>in H <sub>2</sub> O/ACN (50/50) |
| Sample temp.: | 15 °C   |



### ORDERING INFORMATION

| Description                                       | P/N                         |
|---|-----------------------------|
| XBridge BEH Phenyl, 3.5 µm,<br>4.6 x 50 mm Column | <a href="#">186003332</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa   | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [XBRIDGE4](#) at waters.com

## Analysis of Tricyclic Antidepressants at pH 7.0

### EXPERIMENTAL

#### LC conditions


|                   |  |
|-------------------|--|
| System:           | Alliance 2695 with 2996 PDA detector                                       |
| Column:           | XBridge BEH C <sub>18</sub> , 5 µm, 4.6 x 150 mm                           |
| Mobile phase:     | 20 mM sodium phosphate buffer, pH 7.0/<br>acetonitrile/methanol (30/35/35) |
| Separation mode:  | Isocratic  |
| Flow rate:        | 1.5 mL/min   |
| Column temp.:     | 25 °C  |
| Injection volume: | 10 µL  |
| UV detection:     | 254 nm   |

#### Sample preparation


Sample concentration: 20 µg/mL in water

### ORDERING INFORMATION


| Description  | P/N                         |
|--|-----------------------------|
| XBridge BEH C <sub>18</sub> , 5 µm,<br>4.6 x 150 mm Column | <a href="#">186003116</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa            | <a href="#">186005666CV</a> |




1. Nortriptyline




2. Imipramine



3. Amitriptyline



4. Clomipramine



For complete experimental details, refer to full application note [XBRIDGE3](#) at waters.com

## Analysis of Tricyclic Antidepressants at pH 10.5

### EXPERIMENTAL

#### LC conditions






|                   |   |
|-------------------|---|
| System:           | Alliance 2695 with 2996 PDA detector                            |
| Column:           | XBridge BEH C <sub>18</sub> , 5 µm, 4.6 x 150 mm                |
| Mobile phase:     | 10 mM ammonium bicarbonate buffer, pH 10.5/acetonitrile (25:75) |
| Separation mode:  | Isocratic   |
| Flow rate:        | 1.5 mL/min  |
| Column temp.:     | 25 °C   |
| Injection volume: | 10 µL   |
| UV detection:     | 254 nm  |

#### Sample preparation

Sample concentration: 20 µg/mL in water

#### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH C <sub>18</sub> , 5 µm, 4.6 x 150 mm Column | <a href="#">186003116</a>   |
| TruView LCMS Certified Vial w/ Preslit Septa            | <a href="#">186005666CV</a> |



For complete experimental details, refer to full application note [720005567EN](#) at waters.com

## Analysis of UPC<sup>2</sup> Gradient Standard by HPLC

### EXPERIMENTAL


#### LC conditions

|                   |   |
|-------------------|---|
| System:           | ACQUITY Arc with 2998 PDA detector              |
| Column:           | XBridge BEH C <sub>18</sub> , 5 µm, 4.6 x 50 mm |
| Mobile phase A:   | 0.1% formic acid in water                       |
| Mobile phase B:   | 0.1% formic acid in methanol                    |
| Gradient:         | 5 to 80% B over 9 min                           |
| Flow rate:        | 1.0 mL/min                                      |
| Column temp.:     | 30 °C   |
| Injection volume: | 5.0 µL  |
| UV detection:     | 254 nm  |

#### Sample preparation

Combine 100 µL of the UPC<sup>2</sup> Gradient Standard with 900 µL of the 50/50 water/methanol solution.

Sample temp.: 10 °C



### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH C <sub>18</sub> , 5 µm,<br>4.6 x 50 mm Column | <a href="#">186003113</a>   |
| UPC <sup>2</sup> Gradient Standard                        | <a href="#">186006551</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa           | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [720005567EN](#) at waters.com

## Analysis of UPC<sup>2</sup> Gradient Standard by UHPLC

### EXPERIMENTAL


#### LC conditions

|                   |   |
|-------------------|---|
| System:           | ACQUITY Arc with 2998 PDA detector          |
| Column:           | CORTECS C <sub>18</sub> , 2.7 μm, 3 x 50 mm |
| Mobile phase A:   | 0.1% formic acid in water                   |
| Mobile phase B:   | 0.1% formic acid in methanol                |
| Gradient:         | 5 to 80% B over 2.5 min                     |
| Flow rate:        | 1.5 mL/min                                  |
| Column temp.:     | 30 °C                                       |
| Injection volume: | 2.1 μL                                      |
| UV detection:     | 254 nm                                      |

#### Sample preparation

Combine 100 μL of the UPC<sup>2</sup> Gradient Standard with 900 μL of the 50/50 water/methanol solution.

Sample temp.: 10 °C



### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| CORTECS C <sub>18</sub> , 2.7 μm,<br>3.0 x 50 mm Column | <a href="#">186007370</a>   |
| UPC <sup>2</sup> Gradient Standard                      | <a href="#">186006551</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa         | <a href="#">186005666CV</a> |

For complete experimental details, refer to full application note [WA64117](#) at waters.com

## Analysis of Uric Acids

### EXPERIMENTAL


#### LC conditions

|                   |   |           |           |
|-------------------|---|-----------|-----------|
| System:           | Alliance HPLC with 2998 PDA detector                            |           |           |
| Column:           | XBridge BEH Amide,<br>3.5 µm, 4.6 x 250 mm                      |           |           |
| Mobile phase A:   | 50/50 acetonitrile/water with<br>10 mM ammonium acetate, pH 5.0 |           |           |
| Mobile phase B:   | 90/10 acetonitrile/water with<br>10 mM ammonium acetate, pH 5.0 |           |           |
| Gradient:         | <u>Time</u>   | <u>%A</u> | <u>%B</u> |
|                   | 0.00  | 0.1       | 99.9      |
|                   | 50.00   | 50        | 50.0      |
|                   | 50.10   | 0.1       | 99.9      |
|                   | 60.00   | 0.1       | 99.9      |
| Flow rate:        | 1.2 mL/min  |           |           |
| Column temp.:     | 25 °C   |           |           |
| Injection volume: | 60.0 µL   |           |           |
| UV detection:     | 285 nm  |           |           |

#### Sample preparation

Sample was diluted with 50:50 acetonitrile/water and filtered using 0.45 µm PVDF syringe filter.

Sample concentration: 10 µg/mL



#### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH Amide, 3.5 µm,<br>4.6 x 250 mm Column         | <a href="#">186004870</a>   |
| Acrodisc, Syringe Filter,<br>PVDF, 13 mm, 0.45 µm, 100/pk | <a href="#">WAT200512</a>   |
| Waters LCMS Certified Vial                                | <a href="#">600000751CV</a> |

For complete experimental details, refer to full application note [WA64120](#) at waters.com

## Analysis of Water-Soluble Vitamins


### EXPERIMENTAL

#### LC conditions

|                   |   |           |           |
|-------------------|---|-----------|-----------|
| System:           | Alliance HPLC with 2998 PDA detector                            |           |           |
| Column:           | XBridge BEH Amide,<br>3.5 µm, 4.6 x 250 mm                      |           |           |
| Mobile phase A:   | 50/50 acetonitrile/water with<br>10 mM ammonium acetate, pH 9.0 |           |           |
| Mobile phase B:   | 90/10 acetonitrile/water with<br>10 mM ammonium acetate, pH 9.0 |           |           |
| Gradient:         | <u>Time</u>   | <u>%A</u> | <u>%B</u> |
|                   | 0.00  | 0.1       | 99.9      |
|                   | 35.00   | 70        | 30.0      |
|                   | 35.10   | 0.1       | 99.9      |
|                   | 45.00   | 0.1       | 99.9      |
| Flow rate:        | 1.2 mL/min  |           |           |
| Column temp.:     | 30 °C   |           |           |
| Injection volume: | 60.0 µL   |           |           |
| UV detection:     | 265 nm  |           |           |

#### Sample preparation

Add 25 mL of 50:50 acetonitrile/water to ~3 g sample, homogenize, centrifuge at 3200 rpm for 30 minutes, collect supernatant and filter using 0.45 µm PVDF syringe filter.



### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH Amide, 3.5 µm,<br>4.6 x 250 mm Column         | <a href="#">186004870</a>   |
| Acrodisc, Syringe Filter,<br>PVDF, 13 mm, 0.45 µm, 100/pk | <a href="#">WAT200512</a>   |
| Waters LCMS Certified Vial                                | <a href="#">600000751CV</a> |

For complete experimental details, refer to full application note [720005157EN](#) at [waters.com](#)

## Analysis of Zidovudine

### EXPERIMENTAL

#### LC conditions

|                   |  |
|-------------------|--|
| System:           | Alliance HPLC                                  |
| Column:           | CORTECS C <sub>18</sub> , 2.7 μm, 4.6 x 150 mm |
| Mobile phase:     | 80:20 water:methanol                           |
| Separation mode:  | Isocratic                                      |
| Flow rate:        | 0.9 mL/min                                     |
| Column temp.:     | 30 °C  |
| Injection volume: | 6.0 μL   |
| UV detection:     | 265 nm   |



#### Sample preparation

Zidovudine and its related compounds B and C reference standards were purchased from the USP. A sample containing 1.0 mg/mL zidovudine, 1.0 μg/mL related compound B, and 2.0 μg/mL related compound C was created in methanol and placed into a Waters LCMS Certified Max Recovery Vial injection.

#### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| CORTECS C <sub>18</sub> , 2.7 μm,<br>4.6 x 150 mm Column | <a href="#">186007378</a>   |
| Neutrals QC Reference Material                           | <a href="#">186006360</a>   |
| Waters LCMS Certified Max<br>Recovery Vial               | <a href="#">600000749CV</a> |

1. Related compound C
2. Zidovudine
3. Related compound B



For complete experimental details, refer to full application note [720004079EN](#) at waters.com

## Analysis of Ziprasidone HCl

### EXPERIMENTAL

#### LC conditions


|                   |  |
|-------------------|--|
| System:           | Alliance 2695  |
| Column:           | XBridge BEH C <sub>8</sub> , 5 μm, 4.6 x 150 mm                                |
| Mobile phase:     | 60:40 buffer:methanol  |
| Buffer:           | 25 mM potassium phosphate, monobasic in water, pH 3.0 with potassium hydroxide |
| Separation mode:  | Isocratic  |
| Flow rate:        | 1.5 mL/min   |
| Column temp.:     | 40 °C  |
| Injection volume: | 20 μL  |
| UV detection:     | 229 nm   |

#### Sample preparation

Ziprasidone capsules, contents made up to 0.23 mg/mL in diluent (60:40 methanol:water). Ziprasidone standard, made up to 0.23 mg/mL in diluent. Samples were filtered through a 0.2 μm PTFE membrane prior to analysis.

### ORDERING INFORMATION

| Description  | P/N                         |
|--|-----------------------------|
| XBridge BEH C <sub>8</sub> , 5 μm, 4.6 x 150 mm Column | <a href="#">186003017</a>   |
| TruView LCMS Certified Vial w/ Preslit Septa           | <a href="#">186005666CV</a> |



For complete experimental details, refer to full application note [720004697EN](#) at waters.com

## Analysis of Ziprasidone HCl - Early-Eluting Impurities

### EXPERIMENTAL

#### LC conditions

|                   |  |
|-------------------|--|
| System:           | Alliance 2695 with<br>2489 UV/Visible detector                               |
| Column:           | XBridge BEH C <sub>8</sub> , 5 μm, 4.6 x 150 mm                              |
| Mobile phase:     | 2:3 methanol/buffer  |
| Buffer:           | 50 mM potassium phosphate monobasic,<br>pH 3.0 adjusted with phosphoric acid |
| Separation mode:  | Isocratic  |
| Flow rate:        | 1.5 mL/min   |
| Column temp.:     | 40 °C  |
| Injection volume: | 20 μL  |
| UV detection:     | 229 nm   |


#### Sample preparation

All solutions were prepared in methanol/water/concentrated HCl at a composition of 20:5:0.01 to comply with the impurities methods defined in the USP Monograph for Ziprasidone HCl.

Sample temp.: 10 °C

### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH C <sub>8</sub> , 5 μm,<br>4.6 x 150 mm Column | <a href="#">186003017</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa           | <a href="#">186005666CV</a> |



For complete experimental details, refer to full application note [720004697EN](#) at waters.com

## Analysis of Ziprasidone HCl - Late-Eluting Impurities

### EXPERIMENTAL

#### LC conditions

|                   |  |
|-------------------|--|
| System:           | Alliance 2695 with<br>2489 UV/Visible detector   |
| Column:           | XBridge BEH C <sub>8</sub> , 5 µm, 4.6 x 150 mm  |
| Mobile phase:     | 11:1:8 acetonitrile/methanol/buffer  |
| Buffer:           | 50 mM potassium phosphate<br>monobasic, pH 6.0 adjusted<br>with 5N potassium hydroxide |
| Separation mode:  | Isocratic  |
| Flow rate:        | 1.0 mL/min   |
| Column temp.:     | 35 °C  |
| Injection volume: | 20 µL  |
| UV detection:     | 229 nm   |


#### Sample preparation

All solutions were prepared in methanol/water/concentrated HCl at a composition of 20:5:0.01 to comply with the impurities methods defined in the USP Monograph for Ziprasidone HCl.

Sample temp.: 10 °C

#### ORDERING INFORMATION

| Description   | P/N                         |
|---|-----------------------------|
| XBridge BEH C <sub>8</sub> , 5 µm,<br>4.6 x 150 mm Column | <a href="#">186003017</a>   |
| TruView LCMS Certified Vial<br>w/ Preslit Septa           | <a href="#">186005666CV</a> |



# Compound Index

|  |                |
|--|----------------|
| 1,3,5-Trinitrobenzene.....                         | 104            |
| 1,3-Dimethyluric acid .....                        | 147            |
| 1,3-Dimethyluric Acid.....                         | 35             |
| 1,3-Dinitrobenzene .....                           | 104            |
| 1-(4-hydroxypentyl)-1 H-indol-3-yl).....           | 137            |
| 1-(5-hydroxypentyl)-1 H-indol-3-yl).....           | 137            |
| 1,7-Dimethyluric acid .....                        | 35             |
| 1,7-Dimethylxanthine .....                         | 35             |
| 1-Methyluric acid .....                            | 147            |
| 1-Methylxanthine .....                             | 35             |
| 1R,4R Trans abacavir .....                         | 13             |
| 2,4,5-Trihydroxybutyrophenone .....                | 81, 82         |
| 2-5 Dimenthylbenzaldehyde .....                    | 71             |
| 2,6-Di-tert-butyl-4-hydroxymethylphenol.....       | 81, 82         |
| 2-Methylimidazole .....                            | 87             |
| 2-(methyl)propyl methylphosphonic acid (MMPA)..... | 113, 114       |
| 3,7-Dimethyluric acid .....                        | 147            |
| 4-Methylimidazole .....                            | 87             |
| 5-Fluorocytosine .....                             | 43             |
| 5-Fluorouracil.....                                | 53             |
| 5-HIAA.....  | 39             |
| 5-HT .....   | 95             |
| 5-Methoxy-2-benzimidazole-2-thiol .....            | 110            |
| 6,7-Dihydroxybergomottin .....                     | 72             |
| 6',7'-Epoxybergamottin .....                       | 72             |
| 6-Acetylmorphine .....                             | 14, 97, 98, 99 |
| 6-AM .....   | 115, 116       |
| 7-Geranyloxycoumarin .....                         | 72             |
| α-OH Midazolam .....                               | 49             |

## A

|                         |          |
|-------------------------|----------|
| AB 001.....             | 137      |
| Abacavir .....          | 13       |
| Abacavir glutarate..... | 12       |
| Abamectin.....          | 25, 26   |
| Acebutolol.....         | 120      |
| Acenaphthene.....       | 123, 125 |
| AcesulfameK.....        | 129      |
| Acetaldehyde.....       | 36, 71   |
| Acetaldehyde-DNPH.....  | 46       |
| Acetaminophen.....      | 122, 124 |
| Acetone .....           | 71       |
| Acetone-DNPH .....      | 46       |
| Acetylcholine.....      | 102      |
| Acid red 26.....        | 19       |

|                         |  |
|-------------------------|--|
| Acrolein.....           | 71                                     |
| Acrylamide.....         | 15                                     |
| Adenine .....           | 106, 123                               |
| Aflatoxins B1.....      | 16, 17                                 |
| Aflatoxins B2.....      | 16, 17                                 |
| Aflatoxins G1 .....     | 16, 17                                 |
| Aflatoxins G2.....      | 16, 17                                 |
| AI 1.....               | 119                                    |
| Allantoin .....         | 18                                     |
| Alprazolam.....         | 115, 116                               |
| Alprenolol (IS).....    | 120                                    |
| Amitriptyline.....      | 29, 27, 29, 30, 49, 125, 142, 143, 144 |
| Amoxicillin.....        | 20                                     |
| Amphetamine.....        | 115, 116                               |
| Apigenin glucoside..... | 52                                     |
| Arabinose .....         | 94                                     |
| Ascorbic acid.....      | 23, 24, 148                            |
| Aserine.....            | 77                                     |
| Aspartame.....          | 129                                    |
| Atenolol .....          | 31, 120                                |
| Atorvastatin.....       | 132                                    |

## B

|                                 |              |
|---------------------------------|--------------|
| B12.....                        | 148          |
| Basic red 9 .....               | 19           |
| Basic violet 14.....            | 19           |
| Benzaldehyde .....              | 71           |
| Benzamide .....                 | 112          |
| Benzilic acid .....             | 101          |
| Benzoate .....                  | 129          |
| Benzoic acid .....              | 91, 92       |
| Benzoic acid .....              | 91, 92       |
| Berberine 336.1.....            | 76           |
| Bergamottin .....               | 72           |
| Bezafibrate.....                | 120          |
| Bromazepam .....                | 50           |
| Budesonide .....                | 32           |
| Buprenorphine .....             | 33, 115, 116 |
| Buprenorphine glucuronide ..... | 33           |
| Bupropion .....                 | 49           |
| Butanal .....                   | 36, 71       |
| Butylated hydroxyanisole .....  | 81, 82       |
| Butylparaben .....              | 125          |
| BZE .....                       | 115, 116     |

**C**

|   |                           |
|---|---------------------------|
| Caffeine .....                                | 34, 35, 37, 129, 145, 146 |
| Canadine.....                                 | 76                        |
| Carbadox .....                                | 21, 22                    |
| Carbamazepine.....                            | 120                       |
| Carnosine .....                               | 77                        |
| Catechin.....                                 | 37                        |
| Catechin gallate .....                        | 37                        |
| Cefaclor .....                                | 41                        |
| Cefadroxile.....                              | 41                        |
| Cellobiose.....                               | 40                        |
| Cephalexin .....                              | 41                        |
| Cephradine .....                              | 41                        |
| Cetylpyridinium chloride .....                | 100                       |
| Chlortetracycline .....                       | 138                       |
| Choline.....                                  | 102                       |
| Cimetidine .....                              | 28                        |
| Ciprofloxacin.....                            | 120                       |
| Clarithromycin.....                           | 42                        |
| Clenbuterol.....                              | 28                        |
| Clofibric acid.....                           | 120                       |
| Clodogrel COOH .....                          | 49                        |
| Clomipramine .....                            | 143, 144                  |
| Clonazepam .....                              | 50, 115, 116              |
| Clopidogrel .....                             | 49                        |
| Clozapine .....                               | 49                        |
| Codeine .....                                 | 115, 116                  |
| Coumarin .....                                | 145, 146                  |
| Creatine .....                                | 77                        |
| Creatinine .....                              | 77                        |
| Crotonaldehyde.....                           | 36, 71                    |
| Crotonaldehyde-DNPH.....                      | 46                        |
| Cyclohexanone.....                            | 36                        |
| Cyclohexanone-DNPH.....                       | 46                        |
| Cyclohexyl methylphosphonic acid (CMPA) ..... | 101, 113, 114             |
| Cystosine.....                                | 123                       |
| Cytosine .....                                | 43, 106                   |

**D**

|                              |          |
|------------------------------|----------|
| DA.....                      | 95       |
| dADP.....                    | 107      |
| Daidzein.....                | 130, 131 |
| Daidzin .....                | 130, 131 |
| dAMP .....                   | 107      |
| dCMP .....                   | 107      |
| Decanal.....                 | 36       |
| Dehydroacetic acid .....     | 54       |
| Descyclopropyl abacavir..... | 12, 13   |
| Desipramine .....            | 142      |
| dGMP .....                   | 107      |
| DHT.....                     | 49       |
| Diazepam.....                | 115, 116 |
| Diclofenac .....             | 105, 120 |
| Diethyl phthalate.....       | 93       |
| Dihydro berberine 338.1..... | 76       |
| Dihydrocarbamazepine.....    | 120      |
| Dihydrocodeine .....         | 115, 116 |
| Diltiazem .....              | 27       |
| Dimethyl yellow .....        | 136      |
| Dipropylphthalate .....      | 125      |
| Direct red 28 .....          | 19       |
| Disperse blue 1 .....        | 45       |
| Disperse blue 3.....         | 19, 45   |
| Disperse blue 7 .....        | 19       |
| Disperse blue 35.....        | 19, 45   |
| Disperse blue 102.....       | 19       |
| Disperse blue 106.....       | 19, 45   |
| Disperse blue 124 .....      | 19, 45   |
| Disperse brown 1.....        | 19       |
| Disperse orange 1.....       | 19       |
| Disperse orange 3.....       | 19, 45   |
| Disperse orange 11.....      | 19       |
| Disperse orange 37 .....     | 19, 45   |
| Disperse orange 149 .....    | 19       |
| Disperse red 1.....          | 19, 45   |
| Disperse red 11 .....        | 19       |
| Disperse red 17 .....        | 19       |
| Disperse yellow 1.....       | 19       |
| Disperse yellow 3 .....      | 19, 45   |
| Disperse yellow 23 .....     | 19       |
| Disperse yellow 39 .....     | 19       |
| Disperse yellow 49 .....     | 19       |

|                                    |            |
|------------------------------------|------------|
| Dofetilide.....                    | 47         |
| Dofetilide related compound A..... | 47         |
| Domiphen bromide .....             | 100        |
| Donepezil.....                     | 48         |
| DOPAC.....                         | 39         |
| Dopamine.....                      | 38, 39, 95 |
| Doramectin.....                    | 25, 26     |
| Doxepin.....                       | 112, 142   |
| Doxylamine.....                    | 112        |

## E

|   |               |
|---|---------------|
| EDDP .....                              | 115, 116      |
| Enrofloxacin (IS).....                  | 120           |
| EP .....                                | 95            |
| Epicatechin gallate.....                | 37            |
| Epigallocatechin .....                  | 37            |
| Epigallocatechin gallate .....          | 37            |
| Epinephreine.....                       | 38            |
| Epinephrine .....                       | 39, 95        |
| Epinomectin.....                        | 25, 26        |
| Erythritol .....                        | 133, 134      |
| Estradiol .....                         | 51            |
| Estrone.....                            | 51            |
| Ethynodiol dihydrogesterone .....       | 80            |
| Ethyl methylphosphonic acid (EMPA)..... | 101, 113, 114 |
| Ethylparaben.....                       | 51            |
| Extromethorphan HCl.....                | 44            |

## F

|                           |   |
|---------------------------|---|
| Fenoprofen .....          | 105, 112  |
| Fenoprop (IS).....        | 120   |
| Fentanyl.....             | 49, 115, 116  |
| Ferulic acid .....        | 52  |
| Fexofenadine .....        | 49  |
| Flavone .....             | 112, 145, 146   |
| Flunitrazepam .....       | 50, 115, 116  |
| Folic acid.....           | 148   |
| Formaldehyde .....        | 36, 71  |
| Formaldehyde-DNPH .....   | 46  |
| Fructose .....            | 40, 55, 56, 57, 58, 59, 60, 61, 62,<br>63, 64, 65, 66, 67, 68, 69, 70, 94 |
| Fucose.....               | 96  |
| Fumaric acid .....        | 111   |
| Furanocoumarin dimer..... | 72  |
| Furazolidone .....        | 21  |

## G

|                            |   |
|----------------------------|---|
| Galactose.....             | 96  |
| Galantamine.....           | 73  |
| Gallic acid.....           | 37  |
| Gallocatechin gallate..... | 37  |
| Genistein.....             | 130, 131  |
| Genistin .....             | 130, 131  |
| Ginsenoside Rb1 .....      | 74, 75  |
| Glucose.....               | 40, 55, 56, 57, 58, 59, 60, 61, 62,<br>63, 64, 65, 66, 67, 68, 69, 70, 94, 96 |
| Glycitein .....            | 130, 131  |
| Glycitin .....             | 130, 131  |

## H

|                               |          |
|-------------------------------|----------|
| Heptanal.....                 | 36       |
| Hexanal.....                  | 36, 71   |
| HVA.....                      | 39       |
| Hydrastine.....               | 76       |
| Hydrocodone.....              | 115, 116 |
| Hydromorphone.....            | 115, 116 |
| Hydroxyisophthalic acid ..... | 112      |

## I

|   |                       |
|---|-----------------------|
| Ibuprofen .....                             | 105, 120              |
| Imipramine.....                             | 29, 30, 142, 143, 144 |
| Inositol.....                               | 94                    |
| Irbesartan .....                            | 78                    |
| Isoascorbic acid .....                      | 23, 24                |
| Isobutyl methylphosphonic acid .....        | 101                   |
| Isocorypalmine .....                        | 76                    |
| Isopropyl methylphosphonic acid (IMPA)..... | 101, 113, 114         |
| Isosakuranetin .....                        | 52                    |
| Isovaleraldehyde .....                      | 71                    |
| Ivermectin .....                            | 25, 26                |

## K

|                  |     |
|------------------|-----|
| Ketoprofen ..... | 120 |
|------------------|-----|

**L**

|                     |                                    |
|---------------------|------------------------------------|
| Labetalol.....      | 27                                 |
| Labetolol.....      | 31                                 |
| Lactic acid.....    | 111                                |
| Lactose.....        | 55, 56, 57, 58, 59, 60, 61, 62, 63 |
| Lamotrigine.....    | 79                                 |
| Leucine.....        | 124                                |
| Levonorgestrel..... | 80                                 |
| Lidocaine.....      | 83                                 |
| Loratadine.....     | 84                                 |
| Loratidine.....     | 85, 86                             |
| Lorazepam.....      | 50, 115, 116                       |
| Lovastatin.....     | 132                                |

**M**

|                            |   |
|----------------------------|---|
| M3G.....                   | 97  |
| Maleic acid.....           | 111   |
| Maltoheptaose.....         | 40, 64, 66, 67, 68, 69, 70  |
| Maltohexaose.....          | 40, 64, 66, 67, 68, 69, 70  |
| Maltooligosaccharides..... | 40, 64, 65, 66, 67, 68, 69, 70  |
| Maltopentaose.....         | 40, 64, 66, 67, 68, 69, 70  |
| Maltose.....               | 55, 56, 57, 58, 59, 60, 61, 62,<br>63, 64, 65, 66, 67, 68, 69, 70, 94 |
| Maltotetraose.....         | 40, 64, 66, 67, 68, 69, 70  |
| Maltotriose.....           | 64, 66, 67, 68, 69, 70, 94  |
| Mangiferin.....            | 52  |
| Mannitol.....              | 94  |
| Mannose.....               | 40, 96  |
| MDA.....                   | 50, 115, 116  |
| MDEA.....                  | 115, 116  |
| MDMA.....                  | 50, 115, 116  |
| Melezitose.....            | 40  |
| Meperidine.....            | 115, 116  |
| Metformin.....             | 28  |
| Methacrylamide.....        | 15  |
| Methacrylic acid.....      | 15  |
| Methadone.....             | 115, 116  |
| Methamphetamine.....       | 115, 116  |
| Methyl hydrastine.....     | 76  |
| Methylparaben.....         | 54  |
| Methylphosphonic acid..... | 101   |
| Metoclopramide.....        | 88, 89, 90  |
| Metoprolol.....            | 31, 120   |

|  |                          |
|--|--------------------------|
| MHPG.....                              | 39                       |
| Miconazole.....                        | 91, 92                   |
| Miconazole related compound.....       | 91, 92                   |
| Midazolam.....                         | 49                       |
| Mometasone furoate.....                | 93                       |
| Morphine.....                          | 14, 97, 98, 99, 115, 116 |
| Morphine-3 $\beta$ -D-glucuronide..... | 97, 98, 99               |
| Morphine-N-oxide.....                  | 99                       |
| Moxidectin.....                        | 25, 26                   |
| m-Tolualdehyde.....                    | 71                       |

**N**

|                                     |              |
|-------------------------------------|--------------|
| N-acetylgalactosamine (GalNAc)..... | 96           |
| N-acetylglucosamine (GlcNAc).....   | 96           |
| Nalidixic acid.....                 | 21, 22       |
| Naphthalene.....                    | 125          |
| Naproxen.....                       | 105, 120     |
| N-desmethyl clozapine.....          | 49           |
| NE.....                             | 95           |
| Neu5,7(8),9Ac3.....                 | 126, 127     |
| Neu5,7Ac2.....                      | 126, 127     |
| Neu5,9Ac2.....                      | 126, 127     |
| Neu5Ac.....                         | 126, 127     |
| Neu5Gc.....                         | 126, 127     |
| Neu5Gc9Ac.....                      | 126, 127     |
| Nicotinamide.....                   | 108, 148     |
| Nicotinic acid.....                 | 108, 148     |
| Nimodipine.....                     | 103          |
| Nitrazepam.....                     | 115, 116     |
| Nitrobenzene.....                   | 104          |
| N-methyl serotonin.....             | 95           |
| NMS.....                            | 95           |
| Nobiletin.....                      | 52           |
| Nonanal.....                        | 36           |
| Norpseudorphine.....                | 115, 116     |
| Nordoxepin.....                     | 142          |
| Norepinephrine.....                 | 38, 39, 95   |
| Norfentanyl.....                    | 49, 115, 116 |
| Norfloxacin.....                    | 120          |
| Normeperidine.....                  | 115, 116     |
| Normetanephrine.....                | 38           |
| Norquetiapine.....                  | 49           |
| Nortriptyline.....                  | 49, 143, 144 |

**O**

|  |          |
|--|----------|
| O-(4-Chloro-2,5-diaminopyrimidnyl)-abacavir..... | 13       |
| Octanal .....                                    | 36       |
| Octyl gallate.....                               | 81, 82   |
| O-desmethyl tramadol .....                       | 115, 116 |
| Ofloxacin.....                                   | 120      |
| OH-bupropion.....                                | 49       |
| OH-risperidone .....                             | 49       |
| Oligonucleotides.....                            | 109      |
| Omeprazole.....                                  | 110      |
| Omeprazole desmethoxy .....                      | 110      |
| Omeprazole-n-oxide .....                         | 110      |
| Omeprazole-n-oxide/sulphone .....                | 110      |
| Omeprazole sulphide .....                        | 110      |
| o-Pyrimidine derivative abacavir .....           | 12       |
| O-t-Butyl-abacavir.....                          | 13       |
| o-Tolualdehyde .....                             | 71       |
| Oxazepam .....                                   | 115, 116 |
| Oxolinic acid.....                               | 21, 22   |
| Oxprenolol.....                                  | 31       |
| Oxycodone.....                                   | 115, 116 |
| Oxymorphone .....                                | 115, 116 |
| Oxytetracycline .....                            | 138      |

**P**

|   |              |
|---|--------------|
| Palmatine 352.2 .....                       | 76           |
| Para red .....                              | 136          |
| p-Coumaric acid.....                        | 52           |
| PCP .....                                   | 115, 116     |
| PEG-6.....                                  | 122          |
| PEG-7.....                                  | 122          |
| PEG-8.....                                  | 122          |
| PEG-9 .....                                 | 122          |
| Pentanal .....                              | 36, 71       |
| Peppermint extract.....                     | 117          |
| Phentermine.....                            | 115, 116     |
| p-Hydroxybenzoic acid .....                 | 54           |
| Pinacolyl methylphosphonic acid.....        | 101          |
| Pinacolyl methylphosphonic acid (PMPA)..... | 113, 114     |
| pindolol.....                               | 27           |
| Pindolol.....                               | 31           |
| Prednisone.....                             | 27, 145, 146 |
| Procaine .....                              | 83           |
| Propanal .....                              | 36, 71       |

|                      |   |
|----------------------|---|
| Propoxyphene.....    | 115, 116  |
| Propranolol.....     | 31, 125   |
| Propyl gallate.....  | 81, 82  |
| p-Tolualdehyde ..... | 71  |
| p-Toluamide .....    | 55, 56, 57, 58, 59,<br>60, 61, 62, 63, 64, 66, 67, 68, 69 |
| Pyridoxal .....      | 148   |
| Pyruvic acid.....    | 111   |

**Q**

|                 |    |
|-----------------|----|
| Quetiapine..... | 49 |
| Quinine.....    | 27 |

**R**

|                         |          |
|-------------------------|----------|
| Raffinose.....          | 40       |
| Ranitidine.....         | 28       |
| Ravastatin sodium ..... | 132      |
| Rebaudioside A .....    | 133, 134 |
| Rebaudioside C .....    | 133, 134 |
| Reserpine.....          | 124      |
| Riboflavin.....         | 148      |
| Risperidone .....       | 49       |

**S**

|                        |   |
|------------------------|---|
| Saccharin.....         | 54, 129   |
| Salbutamol.....        | 28  |
| Serotonin .....        | 39, 95  |
| Simvastatin.....       | 128, 132  |
| Sodium saccharine..... | 100   |
| Sorbate .....          | 129   |
| Sorbic acid .....      | 54  |
| Sorbitol .....         | 94  |
| Sotalol .....          | 120   |
| Stevioside.....        | 133, 134  |
| Succinic acid.....     | 111   |
| Sucralose .....        | 135   |
| Sucrose.....           | 40, 55, 56, 57, 58, 59, 60, 61,<br>62, 63, 64, 65, 66, 67, 68, 69, 70 |
| Sudan black B .....    | 136   |
| Sudan I .....          | 136   |
| Sudan II .....         | 136   |
| Sudan III .....        | 136   |
| Sudan IV .....         | 136   |
| Sudan orange G .....   | 136   |

|                       |         |
|-----------------------|---------|
| Sudan red 7 B.....    | 136     |
| Sudan red G.....      | 136     |
| Sulfadimethoxine..... | 21, 124 |
| Sulfaguanidine.....   | 124     |
| Sulfaquinoxaline..... | 21, 22  |
| Suprofen.....         | 105     |

## T

|                                  |                    |
|----------------------------------|--------------------|
| Tangeretin .....                 | 52                 |
| t-Butyl derivative abacavir..... | 12                 |
| Tebuconazole .....               | 119                |
| Temazepam .....                  | 115, 116           |
| Terfenadine.....                 | 49, 124            |
| Tert-butylhydroquinone.....      | 81, 82             |
| Testosterone.....                | 49                 |
| Tetracaine.....                  | 44, 83             |
| Tetracycline .....               | 138                |
| tGuanine.....                    | 106                |
| Theobromine .....                | 34, 35             |
| Theophylline.....                | 34                 |
| Thiamine .....                   | 108, 148           |
| Thiamphenicol .....              | 21                 |
| Thiourea .....                   | 139                |
| Thymine.....                     | 106, 123, 145, 146 |
| Tioconazole .....                | 140                |
| TMP .....                        | 107                |
| Tolmetin.....                    | 105                |
| Topiramate .....                 | 141                |
| Tramadol .....                   | 115, 116           |
| Triprolidine HCl.....            | 44                 |

## U

|                |                  |
|----------------|------------------|
| Uracil.....    | 27, 43, 106, 125 |
| Uric acid..... | 147              |

## V

|                   |     |
|-------------------|-----|
| Val-Tyr-Val ..... | 124 |
| Verapamil.....    | 124 |
| VMA.....          | 39  |

## W

|               |    |
|---------------|----|
| Warfarin..... | 44 |
|---------------|----|

## X

|                |    |
|----------------|----|
| Xanthine ..... | 34 |
| Xylose .....   | 40 |

## Z

|                  |               |
|------------------|---------------|
| Zidovudine ..... | 149           |
| Ziprasidone..... | 150, 151, 152 |

**Sales Offices:**

Australia 61 2 9933 1777  
Austria 43 1 877 18 07  
Belgium and Luxembourg 32 2 726 1000  
Brazil 55 11 4134 3788  
Canada 1 800 252 4752  
China 86 21 6156 2666  
Czech Republic 420 2 617 11384  
Denmark 45 46 59 8080  
Finland 358 9 5659 6288  
France 33 1 30 48 72 00  
Germany 49 6196 400 600  
Hong Kong 852 2964 1800  
Hungary 36 1 350 5086  
India 91 080 49292200 03  
Ireland 353 1 448 1500  
Israel 9723 3731391  
Italy 39 02 265 0983  
Japan 81 3 3471 7191  
Korea 82 2 6300 9200  
Malaysia 603 78411688  
Mexico 52 55 52 00 1860  
The Netherlands 31 76 508 7200  
Norway 47 6 384 6050  
Poland 48 22 101 5900  
Portugal 351 21 893 6177  
Puerto Rico 1 787 747 8445  
Singapore 65 6593 7100  
Spain 34 93 600 9300  
Sweden 46 8 555 115 00  
Switzerland 41 56 676 7000  
Taiwan 886 2 2508 5500  
UAE 971 4 214 62 38  
UK 44 208 238 6100  
US 1 800 252 4752

For your local sales office, please visit [www.waters.com/contact](http://www.waters.com/contact)

**[www.waters.com/HPLCcolumns](http://www.waters.com/HPLCcolumns)**

**Waters**

THE SCIENCE OF WHAT'S POSSIBLE.®

Waters, The Science of What's Possible, ACQUITY, ACQUITY UPLC, Alliance, APC, Atlantis, CORTECS, Empower, Nova-Pak, Oasis, QDa, Sep-Pak, SunFire, TruView, UPC<sup>2</sup>, XBridge, XSelect, Xevo, and UPLC are registered trademarks of Waters Corporation. ACQUITY Arc, AflaOchra HPLC, Arc, AutoPurification, BEH Technology, CSH, DisQuE, OBD, and Ostro are trademarks of Waters Corporation. VICAM and AflaTest are registered trademarks of VICAM, A Waters Company. Acrodisc is a registered trademark of Pall Corporation. Agilent is a registered trademark of Agilent Technologies. Rhinocort AQUA is a trademark of AstraZeneca. Burrell Wrist-Action is a trademark of Burrell Scientific. AccuStandard is a registered trademark of AccuStandard Inc. Robitussin is a registered trademark of Pfizer Inc. AVAPRO is a trademark of Bristol-Myers Squibb Company. All other trademarks are the property of their respective owners.

**Waters Corporation**  
34 Maple Street  
Milford, MA 01757 U.S.A.  
T: 1 508 478 2000  
F: 1 508 872 1990  
[www.waters.com](http://www.waters.com)

©2017 Waters Corporation. Produced in the U.S.A.  
May 2017 720005899EN IH-PDF